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Abstract 
Zika virus (ZIKV) is a member of the Flavivirus genus of the family Flaviviridae. 
Members of this genus possess a single-stranded positive-sense RNA genome 
which are flanked by 5’ and 3’ untranslated regions. Previously, ZIKV infection 
was thought to cause symptomatic infection in 20% of patients, characterised by 
a non-purulent rash and a mild fever. However, recent ZIKV outbreaks have seen 
the emergence of novel neurological sequelae associated with ZIKV infection. 
These symptoms affected the central and peripheral nervous systems (CNS and 
PNS, respectively) of neonates and adults (congenital ZIKV syndrome and 
Guillain-Barré syndrome, respectively). Consequently, prior to commencement 
of this thesis, the knowledge of ZIKV interactions within the CNS and PNS was 
limited. Therefore, the primary aim of this thesis was to expand the current 
knowledgebase of ZIKV infection within cells of the CNS and PNS.  
 
The work presented herein assessed available tools to study ZIKV infection in 
vitro, including testing previously uncharacterised commercial antibodies 
targeting the ZIKV envelope (ZIKV E) and NS1 proteins. Subsequently, a suitable 
antibody raised against the ZIKV E was identified and used in downstream 
analyses.  
 
A model system of ZIKV infection of the CNS and PNS using mixed-cell co-
cultures derived from mouse spinal cord (CNS) or dorsal root ganglion (PNS) was 
used to determined cell-type specific susceptibility to ZIKV infection. It was 
found that cells of the PNS are refractory to ZIKV infection, whereas cells of the 
CNS are permissive to ZIKV infection. In the CNS, oligodendrocytes and their 
precursors were the most susceptible cell type to ZIKV infection. Moreover, 
when infecting CNS co-cultures at a time point which reflects prenatal life 
through to post-natal life, white matter structures (myelin sheath and axons) are 
injured. However, neuronal cell bodies remained healthy. Using purified primary 
neuronal cultures derived from mouse spinal cord, it was determined that 
neurons were refractory to ZIKV infection in the absence of accompanying glial 
cells. This suggests axonal damage may not be a result of direct infection of 
neurons themselves and may be a consequence of oligodendrocyte infection and 
injury.  
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Transcriptomic analyses of ZIKV-infected CNS co-cultures revealed that ZIKV 
infection induces the upregulation of genes involved in antiviral responses and 
inflammatory pathways, including TNF and ROS/NO pathway components; these 
pathways may be involved in exacerbating injury to white matter structures 
within ZIKV-infected CNS-co-cultures.  
 
In summary, the results described in this thesis show that ZIKV can infect the 
early post-natal CNS. Furthermore, ZIKV-infection of this murine model 
demonstrates that infection induces the injury and depletion of myelin and 
axons. This is likely to be due to a combination of effects such as direct viral 
infection, cell death of oligodendrocytes, and secreted inflammatory factors. 
Myelination occurs late in foetal development and carries on into early 
adulthood. These data, in combination with precedent pathological findings, 
suggest that ZIKV-infected children born absent of microcephaly may develop 
other, more subtle, neurological sequelae later in life.  
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1 Introduction 
1.1 Molecular biology of the Flaviviridae 
1.1.1 Classification 
The Flaviviridae is a family of small, enveloped viruses which possess a single-
stranded, positive-sense RNA genome between 9-13 kb in length. The family 
comprises over 100 species which are further categorised into 4 genera: 
Flavivirus, Pestivirus, Hepacivirus, and Pegivirus (Simmonds et al., 2017).  
Pestiviruses are important pathogens of animals, infecting pigs and ruminants; 
they are transmitted through direct and indirect contact with infected bodily 
fluids. A notable member of this genus is bovine viral diarrhoea virus (BVDV), 
associated with respiratory, reproductive and gastrointestinal disease of cattle 
(Smith et al., 2017). 
Pegiviruses have been detected in a wide range of mammals in addition to bats 
and rodents and are categorised into species (Pegivirus A-K; Pegivirus C 
possesses 6 genotypes which infect humans) (Adams et al., 1998, Simmonds et 
al., 2017). Pegivirus frequently cause persistent infections with rare disease 
consequence in humans, whereas Theiler’s disease in horses has been associated 
with Pegivirus infection (Chandriani et al., 2013) . 
Hepaciviruses have a broad host range, infecting a variety of mammals, rodents 
and bats. The most well characterised virus of the genus is hepatitis C virus, of 
the species Hepacivirus C. Members of this genus cause acute and chronic 
disease of the liver (Smith et al., 2016).  
Members of the Flavivirus genus are predominantly arthropod-borne viruses 
(arboviruses), spread via infection of mosquitoes or ticks which subsequently 
transmit the virus to the primary host, mammals and birds, when taking a 
bloodmeal (Section 1.3.2). Many important human pathogens belong to the 
genus Flavivirus, for instance yellow fever virus (YFV), Japanese encephalitis 
(JEV), West Nile virus (WNV), dengue virus (DENV), and the recently emerged, 
Zika virus (ZIKV). Human Flavivirus infection results in a range of pathological 
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outcomes from asymptomatic infection to severe haemorrhagic or neurological 
manifestations (Maximova and Pletnev, 2018). Other members of this family, 
such as louping ill virus (LIV) and Tembusu virus (TMUV), cause disease of socio-
economic consequence within animals (Zhang et al., 2017, Dagleish et al., 
2018).  
1.1.2 Genome organisation 
Flaviviruses have a single-stranded, positive-sense RNA genome of around 11 kb 
in length. The genome comprises a single open reading frame (ORF) flanked by 
5’ and 3’ untranslated regions (UTR’s) (Figure 1–1). Furthermore, flavivirus 
genomes possess a 5’ cap, but lack a poly(A) tail. The genome encodes three 
structural genes: Capsid (C), Pre-membrane/membrane (PrM), Envelope (E), in 
addition to seven non-structural genes: NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5 (Figure 1–1). As flaviviruses contain a positive-sense RNA genome, these 
genomes can be translated directly by host cell machinery (membrane-
associated ribosomes of the rough endoplasmic reticulum [ER]). The ORF is 
translated as a single polyprotein which is cleaved by host and viral proteases, 
subsequently producing ten viral proteins – their namesake corresponds to their 
gene name. The structural proteins are implicated in the assembly of progeny 
virions, whereas the non-structural proteins, which are pleiotropic in nature, are 
involved in numerous aspects of the virus life cycle. Non-structural proteins 
potentiate viral replication and virion assembly through interactions with host 
and viral proteins to render the host cell conducive to viral reproduction; 
combat host antiviral responses; act as scaffolds for viral replication; catalyse 
viral replication processes. 
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Figure 1–1 Flavivirus genus genome organisation and membrane topology of proteins in the 
ER 
A. Schematic representation of the Flavivirus genome structure. Flaviviruses comprise a single open 
reading frame which is flanked by 5’ and 3’ untranslated regions (UTRs), shown as stem loop 
structures on the diagram. The genome is capped but lacks a poly(A) tail. Structural proteins are 
organised closer to the 5’ region, and non-structural proteins towards the 3’ region. B. A simplified 
schematic of flavivirus protein topology across the ER membrane. The genome is translated as single 
polyprotein, which is cleaved by viral and host proteases within the ER. Figure adapted from 
(Neufeldt et al., 2018). 
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1.1.3 Flavivirus genus genome: gene products 
1.1.4 Capsid 
The capsid (C) protein is largely considered a structural protein which is 
implicated in virus assembly. It is a small protein of approximately 14 kDa that 
possesses an affinity for both nucleic acids and lipid membranes. The primary, 
and most critical function of the C protein is to encapsidate nascent viral RNA, 
forming the nucleocapsid, and to aid its incorporation into progeny virions. 
Structural data of the DENV C protein, obtained by NMR, revealed each C protein 
monomer is composed of four α-helices (α1-4), with a flexible N terminal region 
(Ma et al., 2004). Upon dimerization, the C protein forms structures which 
facilitate association with lipid bilayers, via a hydrophobic cleft formed by α2 
helices, and the viral genome via positively charged, arginine-rich regions 
formed by α4 helices (Markoff et al., 1997, Kiermayr et al., 2004). The 3D 
structures of WNV C and ZIKV C protein possess similar gross topologies to DENV 
C protein (Shang et al., 2018). However, ZIKV C protein possesses a larger 
flexible N terminal domain, and shorter α1 helix compared to either WNV or 
DENV (Shang et al., 2018). It is thought that the pre-α1 region of ZIKV C acts to 
further stabilise dimer interactions, in addition to specific residues contributing 
to association with lipid droplets (Shang et al., 2018). The structure of the 
nucleocapsid, i.e. viral RNA encapsidated with C protein, is yet to be 
determined.  
The C protein retains the ability to package RNA in-vitro despite deletions made 
to various α-helical structures in WNV or TBEV (Kofler et al., 2002, Schlick et al., 
2009). Furthermore, the C protein localises to discrete cellular organelles 
including lipid droplets, the ER membrane in addition to the nucleus (Roby et 
al., 2015); this suggests alternative roles for C protein functionality.  
It has been found that the nuclear trafficking of C is mediated by the presence 
of a nuclear localisation signal (NLS) within the protein; in DENV and WNV this is 
a bi-partite NLS which enables C to interact with importin-α to facilitate nuclear 
translocation (Mori et al., 2005, Bhuvanakantham et al., 2010, Colpitts et al., 
2011). The role of C in the nucleus is ill-defined, though some interactions have 
been identified: DENV C has been shown to interact with four histone proteins 
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(H2A, H2B, H3 and H4) in addition to heterogenous nuclear ribonucleoprotein K 
(hnRNP K), all of which are implicated in the regulation of host gene expression 
(Colpitts et al., 2011). 
It has also been demonstrated that the C proteins of both YFV and ZIKV possess 
the capability to bind dsRNA, suggesting a role for C protein in the suppression 
of RNA silencing, though no mechanistic data is available to support this claim 
yet (Samuel et al., 2016, Shang et al., 2018). 
1.1.5 Pre-membrane/membrane (prM) 
prM is a membrane glycoprotein of approximately 19-21 kDa. Through 
associations with the E protein, prM is an integral component of the Flavivirus 
virion. An N-terminal signal sequence at the C/prM junction enables the 
translocation of prM into the ER lumen during polyprotein translation (Lobigs et 
al., 2010). Host cell signalase cleaves prM from this signal sequence in the ER 
lumen – a process which is dependent on prior cleavage of C by the NS2B/3 
protease (Lobigs et al., 2010). prM is anchored to the ER lumen via two C-
terminal transmembrane helices. The protein exists in an immature (prM) and 
mature form (M); prM maturation is mediated by furin cleavage of the pr peptide 
in the trans-Golgi network, generating the mature M protein which is 
approximately 10 kDa in size (Stadler et al., 1997, Yu et al., 2008). 
In addition to its structural role, prM has several other proposed roles in 
including: assisting chaperone-mediated folding of the E protein (Lorenz et al., 
2002, Konishi and Mason, 1993), contributing to pH-dependent conformation 
rearrangements of trimeric prM/E heterodimer spikes in immature virions (Zhang 
et al., 2012), and preventing premature fusion during virion egress by concealing 
the fusion loop of E (Yu et al., 2009). The interactions between prM/E and its 
role in virus particle formation is explored further in section 1.1.6. 
1.1.6 Envelope 
The envelope (E) protein constitutes the major component of the virus envelope. 
It is a large (approximately 53 kDa), membrane-bound glycoprotein which is 
responsible for binding cell surface receptors to facilitate virus entry. The E 
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protein decorates the outer surface of the virus particle, and as such, it is a 
major antigenic target for the development of neutralising antibodies.  
Each E protein monomer comprises three β-barrel domains: DI, DII and DIII 
(Figure 1–2). The three domains are connected by flexible hinges which mediate 
conformational changes essential for virus infectivity (Zhang et al., 2004). DI 
constitutes the central domain, which harbours the N terminus and acts as an 
anchor for the hinge point of DII. DII is a large distal domain, containing the loop 
peptide which is involved in virus fusion during cell entry (Allison et al., 2001). 
The C-terminal DIII domain is an immunoglobulin-like domain containing the 
receptor binding motif, which is critical for virus entry. 
The E protein undergoes major conformational changes during the virus life 
cycle. Initially, the immature virus particle is composed of 60 trimeric surface 
spikes; each spike is composed of a trimer of prM-E heterodimers (Zhang et al., 
2003, Prasad et al., 2017) (Figure 1–2A). The fusion loop of each E protein is 
concealed by prM proteins at the tip of each spike, thereby preventing early 
fusion events (Yu et al., 2009, Heinz et al., 1994). The first major 
conformational change occurs within the trans-Golgi network, resulting in the 
furin cleavage of the pr peptide (Yu et al., 2008). Subsequently, the 60 trimers 
rearrange into 90 E homodimers which are in an anti-parallel configuration 
(Plevka et al., 2014) (Figure 1–2B). The 90 E dimers are arranged in a 
‘herringbone’ pattern, formed of three adjacent homodimers, which lie flat on 
the virion surface (Kuhn et al., 2002, Mukhopadhyay et al., 2003) (Figure 1–2D). 
prM remains associated with E in mature intracellular virions, and its release 
coincides with virus egress (Zhang et al., 2012, Zhang et al., 2013) (Figure 1–2C). 
In the mature virion, the fusion loop is buried within DI and DII of the opposing 
monomer (Allison et al., 2001). The second major conformational change occurs 
during virus entry. Upon internalisation, the virus particle enters the endosomal 
pathway, progression through which results in pH mediated exposure of the 
fusion loop. The fusion loop penetrates the endosomal membrane, causing the 
fusion of virus and endosomal membranes, liberating the viral genome into the 
cytoplasm (Bressanelli et al., 2004, Modis et al., 2004). 
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Figure 1–2 The structural rearrangements of the envelope protein during Flavivirus particle 
maturation.  
Flavivirus virions are first generated as immature particles. Envelope/prM heterodimers assemble to 
form trimeric spikes on the ER membrane (the envelope protein has been coloured according to its 
domains: red, blue, yellow, correspond to DI, DII and DIII respectively. Green denotes the 
transmembrane region). A. The nucleocapsid interacts with the trimeric spikes, causing the particle 
to bud into the ER lumen. B. The virion is transported through the trans-Golgi network, where 
changes in pH and furin cleavage of prM result in a major conformational change in the envelope 
protein, causing it to form dimers which lie flat on the surface of the virion. PrM is still associated with 
E at this stage. C/D. Following exocytosis, prM disassociates from E, producing the mature, 
infectious progeny virion. The E dimers form a herringbone pattern on the surface of the virion, as 
shown in D. The fusion peptide is coloured in orange and is concealed until virus entry. Figure from 
(Rey et al., 2018). 
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1.1.7 NS1 
NS1, like many of the Flavivirus genus non-structural proteins, is a multifaceted 
protein. Dependent upon glycosylation status, the molecular weight of NS1 
ranges from 46-55 kDa. Furthermore, NS1 can associate to form higher order 
structures, which also dictate functionality; NS1 can exist as a monomer, dimer 
(membrane-bound, mNS1) or a hexamer (secreted, sNS1).  
The extent of glycosylation influences virulence, viral replication and 
determines whether NS1 is secreted (sNS1). Monomeric NS1 initially undergoes 
N-linked glycosylation at sites Asn-130 and Asn-207, which is performed by 
glycosidase within the ER (Pryor and Wright, 1994). Further modifications carried 
out by glycosidases and glycosyltransferases takes place in the trans-Golgi 
network, enabling NS1 to form a soluble hexamer which is secreted from the cell 
(Somnuke et al., 2011). The sNS1 hexamer is composed of three dimers 
associating to form a barrel with a hydrophobic core; sNS1 forms a lipoprotein 
particle, carrying lipid cargo within its core (Gutsche et al., 2011). sNS1 plays a 
crucial, yet widely mechanistically debated, role in DENV pathogenesis, 
contributing to haemorrhagic manifestations observed severe DENV infections. 
Furthermore, sNS1 is found circulating in the sera of patients infected with 
DENV, and as such is used as an early diagnostic biomarker (Young et al., 2000, 
Rastogi et al., 2016). 
1.1.8 NS2A 
NS2A is a hydrophobic, membrane-associated protein approximately 22 kDa in 
size. Like the other non-structural proteins, NS2A is pleiotropic in nature; as 
such it is implicated in various aspects of the virus life cycle. As demonstrated 
by experiments with Kunjin virus (KUNV), NS2A interacts with high specificity to 
the 3’UTR of viral RNA in addition to other components of the replication 
complex, including NS3 and NS5 (Mackenzie et al., 1998). More recently, an 
A175V substitution in the ZIKV NS2A protein attenuated the virus in vitro and in 
vivo (Márquez-Jurado et al., 2018). 
Mutagenesis studies found a K190S mutation in YFV NS2A inhibited the 
production of virus particles (Kümmerer and Rice, 2002). Further studies using a 
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KUNV replicon demonstrated that the single amino acid substitution in NS2A, 
I59N, blocked virus production (Liu et al., 2003). It was later found that this 
substitution ablates the generation of virus-induced membranous structures 
(Leung et al., 2008). Interestingly, compensatory mutations, namely T149P or 
substitutions with hydrophobic residues at position 59, rescued virus-induced 
membrane rearrangements and the production of virus particles (Leung et al., 
2008). Furthermore, the introduction of an R84A mutation in DENV-2 NS2A 
blocked the intracellular formation of virions (Xie et al., 2013). Together these 
studies implicate NS2A in virus assembly, in addition to the generation of virus-
induced membranous structures - the site of Flavivirus replication (discussed 
further in section 1.1.11). However, further studies are required to provide 
mechanistic insight into these processes.  
NS2A is also involved in the modulation of host immunity. The expression of 
DENV NS2A was sufficient to enable the replication of GFP tagged Newcastle 
disease virus (NDV), an IFN sensitive virus (Muñoz-Jordan et al., 2003). 
Additionally, when acting in combination with NS4A and 4B, DENV-2 NS2A 
inhibits STAT1 phosphorylation, thereby blocking the IFN signalling cascade and 
subsequent IFN response (Muñoz-Jordan et al., 2003). JEV NS2A modulates host 
immunity via an alternative mechanism, involving the blockade of dsRNA-
activated protein kinase PKR (Tu et al., 2012). 
1.1.9 NS2B 
NS2B acts as a cofactor, supporting the enzymatic activity of NS3. It is a small, 
integral membrane protein of ~14kDa in size. It contains a conserved central 
hydrophilic region which is flanked by three hydrophobic transmembrane 
domains, two reside within the N-terminus and one at the C-terminus (Falgout et 
al., 1993). The central region has been demonstrated to be necessary and 
sufficient for NS3 protease function (Chambers et al., 1993, Falgout et al., 
1993). Whilst the transmembrane domains are not essential for NS3 protease 
activity, studies show that mutagenesis of the predicted transmembrane regions 
negatively impacts virus replication and virion assembly (Li et al., 2016b, 
Chambers et al., 1993, Li et al., 2014). A genome-wide CRISPR/Cas9-based 
screen identified that the loss of signal peptidase complex subunit 1 (SPCS1) 
reduced the yield of a range of flaviruses including: WNV, DENV, ZIKV, YFV, JEV 
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and HCV (Zhang et al., 2016). Ma et al (2018) demonstrated that SPCS1 interacts 
with the transmembrane domains of the NS2B protein from JEV and is implicated 
in post-translational protein processing and virus assembly. SPCS1 was also found 
to interact with WNV and ZIKV NS2B, suggesting this interaction is conserved 
amongst flaviviruses (Ma et al., 2018b). 
1.1.10 NS3 
After NS5, NS3 is the second largest non-structural protein produced by 
flaviviruses (~69kDa). NS3 comprises two functional domains: an N-terminal 
protease and a C-terminal helicase domain (Cui et al., 1998, Wengler, 1991, Li 
et al., 1999). The protease domain, in complex with NS2B which acts as a co-
factor, is critical in viral polyprotein processing. The helicase domain functions 
cooperatively with NS5 (an RNA dependent RNA polymerase; RdRp) to replicate 
viral RNA. The NS3 helicase domain unwinds dsRNA, a replicative intermediate 
molecule, to facilitate the production of positive sense viral RNA genomes 
(carried out by the action of NS5) (Cui et al., 1998, Xu et al., 2019). NS3 also 
exhibits RNA 5’ triphosphatase activity, which is vital in producing capped RNA 
genomes. Progeny genomes possess a terminal 5’ triphosphate, the 
triphosphatase activity of NS3 catalyses the removal of the terminal phosphate, 
which facilitates capping by the action of NS5 (Issur et al., 2009). 
1.1.11 NS4A 
NS4A is a small, integral membrane protein of approximately 16 kDa. NS4A and 
NS4B are connected by the conserved 2K peptide region. Cleavage at the C-
terminus of NS4A by the NS2B/NS3 helicase is a prerequisite for the subsequent 
cleavage event at the N-terminus of NS2B by a host signalase, which liberates 
NS2B from the 2K leader peptide (Lin et al., 1993). Structural data of DENV4 
NS4A in micelles, obtained by solution NMR spectroscopy, revealed six helices: 
three amphipathic N-terminal helices which interact with the membrane, in 
addition to three C-terminal transmembrane helices (Li et al., 2018). The N-
terminus contains regions of hydrophobicity, allowing the amphipathic helices to 
interact with the cytosolic face of the ER membrane (Li et al., 2018, Hung et al., 
2015). Introducing mutations in this region which interferes with its amphipathic 
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nature decreases homo-oligomerisation of NS4A, and abolishes viral replication 
(Stern et al., 2013). 
NS4A is involved in forming virus-induced membranous structures, called vesicle 
packets, which are the site of flavivirus replication and particle formation (Miller 
et al., 2007). The formation of vesicle packets is thought to be a result of NS4A 
homo-oligomerisation which induce membrane curvature (Stern et al., 2013, Lee 
et al., 2015, Hung et al., 2015). The membrane remodelling capabilities of 
flaviviruses have also been ascribed to interactions with host proteins. DENV 
NS4A interacts with the intermediate filament protein, vimentin (Teo and Chu, 
2014). The role of this interaction in membrane remodelling is yet to be 
determined; however, it has been suggested that vimentin may perform a 
structural role in replication complex formation (Teo and Chu, 2014). The host 
protein RTN3.1A (Reticulon 3.1) has also been found to contribute to membrane 
remodelling, possibly via interacting with NS4A; silencing this protein results in 
impaired vesicle packet formation in KUNV, DENV-2 and ZIKV infection and 
decreases replication and particle release (Aktepe et al., 2017). 
Further to its role in membrane remodelling, NS4A also contributes to inhibition 
of type I IFN responses (Dalrymple et al., 2015, Ma et al., 2018a), induces 
autophagy (McLean et al., 2011) and modulate the host stress response to 
benefit viral replication (Hou et al., 2017). 
1.1.12 NS4B 
Once liberated from the viral polyprotein by the action of the NS2B/NS3 
protease, NS4B exists in a ‘pro’ form with an N-terminal leader peptide, 2K-
NS4B. This 30 kDa protein is further processed by a host cell signalase which 
cleaves the 2K region, resulting in mature NS4B production (Lin et al., 1993). 
The 2K peptide forms a transmembrane domain that enables the translocation of 
NS4B into the ER lumen (Miller et al., 2007). However, the 2K peptide is not 
essential for NS4B function.  
NS4B is an integral membrane protein, localising to the ER and ER-derived 
structures (Miller et al., 2006). Its function is implicated in the Flavivirus 
replication complex, though the exact role of NS4B in viral replication remains 
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elusive. A range of mutagenesis and co-localisation studies highlight the capacity 
for NS4B to interact with viral dsRNA (Miller et al., 2006) in addition to other 
Flavivirus non-structural proteins including NS1 (Youn et al., 2012), NS2B (Yu et 
al., 2013), NS3 (Umareddy et al., 2006, Zou et al., 2015a) and NS4A (Zou et al., 
2015b). It has also been demonstrated that NS4B plays a role in Flavivirus 
immune evasion via blockade of type I IFN signalling cascade at the level of 
STAT1 phosphorylation (Liu et al., 2005, Muñoz-Jordán et al., 2005). An 
engineered mutation in WNV NS4B, P38G, was found to be associated with small-
plaque phenotype and temperature sensitivity (Wicker et al., 2012). 
Furthermore, this mutation conferred attenuated neuroinvasive capabilities in 
mice compared to the neurovirulent strain WNV NY-99 (Wicker et al., 2012) -
further demonstrating the range of biological functionality of NS4B.  
1.1.13 NS5 
NS5 is the largest and most conserved protein of the Flaviviridae family 
(approximately 900 amino acids). It comprises two domains which confer 
enzymatic activity; a N-terminal methlytransferase domain (MTase) which is 
connected to a C-terminal RNA-dependent RNA polymerase (RdRp) via a flexible 
linker (Grun and Brinton, 1987). The RdRp domain replicates viral RNA, whereas 
the MTase activity (cooperatively with NS3) produces and methylates the 5’ cap 
on viral progeny RNA molecules (Egloff et al., 2002, Ray et al., 2006, Zhou et 
al., 2007). 
The Flavivirus NS5 protein adopts a structure resembling a right-hand palm, 
fingers and thumb domains which surround an active site (Yap et al., 2007, Malet 
et al., 2007). To date, no structure of an NS5 RdRdp:RNA complex from a 
flavivirus has been solved.  
In addition to its role in viral replication, NS5 is a potent antagonist of the type I 
IFN response (Best, 2017, Cumberworth et al., 2017b). Absent of any other 
interactions with host proteins, NS5 aids the immune evasion strategies of 
flaviviruses by producing a 5’ cap which mimics host RNA structures. The 5’ cap 
of the Flavivirus genome is methylated (N7 and nucleoside-2’-O sites), disguising 
the viral RNA from cytoplasmic pathogen recognition receptors that recognise 
RNA possessing a terminal 5’trisphosphate, in addition to preventing degradation 
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by exoribonucleases. NS5 antagonises the type I IFN response at the level of 
STAT inhibition – the mechanisms of which vary between flaviviruses. NS5 
inhibition of STAT1/2 activation or translocation prevents the upregulation of 
ISGs and the establishment of an antiviral state.  
1.1.14 3’UTR and subgenomic flavivirus RNA 
Flaviviruses produce a non-coding RNA product called sfRNA which is derived 
from the 3’ untranslated region (3’UTR) (Pijlman et al., 2008, Donald et al., 
2016, Göertz et al., 2018, Slonchak and Khromykh, 2018). sfRNA production is a 
result of incomplete degradation of viral genomic RNA (gRNA), facilitated by the 
stalling of cellular 5’-3’ exoribonuclease XRN1 at complex RNA structures 
located in the 3’UTR of flaviviruses (Figure 1–3), thus protecting downstream 
RNA from degradation (MacFadden et al., 2018, Chapman et al., 2014a, 
Chapman et al., 2014b). Resultant RNA species are subsequently formed with an 
average length of ~500 nucleotides; some viruses such as WNV, DENV and YFV 
generate multiple truncated species of sfRNA during infection (Liu et al., 2010, 
Funk et al., 2010, Pijlman et al., 2008). XRN1-resistant RNA (xrRNA) elements in 
sfRNA also have the capacity to halt other exoribonucleases unrelated to XRN1, 
indicating that these structures function as a general block to degradation as 
opposed to halting degradation via specific RNA-protein interactions (MacFadden 
et al., 2018). 
The 3’UTR of flaviviruses form interactions with viral proteins during infection. 
Ribonucleoprotein co-immunoprecipitation of JEV 3’UTR found that the 3’UTR 
interacts with viral NS5 protein (Chang et al., 2013). Furthermore, interactions 
between the 3’UTR of KUNV with capsid (Khromykh and Westaway, 1996) and 
NS2A proteins (Mackenzie et al., 1998) and DENV and JEV with the NS3 protein 
(Chang et al., 2013, Cui et al., 1998) have been demonstrated using various in 
vitro assays. Whether this reflects interactions of viral proteins with the genomic 
3’UTR RNA or the sfRNA itself remains to be determined. Given that most of the 
aforementioned viral proteins are involved in replication complex formation, it 
would seem likely that these interactions exist with genomic RNA. However, as 
the sequences are conserved between the two RNA molecules, these interactions 
could also exist with sfRNA.  
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Figure 1–3 Schematic representation of the Flavivirus 3’UTR (based upon ZIKV 3’UTR) 
The 3’UTR of flaviviruses is composed of highly structured RNA. sfRNA is produced as a result of 
incomplete degradation of the viral genome by host cellular ribonuclease XRN1. The structure of 
sfRNA varies between flaviviruses; however, they share similar motifs. All sfRNA contain stem loop 
(SL) and dumbbell (DB) structures, which are capable of forming pseudoknots. Pseudoknot 
interactions are indicated in A by lines joining nucleotides with other nucleotides highlighted in green 
(A) Secondary structure of ZIKV 3’UTR (Natal strain). The sfRNA of ZIKV produces two sfRNAs of 
differing lengths which can be ascribed to the stalling of XRN1 at different positions of the genome. 
xrRNA1 is produced by stalling at SL-I, and xrRNA2 at SL-II. Here the full length sfRNA molecule is 
shown (B) Predicted tertiary structure of ZIVK 3’UTR RNA/sfRNA containing both SL-I and SL-II. 
Figure adapted from .(Göertz et al., 2018). 
A. 
B. 
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In regards to 3’UTR interactions with host proteins, numerous candidate 
interaction partners have been identified for a range of flaviviruses - 
summarised elsewhere (Roby et al., 2014). These candidates have varying roles 
in translation, RNA processing and stability, and immune modulation. Again, 
these findings reflect interactions with the 3’UTR of the gRNA and not 
specifically the sfRNA, though it is likely sfRNA retains the capacity to interact 
with the suggested proteins. 
Considering the roles of these candidate interaction partners, it would seem 
sfRNA serves to (1) to prevent the degradation of genomic viral RNA; (2) to 
prevent the elicitation of type I IFN responses; and (3) to promote viral 
translation. 
1.2 Flavivirus life cycle 
1.2.1 Cell entry 
Flaviviruses enter cells through receptor-mediated endocytosis, followed by 
fusion of viral and endosomal membranes, resulting in the release of viral 
genomic RNA into the host cytoplasm (Figure 1–4). The binding of the virus to its 
associated receptor, via interactions with the E protein, triggers the 
internalisation of the receptor-virus complex via the formation of clathrin 
coated pits (Chu and Ng, 2004a). The receptors used by flaviviruses to gain 
entrance to the host cell are poorly characterised; numerous candidate 
molecules have been proposed including αvβ3 integrins (Chu and Ng, 2004b), C-
type lectin receptors (Davis et al., 2006), TAM receptors such as Axl (identified 
as a ZIKV entry receptor) and phosphatidylserine receptors (Meertens et al., 
2012, Nowakowski et al., 2016, Laureti et al., 2018). Following receptor binding, 
the clathrin coated pit buds into the host cell from the plasma membrane, 
entering the endocytic trafficking cycle, whereby the endosomal pH lowers 
throughout its progression. The change in endosomal pH triggers conformational 
changes in the Flavivirus E protein, which exposes a fusion loop and 
subsequently causes the formation of a fusion pore. Viral components are 
released from the endosomal compartment into the host cell cytoplasm through 
the newly formed fusion pore. Viral genome replication can then take place 
within the cytoplasm.  
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1.2.2 Translation and Genome Replication 
Positive sense RNA has one of two fates in the Flavivirus life cycle; it can either 
be translated directly by host cell translational machinery to produce viral 
proteins to assist in replication and packaging of progeny virions, or it can be 
used to generate template RNA for genome replication (Figure 1–4). Prior to 
replication, translation must occur to generate proteins involved in viral 
replication. Flavivirus genomes possess a 5’cap, which facilitates direct 
translation of the virus genome by host cell machinery via cap-dependant RNA 
translation. Viral proteins are translated as a single polyprotein which traverses 
the ER membrane via numerous transmembrane domains.  
The polyprotein is processed by the host signal peptidase and further proteases, 
in addition to the viral protease, NS2B/NS3, to yield 10 individual proteins. The 
non-structural proteins have broad functionality, as described previously, in 
immune evasion, remodelling of intracellular membranes and replication 
complex formation, whereas structural proteins are required to assemble 
progeny virions. 
Flavivirus replication takes place in virus-induced ER-derived membranous 
structures (Welsch et al., 2009, Westaway et al., 1997). It is thought that the 
role of these structures is three-fold: to increase the local concentration of 
molecules required for virus replication thereby increasing the efficiency of the 
process, compartmentalisation to spatially coordinate translation and genome 
replication, and to evade immune detection by concealing foreign molecules 
such as dsRNA. The main structures induced by, and involved in, Flavivirus 
replication are membrane vesicles, vesicle packets and convoluted membranes. 
Membrane vesicles are derived from invaginations of the rough ER membrane, 
clusters of which are collectively termed vesicle packets; membrane vesicles 
possess a small pore linking to the cytoplasm, allowing the exchange of small 
molecules and viral RNA (Welsch et al., 2009).  
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Figure 1–4 The Flavivirus life cycle.  
The virus enters the host cell by receptor-mediated endocytosis and progresses through the 
endocytic pathway. Fusion of the viral and endosomal membranes is facilitated by pH-mediated 
conformational changes in the virus envelope protein. This fusion event releases viral RNA into the 
cytoplasm where it is transported to the ER. Viral RNA is translated to produce viral proteins which 
aid viral replication. The virus replicates its genome and forms particles within ER-derived 
membranous structures. Immature virus particles are transported through the trans-Golgi network 
whereby pH-mediated conformational changes of prM/E occur, producing a mature virus particle 
which can be released from the cell by exocytosis. prM is shed in the extracellular milieu. Particles 
which do not possess nucleocapsid structures can also be produced and are non-infectious – these 
are called sub-viral particles (SVPs). Figure from (Heinz and Stiasny, 2017) 
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NS5 and NS3 act cooperatively to provide the enzymatic activity required for 
RNA replication and 5’ capping. First, the positive sense RNA genome forms a 
cyclic structure via complementary sequences in the 5’ and 3’ UTRs, termed the 
cyclisation sequence (Khromykh et al., 2001). Flavivirus RNA (positive sense) 
acts as a template for minus strand synthesis (negative sense RNA); minus strand 
synthesis is required to provide templates for genome replication (Figure 1–5). 
NS5 recognition of a conserved stem loop in the 5’ UTR initiates RdRp activity, 
which generates dsRNA composed of both positive and negative sense RNA 
(Weber et al., 2006). The helicase activity of NS3 unwinds the dsRNA, liberating 
negative sense RNA to act as a template for the production of progeny viral RNA. 
Progeny viral RNA (positive sense) is capped and methylated prior to packaging. 
The triphosphatase activity of NS3 removes the terminal phosphate from the 5’ 
triphosphate, which is replaced with a guanosine monophosphate moiety by the 
action of the NS5 guanylyltransferase (Cui et al., 1998). The methyltransferase 
domain of NS5, using S-adenosyl-L-methionine as a methyl donor, methylates the 
cap structure at position N7, and the 2’-O position of the ribose of the first RNA 
nucleotide (Egloff et al., 2002, Issur et al., 2009). This results in a 5’ type 1 cap 
structure (m7GpppNm-RNA) on progeny viral genomes. 
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Figure 1–5 Flavivirus genome replication strategy 
The virus genome is released into the cytoplasm after fusion of the virus and endosomal membranes. 
The RdRp function of NS5 transcribes an anti-sense genome (minus strand synthesis) using the 
genome as a template; this produces a dsRNA intermediate. The helicase function of NS3 unwinds 
this intermediate structure so that the NS5 protein can transcribe positive sense RNA, this time using 
the negative strand as the template. This results in the formation of dsRNA composed of positive 
and negative sense RNA, in addition to a further copy of the positive sense RNA. The positive sense 
RNA can then be capped and methylated by the enzymatic action of NS3/NS5, and subsequently 
packaged into progeny virions. Created with BioRender. 
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1.2.3 Packaging and egress 
Nascent viral RNA exits the site of replication via a pore in the vesicle packet, 
allowing it to be packaged into budding virions which are formed at the opposing 
ER-derived membrane (Welsch et al., 2009). In order to generate the virus 
envelope, prM and E must form heterodimers, which further multimerise into 
heterotrimeric prM/E spikes at the ER membrane. This induces membrane 
curvature and facilitates the budding of immature virions into the ER lumen. To 
generate infectious virus particles, prior to budding, the nucleocapsid (capsid 
proteins associated with viral genomic RNA) must associate with prM/E – this 
process is poorly characterised. Once virions bud into the ER lumen, they enter 
the host cell secretory pathway, progressing through the trans-Golgi network. A 
series of post-translational modifications and conformational changes (section 
1.1.6) occur which generate the mature virus particle. Once released into the 
extracellular space by exocytosis, the pr portion of prM is shed, resulting in 
infectious progeny virions. 
 
Figure 1–6 Schematic representation of RNA replication and packaging 
Flavivirus replication and particle formation occurs within virus-induced ER-derived membranous 
structures. 1. Virus replication takes place within vesicle packets by the replication complex (RC). 
Nascent viral RNA is transported through a pore in the vesicle packet to the site of virus assembly. 
2. Progeny virus particles assembly on the cytosolic face of the ER membrane, and bud into the ER 
lumen to be transported through the exocytic pathway. Created with BioRender.    
1. 
2. 
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1.3 Zika virus 
1.3.1 The epidemiological history of ZIKV 
Zika virus (ZIKV) is a member of the Flavivirus genus of the family Flaviviridae. 
It was first isolated in 1947 from the serum of sentinel rhesus monkey enrolled in 
a YFV study, caged in a canopy of the Ziika forest (the namesake of the virus), 
Uganda (DICK et al., 1952). It was isolated again the following year in the same 
forest from a pool of A. africanus mosquitoes (DICK et al., 1952); the first human 
case was detected in Nigeria in 1954 (MACNAMARA, 1954, SIMPSON, 1964). In 
subsequent years, serological and entomological data indicated sporadic ZIKV 
infections occurred over West and Central Africa (Figure 1–7), and South-East 
Asia (Figure 1–8) (HADDOW et al., 1964, Marchette et al., 1969, Robin and 
Mouchet, 1975, Jan et al., 1978, Fagbami, 1979, Olson et al., 1981, Saluzzo et 
al., 1981, McCrae and Kirya, 1982, Darwish et al., 1983, Monlun et al., 1993, 
Lanciotti et al., 2008, Duffy et al., 2009, Heang et al., 2012, Haddow et al., 
2012).
 
Figure 1–7 Geographical distribution of documented evidence of ZIKV infection in Africa 
Evidence of ZIKV infection was either in the form of serological and entomological data or by virus 
isolation. The darker shading of orange represents more recent data was documented. Where two 
dates are shown for the same location, is indicative of two independent data points. This is a 
rendering demonstrating geographical distribution of ZIKV infection until February 2016. Figure from 
(Kindhauser et al., 2016). 
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The first documented epidemic occurred in 2007 in Yap island, Micronesia, 
where 49 residents had confirmed ZIKV infection and 73% had serological 
evidence of a recent ZIKV infection (Lanciotti et al., 2008, Duffy et al., 2009). 
Thereafter, outbreaks occurred in French Polynesia (2013), New Caledonia 
(2014), the Cook Islands (2014) and Easter Island (2014) (Figure 1–8 and Figure 1–
9) (Cao-Lormeau et al., 2014, Dupont-Rouzeyrol et al., 2015, Pyke et al., 2014, 
Tognarelli et al., 2016). Phylogenetic studies highlighted that the ZIKV 
sequences from the French Polynesian outbreak are more related to the strains 
from South-East Asia than those from the Yap island outbreak, which is 
indicative of independent introductions into Polynesia from Asia (Faye et al., 
2014).  
 
Figure 1–8 Geographical distribution of documented evidence of ZIKV infection across Asia 
and the Pacific  
Evidence of ZIKV infection was either in the form of serological and entomological data or by virus 
isolation. The darker shading of orange represents more recently acquired data. Two dates shown 
for the same location is indicative of two independent data points. This is a rendering demonstrating 
geographical distribution of ZIKV infection until February 2016. Figure from (Kindhauser et al., 2016). 
The largest ZIKV outbreak to date originated in the State of Bahia, Brazil in 2015 
which rapidly spread neighbouring states such as Pernambuco, then throughout 
Brazil and central America, with reports of ZIKV transmission reaching Florida, 
and further afield via travel imported cases (Figure 1–9) (Campos et al., 2015, 
Zanluca et al., 2015). By October 2015, Bahia reported 56,318 suspected cases 
of ZIKV infection; owing to the scale of the subsequent outbreak, Brazil ceased 
counting cases of ZIKV (WHO, 2015). The 2014 World Cup football tournament 
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and the Va’a canoe event (2014), both held in Rio de Janeiro, have been 
implicated in the introduction of ZIKV into Brazil. Conversely, one molecular 
clock analysis suggests that the introduction of ZIKV into Brazil predates both 
these events (Faria et al., 2016). The subsequent outbreak was declared a Public 
Health Emergency of International Concern (PHEIC) in February 2016 (WHO, 
2015). Symptomatic ZIKV infection is thought to occur in 1/5 patients, 
establishing a mild-febrile illness with a maculopapular rash (further details of 
ZIKV disease are explored in section 1.3.3). A curiosity of the 2015-2016 
outbreak was the unprecedented increase in the incidence of neurological 
disease complications, which were spatiotemporally associated with ZIKV 
infection. The aetiology of such conditions at the time were unknown, and as 
such was the precipitating factor for the declaration of ZIKV as a PHEIC. As of 
March 2017, the World Health Organisation (WHO) reported 61 areas with 
ongoing ZIKV transmission since its first introduction or reintroduction from 2015 
onwards (WHO, 2017). More recently a large, previously unreported outbreak in 
Cuba was identified retrospectively via a genomics approach; the outbreak in 
Cuba peaked in 2017, as ZIKV cases in the Americas were reported to be waning 
(Grubaugh et al., 2019).  
The ZIKV outbreak 2015-2016 was infamous due to the unprecedented increase 
in the number cases of neurological disorders, namely microcephaly and 
Guillain-Barré syndrome (discussed further in sections 1.3.3.3 and 1.3.4). 
Retrospective analyses of the 2013 ZIKV outbreak in French Polynesia, identified 
a 20-fold increase in the number of cases of Guillain-Barré syndrome, found to 
be associated with ZIKV infection (Cao-Lormeau et al., 2016). Evidence for a 
causal link between ZIKV infection and microcephaly was established through a 
series of case studies performed on post-mortem new-borns with microcephaly 
and suspected ZIKV infection (Martines et al., 2016, Mlakar et al., 2016, Driggers 
et al., 2016). Specimens, including tissue from the central nervous system, 
tested positive for ZIKV by RT-PCR and histopathologic methods; in one case, the 
virus was successfully isolated from the tissue (Mlakar et al., 2016). Since 2015, 
31 countries or territories have reported microcephaly or other central nervous 
system disorders potentially associated with ZIKV infection, and 23 countries or 
territories have reported ZIKV-related GBS (WHO, 2017).   
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Figure 1–9 Geographical distribution of documented evidence of ZIKV infection across 
Central and South America 
Evidence of ZIKV infection was either in the form of serological and entomological data or by virus 
isolation. The darker shading of brown represents more recently acquired data. Two dates shown for 
the same location is indicative of two independent data points. This is a rendering demonstrating 
geographical distribution of ZIKV infection until February 2016. Figure from (Kindhauser et al., 2016). 
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1.3.2 ZIKV transmission 
ZIKV is an arthropod-borne virus (arbovirus). Arboviruses are maintained in 
nature through transmission cycles between a vertebrate host and a 
hematophagous arthropod e.g. mosquitoes, ticks, midges and sandflies. ZIKV is 
primarily transmitted by Aedes species (Ae.) mosquitoes, in particular Ae. 
aegypti and Ae. Albopictus mosquitoes, which are prevalent in tropical and 
subtropical regions (Figure 1–10).  
The Ae. aegypti mosquito is predominantly active during the day and has a 
propensity to feed on human blood – though it will feed on other non-human 
vertebrates (Christophers, 1960). This mosquito has adapted to survive in close 
proximity to humans and breeds in artificial containers of fresh water e.g. pools 
of water collected in tyres, flower pots, water storage tanks etc (Christophers, 
1960). In addition to ZIKV, Ae. aegypti also transmit other arboviruses such as 
DENV, YFV and chikungunya virus.Ae. albopictus originated in tropical forests of 
South-East Asia; trade and travel practices have perpetuated the global 
dispersion of this mosquito species (ECDC, 2016). Ae. albopictus are more 
tolerant of milder temperatures than Ae. aegypti, as such Ae. albopictus can be 
found in abundance in southern regions of Europe (Figure 1–10) (Caminade et al., 
2012, Ding et al., 2018). Adult females are day biters, preferably feeding 
outdoors on a range of blood hosts including humans, mammals, birds, reptiles 
and amphibians. Ae. albopictus can breed in natural habitats such as bodies of 
fresh water held by terrestrial plants, and rock pools, in addition to artificial 
habitats such as tyres (ECDC, 2016). Like Ae. aegypti, Ae. albopictus can also 
transmit DENV and chikungunya virus; in experimental conditions Ae. albopictus 
serves as a competent vector of 22 other arboviruses of medical and veterinary 
concern including YFV, JEV and Rift Valley fever virus (Schaffner et al., 2013). 
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Figure 1–10 Predicted global distribution of Aedes species mosquitoes 
The probability of occurrence of Aedes aegypti (A) and Aedes albopictus (B) mosquitoes across the 
world (0-1). Red indicates regions highly suitable for growth (1), and blue regions which are less 
suitable (0). Aedes species mosquitoes are prevalent in tropical and sub-tropical regions. Aedes 
albopictus mosquitoes are more prevalent in Europe and Northern America, than Aedes aegypti. 
Some areas in Europe such as Italy and Spain may also provide suitable habitats for Aedes aegypti 
growth and survival. Figure from (Ding et al., 2018). 
A. 
B. 
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Transmission occurs when the mosquito ingests a viraemic blood meal taken 
from a vertebrate host; the virus then replicates within the mosquito, 
disseminating throughout the tissues via the arthropod haemolymph until it 
reaches the salivary glands. The virus can then be transmitted to a vertebrate 
through salivary secretions when ingesting the next bloodmeal (Figure 1–11). 
This cycle maintains many arboviruses in nature, and is usually dependent upon 
non-human vertebrates, with humans generally being considered a ‘dead-end 
host’. However, urban transmission cycles can be established whereby 
transmission is reliant solely upon human-mosquito transmission, as is the case 
for DENV and Chikungunya virus (Weaver and Reisen, 2010); this route of 
transmission can potentiate epidemics, and maintain a virus population within 
urban areas (Figure 1–11). Between 2015 and September 2019, there were no 
reports  of autochthonous transmission of ZIKV amongst mosquitos in Europe, 
despite an estimated 2130 travel imported cases being recorded since the 
outbreak in 2015 (ECDC, 2017). In October 2019, three cases of locally acquired 
ZIKV infection were confirmed in southern France (Hyères, Var department) 
(Giron et al., 2019). Investigations suggest that these cases provide the first 
evidence of mosquito (Ae. albopictus) transmitted ZIKV infection in Europe.  
In addition to mosquito-borne transmission, several other routes have been 
identified for the transmission of ZIKV including intrauterine transmission from 
mother to foetus, sexual transmission (male-female, female-male, male-male), 
and via contaminated blood products (Grischott et al., 2016). Furthermore, ZIKV 
RNA has been detected in several bodily fluids including saliva (Musso et al., 
2015a), breast milk (infective viral particles have also detected) (Dupont-
Rouzeyrol et al., 2016, Besnard et al., 2014), urine (Gourinat et al., 2015) and 
semen (Musso et al., 2015b). These fluids may be exploited for diagnostic 
purposes e.g. urine and saliva (see Section 1.3.3.2 for more information relating 
to ZIKV diagnostics). 
Maternal-foetal transmission of ZIKV is an important transmission route of 
serious biological consequence. This was highlighted by the 2015-2016 outbreak, 
whereby a rise in ZIKV-associated neurodevelopmental disorders was 
documented in neonates born to mothers who had been infected with ZIKV 
during pregnancy. ZIKV exhibits broad cellular tropism within the human 
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placenta including placental trophoblasts, fibroblasts, endothelial cells and 
Hoffbauer cells (foetal macrophages), in addition to umbilical cord tissue (El 
Costa et al., 2016, Miner and Diamond, 2017). It has been postulated that the 
breach of the maternal-foetal barrier is multifactorial and may involve a 
combination of: viral cytopathic effects, soluble factors which regulate immune 
trafficking, and antibody-virus complex formation (Pereira, 2018). However, the 
mechanisms underlying ZIKV maternal-foetal transmission remain to be 
determined. 
 
Figure 1–11Transmission cycles of the Zika virus 
It has been postulated that a sylvatic cycle exists for ZIKV, though this may be a historical feature of 
ZIKV transmission. Sylvatic cycles of arbovirus transmission occur between primates and the 
arthropod host. The arthropod (in the case of ZIKV, the Aedes aegypti mosquito) takes a bloodmeal 
from a viraemic primate, the virus replicates in the mosquito and is transmitted via salivary secretions 
upon subsequent bloodmeals from a ZIKV-naïve primate. Urban transmission cycles remain the main 
form of transmission for ZIKV. Like in the sylvatic cycle, the virus is transmitted between humans by 
the Aedes aegypti mosquito during blood feeds. An infected individual can also transmit the virus via 
other routes, including contaminated blood products during blood transfusions, sexual transmission 
and vertical transmission in utero. Figure adapted from (Rather et al., 2017). 
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1.3.3 ZIKV Disease and Diagnosis 
 Symptomatic ZIKV infection 
ZIKV typically establishes an asymptomatic infection, causing symptoms in 
roughly 20% of patients, resolving within a week of onset (SIMPSON, 1964, Filipe 
et al., 1973). Symptomatic ZIKV infection is characterised by a maculopapular 
rash, mild fever, malaise, pruritus (itching), arthralgia (joint pain), retro‐orbital 
pain/headache, myalgia (muscle pain/weakness), conjunctivitis, and/or oedema 
of the extremities (SIMPSON, 1964, Olson et al., 1981, Lanciotti et al., 2008, 
Duffy et al., 2009). In rare cases, severe clinical sequalae can occur, highlighted 
by recent ZIKV outbreaks (Cao-Lormeau et al., 2016, Mlakar et al., 2016). 
Guillain-Barré syndrome, a peripheral neuropathy, and congenital ZIKV syndrome 
are notable severe conditions associated with ZIKV infection (detailed further in 
section 1.3.3.3 and 1.3.4, respectively). 
 Diagnosing ZIKV infection 
The diagnosis of suspected ZIKV infection requires the collection of specimens, 
and obtaining a detailed patient history including: symptoms, date of onset, 
duration of symptoms, contact with known ZIKV cases, travel history and 
vaccination history (e.g. YFV, JEV, DENV) (WHO, 2016). At the time of the Brazil 
outbreak, the recommended specimens to be collected for nucleic acid testing 
(by RT-PCR) included whole blood, serum and/or urine (if symptom onset ≤ 7 
days prior) (WHO, 2016). For the diagnosis of patients who presented with 
symptom onset ≥ 7 days, serological testing of whole blood and serum (IgM and 
IgG enzyme linked immunosorbent assays; ELISAs) or plaque reduction 
neutralisation test (PRNT) was recommended (WHO, 2016). Serological 
diagnostic testing is particularly useful in diagnosing prior ZIKV infections, as the 
resultant viraemia is short-lived; however, serology cannot confirm active ZIKV 
infection (Fagbami, 1979, Shan et al., 2017, Lanciotti et al., 2008).  
Conventional molecular and serological diagnostic tests are performed in a 
laboratory setting, often requiring processing of specimens prior to the chosen 
diagnostic test. Furthermore, in some cases cross-reactivity with other related 
viruses, such as DENV, can occur (Singh et al., 2017). New methodologies which 
can be performed at point of care are being developed for rapid ZIKV 
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diagnostics, for example loop-mediated isothermal amplification (LAMP) based 
assays to detect ZIKV RNA (Silva et al., 2019). Reverse-transcription (RT) LAMP is 
a one-step method used to rapidly amplify and detect target RNA. Firstly, RNA is 
reverse transcribed into complementary DNA (cDNA). Target cDNA is then 
amplified using four specific primers which allow for the formation of loop 
structures, which drive the amplification of concatemer cDNA via a self-priming 
mechanism (Notomi et al., 2015). Unlike conventional PCR, target amplification 
doesn’t require thermocycling and instead occurs at one constant temperature 
(between 60-65 °C); furthermore RT-LAMP can be completed in under 1 hour. 
Detection of the amplified product can be performed by observing the turbidity 
and/or colour of the sample, either produced from magnesium pyrophosphate (a 
by-product of the reaction), or from inclusion of a fluorescent dye which reacts 
specifically with double-stranded DNA (Notomi et al., 2015). Moreover, this 
method is compatible with liquid specimens without the need for RNA extraction 
(Silva et al., 2019). However, further development is required prior to 
commercialisation.  
A combination of foetal ultrasound and neuroimaging techniques such as 
computed tomography (CT) and magnetic resonance imaging (MRI) scans can be 
used to detect some neurodevelopmental abnormalities associated with 
congenital ZIKV syndrome (de Fatima Vasco Aragao et al., 2016) (see section 
1.3.4 for more information of congenital ZIKV infection). 
 ZIKV-associated Guillain-Barré Syndrome (GBS) 
GBS is characterised by a rapidly progressive symmetrical weakness of muscles in 
the arms and legs, reduced tendon reflexes and sensory symptoms (Willison et 
al., 2016). However, disease progression and clinical presentation is variable 
between patients and can result in facial palsy, an inability to walk and 
respiratory distress, requiring hospitalisation (Leonhard et al., 2018). Patients 
recovering from GBS may need extensive physiotherapy, placing not only a 
substantial burden on the quality of life of the patient, but also a socio-
economic burden through loss of work.  
GBS is considered to be a post-infectious immune disorder, with two-thirds of 
patients reporting having had an infectious disease one month prior to the 
32 
 
clinical onset of GBS (Willison et al., 2016). Several pathogens have been 
associated with the development of GBS such as: Campylobacter jejuni, 
Mycoplasma pneumoniae, Haemophilus influenzae, cytomegalovirus, hepatitis E 
virus, and Epstein-Barr virus (Jacobs et al., 1998, Mori et al., 2000). More 
recently, ZIKV infection has been associated with GBS (Cao-Lormeau et al., 
2016). The current model underpinning the development of GBS is that an 
infectious agent triggers an inappropriate immune response which subsequently 
injures nerve components. Such is the case in GBS related to infection with C. 
jejuni (Yuki et al., 2004). The lipo-oligosaccharides of C.jejuni mimic 
gangliosides found on peripheral nerves, resulting in autoreactive antibody 
production – nerve components are injured as a consequence (Yuki et al., 2004). 
In ZIKV-associated GBS, some cases report the onset of GBS occurs in quick 
succession of, or even concurrent with symptomatic infection, challenging the 
post-infectious auto-immune paradigm of GBS development (Parra et al., 2016). 
Further investigation is required to understand whether ZIKV-associated GBS is a 
result of direct viral infection, or the elicitation of an aberrant immune 
response. 
1.3.4 Congenital ZIKV syndrome 
Microcephaly is the most striking physical phenotype associated with congenital 
ZIKV infection; microcephaly is a congenital disorder whereby the head 
circumference is smaller than the norm for the age and sex (below the 3rd 
percentile) (Figure 1–12). However, an expanding spectrum of 
neurodevelopmental disorders can occur in neonates as a result of ZIKV infection 
– collectively termed ‘congenital ZIKV syndrome’ (CZS). CZS is defined by the 
CDC as a proven, in utero ZIKV infection associated with severe microcephaly in 
which the skull has partially collapsed, decreased brain tissue with a specific 
pattern of brain damage (including subcortical calcifications), damage to the 
back of the eye, congenital contractures and hypertonia which restrict body 
movement soon after birth (CDC, 2019, Moore et al., 2017). However, this 
definition is still debated; other abnormalities are associated with ZIKV 
infection, including: brain asymmetry, craniofacial disproportion, hydrocephalus, 
neuronal migration disorders, excessive scalp skin, tremors, seizures in addition 
to ocular and hearing impairments (Culjat et al., 2016, de Fatima Vasco Aragao 
et al., 2016, Aragao et al., 2017, Leal et al., 2016, Moura da Silva et al., 2016, 
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Pessoa et al., 2018). Moreover, neonates who are born with a head 
circumference within the normal range display evidence of brain-abnormalities 
when assessed using neuroimaging methods (Aragao et al., 2017). 
 
Figure 1–12 Illustrative representation of a neonate with microcephaly 
A. Healthy human baby B. Human baby with microcephaly C. Human baby with severe microcephaly. 
Figure was redrawn from (CDC, 2019). 
Post-natal CT and MRI scans have identified numerous anomalies within the CNS 
of infants with presumed or laboratory confirmed ZIKV infection. These include: 
cortical thinning with abnormal gyral patterns, calcifications (primarily 
subcortical), increased fluid spaces, hypoplasia (underdeveloped or incomplete 
development of tissue) or absence of corpus callosum, cerebellar hypoplasia and 
decreased myelination (Aragao et al., 2017, de Fatima Vasco Aragao et al., 
2016, Chimelli et al., 2017). The gross morphological features of the brain which 
are affected by CZS, are shown in Figure 1–13.  
Even in the absence of CNS morphological anomalies, the potential for slow-
progressing, delayed-onset, chronic neurocognitive disorders remain. Studies in a 
non-human primate model of maternal-foetal ZIKV transmission demonstrate 
ZIKV infection depleted neural stem cells within late foetal neurogenic zones of 
the brain; this led to deficits in neuron maturation and patterning in the 
hippocampus (Adams Waldorf et al., 2018). Moreover, no foetal abnormalities 
were detected by ultrasound. However, foetal brain MRI scans did detect 
abnormalities in 4/5 foetuses which were infected with ZIKV (Adams Waldorf et 
al., 2018). Nonetheless, the damage to hippocampal neural stem cells should not 
be ignored. The hippocampus is involved in learning and memory; neurogenesis 
occurs within the hippocampus occurs in the human through to adolescence 
A. B. C. 
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(Gonçalves et al., 2016). If the findings of Adams Waldorf et al, 2018 are 
replicated in congenital ZIKV infection in humans, the affected individual could 
be at an increased risk of developing neurocognitive and psychiatric disorders 
later in life (Adams Waldorf et al., 2018, Walker et al., 2019). 
CZS is an expanding spectrum of neurodevelopmental disorders. Current 
antenatal ultrasound methodologies are unable to detect subtle neural 
pathologies associated with ZIKV and requires access to MRI imaging, which isn’t 
always feasible (Walker et al., 2019). Furthermore, some ZIKV-associated 
neurological injury may evolve over time. Therefore, non-microcephalic 
neonates which were exposed to ZIKV in gestation should be monitored in 
accordance with current guidelines (Adebanjo et al., 2017).  
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Figure 1–13 Key morphological features of the brain which are altered in congenital zika 
virus syndrome 
A schematic of the human brain in the sagittal plane (A) and axial plane (B), highlighting key 
structures implicated in congenital zika virus syndrome (CZS). In CZS, in addition to overall gross 
reduction in brain matter, the following morphological anomalies can occur: cortical thinning with 
abnormal gyral patterns, calcifications (primarily subcortical), increased ventricular spaces, 
hypoplasia or absence of corpus callosum, cerebellar hypoplasia and decreased myelination. 
Created using BioRender. 
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1.3.5 Teratogenic infections 
Teratogens are agents which disturb foetal development; toxoplasmosis (To), 
rubella (R), cytomegalovirus (C) and herpes simplex virus (H) are collectively 
termed ‘TORCH’ pathogens, which can cause congenital malformations and 
foetal/neonatal mortality. Since the term was coined, the O in TORCH has been 
replaced with ‘other’ to encompass an expanding spectrum of teratogenic 
infections caused by pathogens such as syphilis, varicella-zoster virus, parvovirus 
B19, hepatitis viruses, listeria, enteroviruses, Rift Valley fever virus and human 
immunodeficiency virus. ZIKV is the most recent addition to the group of TORCH 
infections.  
Cytomegalovirus (CMV) is the most common congenital viral infection in the USA 
and affects 5-7/100 live births in developed countries (Lanzieri et al., 2014). 
CMV is a member of the Herpesviridae family of viruses, classified further by the 
subfamily Betaherpesvirinae and genus, Cytomegalovirus (species: Human 
betaherpesvirus 5) (Davison et al., 2003). In terms of their virology, ZIKV and 
CMV are very distant. ZIKV possesses a single stranded positive sense RNA 
genome approximately 11 kb in length, which expresses 12 different gene 
products encoded on a single ORF. Whereas CMV possesses a linear dsDNA 
genome approximately 235 kb in length, comprising over 170 ORFs (Davison et 
al., 2003, Hage et al., 2017). Remarkably, despite their fundamental 
differences, ZIKV and CMV elicit similar clinical manifestations during congenital 
infection. 
CMV infection is asymptomatic in 85-90% of neonates; neurological sequelae 
occurs in >50% of symptomatic CMV-infected neonates at birth (Dollard et al., 
2007). CNS involvement may manifest as white matter abnormalities, 
calcifications, ventriculomegaly, cortical atrophy, cerebellar hypoplasia, cortical 
malformations (e.g. polymicrogyria or lissencephaly [smooth brain]) and 
periventricular cysts (Barkovich and Lindan, 1994, Lucignani et al., 2019). Other 
developmental disorders may be present, for example seizures, cognitive 
dysfunction, sensorineural hearing loss, learning disorders and microcephaly. 
Furthermore, delayed-onset sensorineural hearing loss has been documented in 
patients with asymptomatic congenital-CMV infection, indicating that 
neurological sequelae may continue to develop during childhood development 
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(Lanzieri et al., 2017). All of the aforementioned symptoms have been 
documented in CZS. The molecular mechanisms unpinning these events in both 
CMV and ZIKV infection are unknown and require further investigation.  
1.4 Project aims 
The 2015 ZIKV outbreak was characterised by an unprecedented upsurge in 
neurological disease in adults and neonates; namely Guillain-Barré syndrome and 
congenital ZIKV syndrome, which affect the peripheral and central nervous 
systems, respectively. Prior to this outbreak, ZIKV was associated with sporadic, 
small scale infections in man causing a mild self-limiting febrile illness in 20% of 
patients. Consequently, precedent studies of neurological disease complications 
associated with ZIKV infection were limited. 
The overarching aim of works undertaken in this thesis, was to advance the 
understanding of ZIKV interactions within cells of the central and peripheral 
nervous system.  
Objectives included: 
I. To develop and assess methods to study ZIKV in vitro. 
II. To characterise cell types of the central and peripheral nervous system 
which are permissive to ZIKV infection. 
III. To identify a relevant cell type and analyse changes in the transcriptomic 
profile of ZIKV infected cells compared with uninfected cells. 
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2 Materials and Methods 
2.1 Cell maintenance and passage 
2.1.1 Mammalian cell lines 
The cell line A549, was originally derived from human lung adenocarcinoma 
tissue, and are transformed alveolar basal epithelial cells. This cell line, and its 
derivatives were used to propagate ‘mammalian’ ZIKV PE243 virus stocks and 
used to titrate virus. A549 cells were grown in Dulbecco’s modified Eagles 
medium (DMEM) supplemented with 10% v/v heat inactivated foetal bovine 
serum (FBS; Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (10% 
DMEM). A549 cells expressing the bovine viral diarrhoea virus N terminal 
protease fragment protein (herein referred to as A549 Npro) render the cells 
type-I IFN incompetent by targeting IRF-3 for proteasomal degradation (Hilton et 
al., 2006). A549 Npro cells were maintained in A549 media supplemented with 
10 µg/mL puromycin. A549 Npro cells were kindly provided by R.E. Randall. Cells 
were maintained in 5% CO2 at 37 °C.  
The cell line, Vero E6 (provided by the lab of R.M. Elliott), was originally derived 
from kidney epithelial cells extracted from an African green monkey. This cell 
line was used to characterise a panel of previously untested antibodies raised 
against the ZIKV E and NS1 proteins (Section 3.3.1). Vero E6 cells were 
maintained in 10% DMEM, in 5% CO2 at 37 °C. 
SVGp12 (ATCC® CRL-8621™) is a cell line derived from human foetal astrocytes, 
transformed by the simian virus SV40 T-antigen. SVGp12 cells were maintained in 
10% DMEM, in 5% CO2 at 37 °C.  
The cell line SFT-R was originally derived from foetal sheep thymus cells.SFT-R 
cells were maintained by Jordan Clark using Iscove's Modified Dulbecco's Media 
(Gibco) supplemented with 10% (v/v) heat-inactivated FBS,in 5% CO2 at 37 °C. 
Lysate derived from SFT-R cells was used as a negative control when testing for 
the expression of GFAP by western blot. 
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When cells were approximately 80-90% confluent, old growth media was 
discarded, and cells were washed once with 5 mL of Versene in phosphate 
buffered saline (PBS; Versene in PBS, EDTA in PBS; E&O Laboratories Ltd). After 
washing, cells were incubated with 1x trypsin solution using a volume sufficient 
to cover the cell monolayer ([Merck] 10x diluted to 1x in Versene/PBS). Cells 
were incubated at 37 °C until the monolayer had detached from the plastic. The 
cells were resuspended in 10% DMEM, which inhibited the action of the trypsin. 
The cells were then pelleted by centrifugation at 1000 rpm for 5 minutes 
(ThermoScientific Heraeus Megafuge 16R, Rotor 75003181 [TX-400 swinging 
bucket rotor]). The supernatant was discarded, and cells were resuspended in an 
appropriate volume of fresh media until homogenous. A fraction of these cells 
were transferred to a fresh flask of appropriate size and fresh growth media was 
applied to cover the surface of plastic. Routine passaging of mammalian cells 
was typically performed using a 1:10 splitting ratio from resuspended cells. 
When a specific number of cells were required, cells were counted using a Bio 
Rad TC20™ automated cell counter (verified by manual cell count with a glass 
haemocytometer with each new cell line), the cells were then diluted as 
appropriate in their respective growth media and transferred to the desired 
plasticware and incubated at 37 °C until required. 
2.1.2 Primary mammalian cells 
Myelinating CNS and PNS cultures, and neuronal cultures were derived from the 
embryos of Ifnar1 knockout (KO; type I interferon incompetent) and wild type 
(WT) mice (A129 mice; 129S7/SvEvBrdBkl-Hprtb-m2 background [B&K Universal]) 
and were kindly provided by V Schultz and J Barrie. Myelinating CNS cultures 
were maintained in serum free differentiation medium (DMEM [4.5 mg/mL 
glucose], 100 U/mL penicillin, 100 μg/mL streptomycin, 10 ng/mL biotin, 1% N1, 
50 nM hydrocortisone, and 10 μg/mL insulin) (Cumberworth et al., 2017a). 
Myelinating PNS cultures were maintained in Minimal Essential Media [MEM 
4 mg/ml glucose], 100 U/ml penicillin, 100 μg/ml streptomycin, 5% horse serum, 
50 ng/ml nerve growth factor, 1% N2, 20 μg/ml bovine pituitary extract, 0.5 μM 
forskolin, 50 μg/ml ascorbic acid). Neuronal cultures were maintained in serum 
free neurobasal medium (NBM) either supplemented with or without 5-Fluoro-2’-
deoxyuridine. Cells were maintained in 5% CO2 at 37 °C. Growth media was 
replenished every 2-3 days by removing 40% of the old media and replacing with 
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60% of fresh growth media (to account for evaporation and prevent drying of 
cells). 
2.1.3 Invertebrate cell lines  
The cell line C6/36 was originally derived from whole larvae of the species Ae. 
albopictus. C6/36 cells were maintained in Schneider’s drosophila media 
supplemented with 10% FBS and 1% penicillin and streptomycin. Cells were 
incubated without CO2 at 28 °C in non-vented tissue culture flasks.  
At approximately 80% confluency, the growth media was removed from the cells 
and a volume of fresh media was applied to the cells. The cells were removed 
from the plastic using a cell scraper (Falcon) and resuspended by pipetting. A 
fraction of these cells was then transferred to a fresh flask containing the 
appropriate volume of growth media (1:15 ratio of resuspended cells:fresh 
media). Routine passaging took place in a non-vented T80 flask.  
2.2 Virus techniques 
2.2.1 Virus origin & propagation 
 Virus propagation of mammalian cell origin  
ZIKV isolates, ZIKV/H.sapiens/Brazil/PE243/2015 (abbreviated to ZIKV PE243, 
Gen Bank accession: KX197192 (Donald et al., 2016)) and MR766 (Gen Bank 
accession: AY632535), was propagated in A549 Npro cells. 
The culture media of a confluent T225 vented flask of A549 Npro cells was 
discarded and the monolayer was washed 1x with PBS. The PBS wash was 
discarded prior to incubation with virus diluted in 10 mL of 2% FBS/PBS to 
achieve a MOI of 0.1 (see section 2.2.3 for MOI calculation). The cells were 
incubated for 1 hour at 37 °C and gently rocked after 30 minutes. The virus was 
discarded, and the cell monolayer washed 1x with PBS prior to the addition of 
complete growth media (section 2.1.1) supplemented with 25 mM HEPES buffer 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The cells were incubated 
at 37 °C until substantial cytopathic effect (CPE) was observed, typically 3-5 
days post infection. The cell supernatant was harvested and clarified of debris 
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by centrifugation at 4000 rpm for 10 minutes (ThermoScientific Heraeus 
Megafuge 16R, Rotor 75003181 [TX-400]). Aliquots of clarified supernatant was 
stored at -80 °C until required. See section 2.2.2 for details of virus titration. 
 Virus propagation of invertebrate cell origin 
ZIKV isolate ZIKV/H.sapiens/Brazil/PE243/2015 was also propagated in mosquito 
cell line C6/36. The procedure follows that of section 2.2.1.1 with minor 
amendments to growth media and incubation conditions. C6/36 cells were 
maintained in Schneider’s drosophila media supplemented with 10% FBS, 1% 
PenStrep and 25 mM HEPES buffer. The cells were incubated in T80 non-vented 
tissue culture flasks at 28 °C without CO2. Cytopathic effect could not be used as 
an indicator of virus infection in invertebrate cells; therefore, cell culture 
supernatant was harvested 3-4 days post infection. The supernatant was clarified 
by centrifugation at 4000 rpm for 10 minutes (ThermoScientific Heraeus 
Megafuge 16R, Rotor 75003181 [TX-400]) and stored at -80 °C until required. 
2.2.2 Titration of virus by plaque assay 
ZIKV titres were determined by standard plaque assay using A549 Npro cells. 
Approximately 1 mL of cells were seeded at a density of 2.5 x 105 cells per well 
of a 12 well plate and incubated overnight at 37 °C (see section 2.1.1 for details 
of cell passage). 10-fold serial dilutions of the virus were performed using PBS 
supplemented with 2% v/v FBS. Growth media was discarded from each well and 
replaced with 200 µL of each dilution. Cells were incubated with virus dilutions 
for 1 hour at 37 °C with gentle agitation after 30 minutes. After incubation, 
virus was aspirated and discarded and replaced with 2 mL of overlay media per 
well (1.2% w/v Avicel [FMC Biopolymer]:2x MEM [Life technologies] 
supplemented with 4% FBS, in 50:50 ratio). The cells were incubated for a 
further 5 days at 37 °C prior to fixation with 8% formaldehyde/PBS at room 
temperature for 1 hour. The overlay and fixative were then discarded and 
replaced with 0.1% w/v toluidine blue stain (Sigma Aldrich). The cells were 
incubated in stain with agitation for 1 hour before the stain was gently washed 
away with tap water. Circular clearings in the stained cell monolayer were 
considered to be plaques and were subsequently counted. Virus plaque forming 
units (PFU)/mL was calculated by the following formula: 
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Plaque forming units (PFU)/mL = (
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑛𝑛𝑜𝑐𝑢𝑙𝑢𝑚 (𝑚𝐿)
) 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
2.2.3 Infection of cells with virus 
The appropriate volume of virus required for infection was determined using the 
following equation: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑥 𝑀𝑂𝐼
𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑟𝑒 
= 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 (𝑚𝐿) 
Virus was diluted in a suitable amount of infection media (2% FBS/PBS) to 
achieve the desired MOI and volume of inoculum. The total infectious volume 
used for a 12 or 24 well plate was 200 µL, and 600 µL for 30 mm dish containing 
3x coverslips of myelinating CNS cultures. Cellular growth media was aspirated 
from vessels and replaced with virus. Cells were incubated at 37 °C for 1 hour 
and gently rocked after 30 minutes to prevent monolayers from drying. Control 
mock infections were treated in parallel with infection medium only (2% 
FBS/PBS). Following incubation, infection medium (with or without virus) was 
aspirated and the cultures returned to the appropriate media for cell 
maintenance until required (as described in section 2.1).  
2.3 Nucleic acid methods 
2.3.1 Polymerase chain reaction (PCR) 
PCR amplification was performed using KOD Hot Start mastermix (ThermoFisher 
Scientific) using primers detailed in Table 2–1. The reaction mixture was set up 
as follows: 
25 µL of KOD hotstart mastermix 
1.5 µL of forward primer (at 10 µM) 
1.5 µL of reverse primer (at 10 µM) 
10 ng of template 
H2O to total reaction volume of 50 µL  
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Table 2–1 Primer sequences used to amplify the 3’UTR region of ZIKV 
 
The cycling conditions were as follows: 
Initial melting period, 2 minutes at 95 °C 
20 seconds at 95 °C (melting) 
10 seconds annealing time (70 °C for SP6 3’UTR FWD/3’UTR REV, 58 °C for 
qGSF/qREV – Table 2–1) 
10 second extension period at 70 °C 
Final 5-minute extension period at 70°C 
Steps 2-4 were repeated for 30 cycles.  
PCR products were separated by agarose gel electrophoresis (section 2.3.2) prior 
to gel purification (2.3.3) and a further round of PCR amplification using the 
sample primer pairs as the primary amplification. PCR products in solution were 
purified by ethanol precipitation (2.3.4) to remove reaction components and a 
sample of precipitated products were analysed by agarose gel electrophoresis to 
assess purity.  
2.3.2 Agarose gel electrophoresis of DNA 
Separation of DNA fragments was achieved using agarose gel electrophoresis. 
Agarose gels were prepared by adding agarose to Tris-acetate-EDTA (TAE; 1x 
TAE, 40 mM Tris, 10 mM acetic acid, 1mM EDTA; ThermoFisher Scientific) buffer 
to a final concentration between 1-2% w/v (depending on fragment sizes to be 
resolved). The agarose/buffer mix was heated until the agarose had completely 
Name Sequence 
SP6 3’UTR 
FWD 
ATTTAGGTGACACTATAGAGCACCAATCTTAATGTTGTCAGGCCTG 
3’UTR REV CCATGGATTTCCCCACACCGGC 
qGSF  CGCTACTTGGGTGAAGAAGG 
qREV  GCGTTCTCGGCCTGACTATAG 
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dissolved, then allowed to cool before the addition of 0.5 µg/mL ethidium 
bromide (EtBr). The solution was poured into a gel sled, a well forming comb 
added at the top of the gel and the gel was allowed to set at room temperature. 
The sled was submerged in TAE buffer inside a horizontal gel electrophoresis 
tank (Bio-Rad) and the well-forming comb was removed. Samples were mixed 
with 6x loading dye (New England Biolabs) and loaded into the gel alongside 
either a 100 bp or 1 kb DNA ladder (New England Biolabs) to facilitate the 
measurement of DNA fragments. Gels were run at 100 V for 40 minutes. Nucleic 
acids were visualised by UV transillumination (Bio-Rad). 
2.3.3 DNA extraction and purification from agarose gel 
DNA products were first separated and visualised as described in section 2.3.2. 
The band of interest was excised from the gel using a scalpel and transferred to 
a fresh 1.5 mL tube. The tube was weighed and the weight of the gel slice 
calculated. The DNA was extracted from agarose gel slices using the Illustra GFX 
PCR DNA and Gel band purification Kit (GE Healthcare) in accordance to the 
manufacturer’s suggested protocol. Briefly, 10 µL of capture buffer was added to 
the tube per 10 mg of gel. The sample was heated to 60 °C for up to 30 minutes, 
until the gel slice had melted. The sample was then transferred to a microspin 
column placed inside a collection tube and centrifuged at 13,500 rpm for 1 
minute (Eppendorf Centrifuge 5418, Rotor FA-45-18-11). The flow through was 
discarded and filter was washed 2x with wash buffer with 1 minute 
centrifugation at 13,500 rpm (Eppendorf Centrifuge 5418, Rotor FA-45-18-11) 
between washes. Following the last wash step, the column was subjected to a 
further 2 minute centrifugation step. The spin column was transferred to a fresh 
tube and the DNA products were eluted by applying 25 µL of nuclease free water 
which had been preheated to 60 °C. The water was allowed to incubate on the 
filter for 5 minutes prior to centrifugation at 13,500 rpm (Eppendorf Centrifuge 
5418, Rotor FA-45-18-11) for 2 minutes. Eluted products were quantified and 
stored at -20 °C until required. 
2.3.4 Ethanol precipitation of nucleic acid products in solution 
0.1 volumes of 3 M sodium acetate pH 5.2 and 2.5 volumes of ice-cold 100% 
ethanol was added to DNA samples in 1.5 mL microcentrifuge tubes. For RNA 
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samples, 2.5 volumes of ice-cold 100% ethanol and ammonium acetate to a final 
concentration of 2.5 M was added. The sample was mixed briefly by inversion. 
Samples were stored at -80 °C overnight to precipitate the nucleic acid. Nucleic 
acid was recovered by centrifugation at 16,000x rpm for 30 minutes at 4 °C 
(Eppendorf Centrifuge 5418, Rotor FA-45-18-11). The supernatant was discarded 
and the DNA/RNA pellet was washed 2x with 70% ethanol with 5 minutes 
centrifugation at 16,000 x rpm (Eppendorf Centrifuge 5418, Rotor FA-45-18-11) 
at 4 °C in between washes. The DNA/RNA pellet was allowed to air dry for 5-10 
minutes before resuspending in an appropriate volume of distilled water (or 
RNase free water for RNA samples). Samples were quantified as per section 
2.3.5. DNA samples were stored at -20 °C and RNA samples were stored at -80 
°C until required.   
2.3.5 Quantification of nucleic acids 
Nucleic acid yields were quantified using a NanoDrop ND-1,000 
spectrophotometer (Thermo Fisher Scientific). In addition to concentration, 
sample purity was assessed by observing the 260/280 and 260/230 ratios. For 
DNA, samples possessing a 260/280 ratio ~1.8 is considered ‘pure’. The 260/280 
ratio is ~2.0 for ‘pure’ RNA samples. The 260/230 ratio is an additional measure 
of nucleic acid purity. Ratio’s lower than 2.0-2.2 may be an indicator of 
contaminants which absorb and 230 nm, such as TRIzol® reagent.   
2.3.6 Sequencing of PCR products 
To verify the successful amplification/modification of products of interest, 
samples were sent for sequencing at Source Biosciences alongside the 
appropriate primers. Resulting sequences were analysed using Geneious version 
7.0 (http://www.geneious.com, (Kearse et al., 2012)). 
2.3.7 In vitro RNA transcription of ZIKV 3’UTR from SP6 promoter 
The template for transcription was generated by PCR amplification of the 3’UTR 
region from the plasmid pCCl-SP6-ZIKV* WT (donated from Prof A. Merits, 
University of Tartu; contains 5’ and 3’ UTRs from ZIKV PE243) using primer pairs 
found in section 2.3.1 (SP6 3’UTR FWD and 3’UTR REV). The reaction generated 
PCR products of the ZIKV PE243 3’ UTR possessing an SP6 promoter immediately 
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upstream of the start of the 3’UTR. PCR products were separated by agarose gel 
electrophoresis and was subsequently purified (section 2.3.2-2.3.3). The purified 
PCR products underwent a further round of PCR amplification using the same 
primer pair as previously described, prior to purification by ethanol precipitation 
(section 2.3.4). A sample of purified PCR products was analysed by agarose gel 
electrophoresis to check the product quality.   
The ZIKV 3’UTR was transcribed using the MEGAscript™ SP6 Transcription Kit 
(Thermo Fisher Scientific). The reaction was set up as described in Table 2–2. 
The reaction was incubated in a PCR cycler overnight at 37 °C. To digest the 
DNA template, 1 µL of TURBO DNase (Thermo Fisher Scientific) per 20 µL 
reaction was added, the samples were briefly mixed and collected by 
centrifugation prior to a further 15 minute incubation at 37 °C. The RNA was 
purified by ethanol precipitation as described in section 2.3.4. 
 
Component Amount per 20 µL reaction 
Biotin-16-UTP (Jena Biosciences) 0.7 mM 
UTP 1.3 mM 
ATP 5 mM 
CTP 5 mM 
GTP 8 mM 
10 x Reaction buffer  2 µL 
SP6-3’UTR template 1 µg 
SP6 enzyme 2 µL 
H2O Total to 20 µL 
Table 2–2 Components of in vitro transcription reaction to produce biotinylated 3’UTR RNA 
In vitro transcription was performed suing the MEGAscript™ SP6 Transcription Kit (Thermo Fisher 
Scientific), and the protocol modified to include biotin-16-UTP, and varying amounts of nucleotides, 
as described in (Chavali et al., 2017). 
 
2.3.8 Denaturing agarose gel electrophoresis of RNA  
The quality of in vitro transcribed RNA was assessed by denaturing agarose gel 
electrophoresis. To make a 1% gel, 1 g of agarose was dissolved in 72 mL of 
distilled water by boiling. Once dissolved, 18 mL of 37% formaldehyde and 10 mL 
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of 10 x MOPS (3-(N-morpholino)propanesulfonic acid) running buffer (1X MOPS 
buffer, 50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1mM EDTA, pH 7.7; 
ThermoFisher Scientific) was added to the solution inside a fume cupboard and 
mixed. An appropriate amount of the gel solution was poured into a gel sled with 
a well forming comb, both of which had been treated with RNaseZAP (Sigma 
Aldrich) prior to the addition of the gel. The gel was allowed to set at room 
temperature.  
Once the gel had set and samples were prepared, the gel sled was submerged in 
1 x MOPS running buffer, the well forming comb was removed and appropriate 
volumes of the samples were added. Samples were run at 100V for 1.5-2 hours. 
The samples were visualised by UV transillumination. 
2.3.9 Isolation of total cellular RNA – TRIzol ®  
To extract total cellular RNA from cell culture, cell culture supernatant was 
discarded and the appropriate volume of TRIzol ®  (Thermo Fischer Scientific) 
was added to the cells for harvest (1 mL per well of a 12 well plate or CNS 
culture dish, 333 µL for PNS samples in 24 well plate [3x wells were pooled to 
give 1 sample]). Cells were incubated with TRIzol ® for 5 minutes prior to 
resuspension and transfer to a fresh RNase-free tube. Samples were stored at -
80 °C until required.  
Samples for RNA extraction were defrosted and 200 µL of chloroform was added 
per 1 mL of TRIzol ®. Samples were vortexed for 15 seconds prior to 
centrifugation at 10,500 rpm at 4 °C (Eppendorf Centrifuge 5418, Rotor FA-45-
18-11). The upper phase (water phase) was carefully removed and transferred to 
a fresh RNase free tube. 0.5 µL of RNase free glycogen (10 mg/mL) and 500 µL of 
isopropanol per 1 mL of TRIzol ® was added to the upper phase, mixed briefly 
and incubated for 10 minutes at room temperature. The sample was subjected 
to centrifugation for 10 minutes at 10,500 rpm at 4 °C to pellet the RNA 
(Eppendorf Centrifuge 5418, Rotor FA-45-18-11). The RNA pellet was washed 2 x 
with 500 µL of 70% ethanol with a 10 minutes centrifugation at 4 °C in between 
washes. The pellet was then air dried prior to resuspension 35 µL of nuclease-
free water. RNA samples were stored at -80 °C until required.  
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2.3.10 Reverse transcription PCR (RT-PCR) 
cDNA synthesis was performed using the SuperScript™ III First-Strand Synthesis 
System (Invitrogen). Reactions were performed in 0.2 µL thin walled PCR tubes. 
Briefly, 1 µg of total cellular RNA was incubated with 1 µL random hexamer 
primers, µL dNTPs and water to total 10 µL. Samples were mixed and incubated 
at 65 °C in a PCR thermocycler for 5 minutes and returned to ice for 1 minute. 4 
µL of 5 x buffer, 3 µL of H2O, 1 µL of DTT, RNaseOUT and SuperScript™ III were 
added to the sample to total 20 µL. The reaction was incubated at 50 °C for 1 
hour followed by a 10-minute incubation at 70 °C to terminate the reaction. 
cDNA samples were stored at -20 °C until required.  
2.3.11 Quantitative PCR (qPCR)  
 General qPCR methodology  
qPCR protocols were performed using the standard curve method. qPCR standard 
were generated by PCR amplification (Section 2.3.1) of the pCCl-SP6-ZIKV* WT 
plasmid using primers qGSF and qREV, and purified as described in sections 
2.3.2-2.3.4. The PCR product was quantified as described in section 2.3.5 and 
10-fold serial dilutions were performed.  
A qPCR master mix was prepared inside a PCR cabinet (Sartorius) and contained 
the following per well: 
10 µL SYBR™ Green PCR Master Mix (Thermo Fisher Scientific) 
1 µL forward primer (from 10 µM stock) 
1 µL reverse primer (from 10 µM stock)   
7 µL RNase free H2O 
 
1 µL of cDNA sample or PCR standard was added to the master mix outside of the 
PCR cabinet, in a different room. The reaction mixture was then applied to a 96 
well qPCR plate in triplicate.  
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 Absolute quantitation of sfRNA vs genomic RNA (gRNA)  
ZIKV sfRNA and gRNA levels were quantified using a differential qPCR assay 
based upon that described in (Bidet et al., 2014). Samples were prepared as per 
section 2.3.11.1. Each qPCR plate contained a range of standards from 0.000927 
ng/µL – 0.927 ng/µL and cDNA samples prepared with primer pairs qGSF/qREV 
and qSF/qREV, cDNA samples prepared with internal control primers GAPDH 
FWD/GAPDH REV, in addition to water only negative controls (primers detailed 
in Table 2–3). One primer specifically recognises gRNA only (qG) by annealing 
upstream of the stop codon of ZIKV PE243, in the NS5 coding region. The other 
primer recognises a region downstream of the stop codon, within the 3’UTR, 
which is shared by both sfRNA and gRNA (qGSF). The reverse primer is shared by 
both forward primers (qREV). To determine the amount of sfRNA, the following 
equation was used: 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑓𝑅𝑁𝐴 =  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐺𝑆𝐹 − 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐺  
 
Name Sequence 
qG  CGCTACTTGGGTGAAGAAGG 
qGSF GTTGTCAGGCCTGCTAGTCAG 
qREV GCGTTCTCGGCCTGACTATAG 
GAPDH FWD (donated by C.Donald) TGCACCACCAACTGCTTAGC 
GAPDH REV (donated by C.Donald) GGCATGGACTGTGGTCATGAG 
Table 2–3 Primers used to determine quantity of genomic and sfRNA, including internal 
control primer pairs 
 
2.4 Cellular protein composition analysis  
2.4.1 Cell lysis & preparation for western blot 
Cell culture supernatant was discarded, and cells washed 1x in sterile PBS. The 
cells were lysed in an appropriate volume of ice-cold lysis buffer (25 mM Tris HCl 
pH 7.6, 150 mM KCl, 5mM EDTA pH 8. 5 mM MgCl2, 1% NP40, 0.1% mM 
dithiothreitol [DTT] (Chavali et al., 2017)) supplemented with cOmplete™ mini 
protease inhibitor cocktail (Roche) and 100 U/ml RNAse OUT (Thermo Fisher 
Scientific) prior to use. The lysate was clarified of insoluble cellular debris by 
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centrifugation at 16,000 rpm (Eppendorf Centrifuge 5418, Rotor FA-45-18-11) for 
5 minutes. The cell lysate was then transferred to a fresh 1.5mL tube and 10x 
Bolt™ Sample Reducing Agent and 4X Bolt™ LDS Sample Buffer (both Thermo 
Fisher Scientific) were added to equal 1X solutions. Protein samples were heated 
at 90 °C for 10 minutes to denature the sample and stored at -20 °C until 
required.  
2.4.2 Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
Samples were prepared as described in section 2.4.1.1 and loaded into Bolt™ 4-
12% Bis-Tris Plus gels (Invitrogen) whilst submerged in 1x Bolt™ MES SDS running 
buffer (Invitrogen). Protein samples were run alongside a sample of SeeBlue™ 
Plus2 Pre-stained Protein Standard (Thermo Fisher Scientific) to aid in size 
determination in downstream applications. Gels were run at 100V for 
approximately 45 minutes, or until the loading dye appeared 2/3’s down the 
length of the gel. Protein gels were either analysed by western blot (sections 
2.4.1.3-2.4.1.4) or stained for total protein composition (section 2.3.1.5). 
2.4.3 Protein transfer 
Proteins were transferred onto a 0.45 μm nitrocellulose membrane (Thermo 
Fisher Scientific) using a Tran-Blot SD semi-dry transfer cell (RioRad) and semi-
dry transfer buffer (48 mM Tris, 39 mM glycine, 0.0375% (w/v) SDS, 20% (v/v) 
methanol) at 15 V for 30 min. The following was assembled and placed into the 
semi dry transfer machine in the following order (1 being closest to the top, 4 
being closest to the bottom): 
1. Whatman 2mm filter paper (soaked in 1x semi-dry transfer buffer) 
2. SDS-PAGE gel (released from original cassette) 
3. Nitrocellulose membrane (soaked in dH2O) 
4. Whatman 2mm filter paper (soaked in 1x semi-dry transfer buffer) 
Protein transfer was carried out at 15V for 35 minutes. 
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2.4.4 Immuno-detection 
Protein samples were transferred to a nitrocellulose membrane as described in 
section 2.4.1.3. The membrane was incubated with agitation in blocking buffer 
(1x PBS, 0.1% v/v Tween-20, 5% w/v non-fat dried milk [Marvel]) for 1 hour at 
room temperature. Following blocking, the membrane was incubated overnight 
at 4 °C with agitation, in the appropriate primary antibody diluted in blocking 
buffer (see table Table 2–4 for primary antibodies). The membrane was washed5 
times for 2 minutes in PBST solution (1x PBS, 0.1% v/v Tween-20). The 
membrane was then incubated with the appropriate secondary antibody (Table 
2–4) diluted in blocking buffer for 45 minutes (secondary antibody with 
fluorescent conjugate) or 1.5 hours (horseradish peroxidase conjugated 
secondary antibody) at room temperature. A further  five 2-minute washes in 
PBST solution was performed prior to protein band visualisation.  
Membranes probed with a secondary antibody conjugated with horseradish 
peroxidase were incubated with Pierce™ ECL (enhanced chemiluminescence) 
Western Blotting Substrate (ThermoFisher Scientific) in accordance with 
manufacturer protocols. Protein bands were visualised by exposing X-ray film to 
the western blot membrane. Western blot membranes processed in this way can 
be found in Chapter 3 only. Western blot membranes probed with a secondary 
antibody conjugated with a fluorescent marker were visualised using a Li-cor 
Odyssey imaging system (Li-cor Biosciences). 
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Antibody name Species Working dilution 
Anti-ZIKV E (clone 0402166, Aalto Bio 
Reagents) 
Mouse 1:5000 
Anti- β-Actin (Sigma-Aldrich) Rabbit 1:2000 
Anti- β-tubulin (Abcam) Mouse 1:5000 
Anti- Musashi-1 (Abcam) Rabbit 1:2000 
Goat anti-mouse IgG conjugated with 
horseradish peroxidase (Abcam) 
Goat 1:2000 
Goat anti-mouse IgG (H+L) cross-adsorbed 
secondary antibody, Alexa Fluor ® 700 
(ThermoFischer Scientific) 
Goat 1:10,000 
Goat anti-rabbit IgG (H+L) cross-adsorbed 
secondary ntibody, Alexa Fluor ® 800 
(ThermoFischer Scientific) 
Goat 1:10,000 
Table 2–4 Antibodies used in Western blot protocols  
Secondary antibodies are highlighted grey. Secondary antibodies conjugated with horseradish 
peroxidase were used to visualise western blot membranes by film exposure. Secondary antibodies 
conjugated with a fluorescent marker (Alexa Fluor ®) were used to visualise western blot membranes 
using the Li-cor Odyssey imaging system (Li-cor Biosciences).  
2.5 Total protein composition analysis 
Cell lysates were prepared as per section 2.4.1.1 and run on a SDS-PAGE as 
described in section 2.4.1.2. The protein gel was washed in dH2O for 5 minutes, 
then removed and replaced with SYPRO® orange protein gel stain (SYPRO® 
[Thermo Fisher Scientific] diluted 1:5000 in 7.5% acetic acid in H2O) for total 
protein composition. The gel was incubated in staining solution for 30 minutes 
with agitation whilst wrapped in tin foil as the reagent was light sensitive. 
Following incubation, the stain was removed, and the gel was washed 3x with 
H2O for 5 minutes a time. The gel was visualised by UV transillumination.  
2.6 Immunostaining 
CNS and PNS co-cultures were cultured in dishes containing glass coverslips 
(section 2.1.2). Coverslips possessing fixed cells were permeabilised in 1 mL of 
PBS containing 0.5% v/v Triton X-100 for 15 minutes. Coverslips were then 
incubated with blocking buffer (PBS supplemented with 5% FBS) for 1 hour. The 
blocking buffer was then aspirated and discarded prior to incubation with the 
appropriate primary antibody (as detailed in Table 2–5) for 2 hours at room 
temperature. Coverslips were then washed 3x with PBS prior to incubation with 
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the appropriate secondary antibody (detailed in Table 2–5) for 1 hour at room 
temperature. Coverslips were then washed 3x with PBS followed by 2x washes 
with distilled water. Coverslips were then mounted onto glass slides using 
VECTORSHEILD® with DAPI mounting media (Vector Laboratories) and sealed 
with nail enamel. Immunofluorescence images were taken using EVOS Fl cell 
imaging system. 
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Antibody name Molecular/Cellular target Working dilution  
Mouse anti-ZIKV E (clone 
0402166, Aalto Bio 
Reagents ) 
ZIKV envelope protein 1:500 
Rabbit anti-NeuN 
(Millipore) 
Neuronal nuclei, NeuN 
(Fox-3) 
1:750 
Rabbit anti-SMI31 
(Biolegend) 
Phosphorylated 
neurofilament (axons) 
1:1500 
Rat anti-MBP (AbD serotec) 
Myelin basic protein 
(myelin sheath) 
1:500 
Rat anti-PLP/DM20 (clone 
AA3, donated by 
Dr.Steven Pfeiffer) 
PLP/DM20 (myelin 
components and 
oligodendrocyte cell 
bodies) 
1:400 
Rabbit anti-GFAP (Dako) 
Glial fibrillary acidic 
protein (astrocytes) 
1:400 
Rat anti- F480 (AbD 
serotec) 
F4/80, an adhesion G 
protein coupled receptor 
(microglia) 
1:600 
Rabbit anti-NG2 (Millipore) 
NG2 – an integral 
membrane proteoglycan 
(oligodendrocyte 
precursor cells) 
1:200 
Mouse anti- Olig2 (Abcam) 
Olig2 – oligodendrocyte 
transcription factor 2 
(immature and mature 
oligodendroglia) 
1:200 
Goat anti-mouse IgG Alexa 
Fluor ® 488 (Invitrogen) 
Mouse IgG 1:10,000 
Goat anti-rabbit IgG Alexa 
Fluor ® 594 (Invitrogen) 
Rabbit IgG 1:10,000 
Goat anti-rat IgG Alexa 
Fluor ® 594 (Invitrogen) 
Rat IgG 1:10,000 
Table 2–5 Primary and secondary antibodies used in immunofluorescence protocols 
Secondary antibodies are highlighted grey. All primary antibodies were incubated at room 
temperature for 2 hours; all secondary antibodies were incubated at room temperature for 1 hour.  
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2.7 3’UTR RNA pull down 
2.7.1 Cell lysate preparation 
Two confluent T225 flasks of A549 cells were infected at MOI 2 as per section 
2.2.3. At 24 hours post infection (h p.i.) the cell culture supernatant was 
discarded and the monolayer washed 2x with ice cold PBS. Per each T225 flask, 
Cells were lysed in 5 mL of ice-cold lysis buffer (as described in section 2.4.1.1). 
Prior to use, the lysis buffer was supplemented with cOmplete™ mini protease 
inhibitor cocktail (Roche), 100 U/mL RNAse OUT (Thermo Fisher Scientific). 
Lysates from 2x T225 flasks were pooled for each replicate to give 10 mL of 
lysate. The lysate was then clarified and stored as described in section 2.4.1.1. 
2.7.2 Bead preparation 
MyOne Streptavidin c1 Beads (Thermo Fisher Scientific) were transferred to a 
fresh RNase free tube and placed in a magnetic tube rack. The storage buffer 
was discarded and beads were washed 2x by resuspending in an equal volume of 
wash buffer (lysis buffer containing 300 mM KCl (Chavali et al., 2017)). The 
beads were then separated from wash buffer in the magnetic stand and beads 
were resuspended in an equal volume of lysis buffer. 
2.7.3 Pull down assay 
Cell lysates (prepared as per section 2.4.3.1) were defrosted and precleared by 
incubating with 50 µL of prepared MyOne Streptavidin T1 Beads (as detailed in 
2.4.3.2) for 30 minutes at 4 °C, with rotation. The lysate was separated from 
the beads using a magnetic rack and 5 mL of lysate was transferred to 2x fresh 
15 mL tubes. To one of the tubes, 50 pmol of biotinylated ZIKV 3’ UTR was 
added. The lysate was then left to incubate with or without RNA for 2 hours at 4 
°C, with rotation. RNA:protein interactions were precipitated by incubating with 
50 µL of prepared MyOne Streptavidin T1 Beads (Thermo Fisher Scientific) for a 
further 1 hour at 4 °C, with rotation. RNA:protein:bead complexes were 
separated from lysate using a magnetic rack. The beads were then washed 3x by 
resuspending the beads with washing buffer (detailed in section 2.4.3.1) to 
reduce non-specific binding to beads. The beads were separated from the wash 
buffer using a magnetic rack and the buffer was discarded. The beads were then 
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resuspended in 40 µL of sample buffer (10x Bolt™ Sample Reducing Agent and 4X 
Bolt™ LDS Sample Buffer, diluted to 1x in nuclease free H2O [both Thermo Fisher 
Scientific]). The samples were then denatured by heating to 90 °C for 10 
minutes, cooled by centrifugation at 13,500 rpm (Eppendorf Centrifuge 5418, 
Rotor FA-45-18-11) for 1 minute and analysed by SDS PAGE and western blot 
(section 2.4.1). 
2.8 Methods involving CNS and PNS co-cultures 
CNS and PNS co-cultures were prepared as previously described in Section 2.1.2. 
2.8.1 Analysis of cell-type specific infection levels in CNS and 
PNS cultures  
CNS and PNS co-cultures were infected on DIV24 with ZIKV (MOI either 0.3 or 3 
PFU/cell) and fixed at 24- or 72 h p.i by incubating with 4% formaldehyde 
(diluted in PBS) for 1 hour at room temperature. The cells were immunolabelled 
as per Section 2.6. For cell quantification, fluorescence microscopy and image 
capture were performed using an Olympus IX70 microscope using Image Pro Plus 
6 software. Ten images per coverslip (minimum of 2 coverslips per cell 
type/infection condition) were taken using the 20x objective. To avoid bias, 
fields of view were selected in the blue (DAPI) channel, following the pattern 
below: 
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Rectangular areas of interest (AOI) of 148,427 μm2 (to enumerate cell type 
specific and ZIKV cells) and 20,000 μm2 (to enumerate DAPI positive cells) were 
placed on each image; cells within and touching west and north borders were 
quantified. Cells were defined as immunopositive structures with a DAPI positive 
nucleus. Pyknotic nuclei were identified based on size, and homogeneity and 
intensity of DAPI staining; pyknotic nuclei being small, condensed and intensely 
labelled. The average cell density per AOI was converted to cells/mm2 using the 
formula: 
Cells/mm2 = cell density per AOI/area of AOI μm2 x 1,000,000 
Representative images for illustration were obtained using a Zeiss LSM 710 
inverted confocal microscope and Zen Black software. 
2.8.2 Extended ZIKV infection in CNS co-cultures 
CNS co-cultures were infected on DIV18 with ZIKV using a MOI of 0.3 PFU/cell. 
Media replenishments occurred every 2 days (detailed in section 2.1.2). At 6 d 
p.i cells were fixed by incubating in 4% formaldehyde at room temperature for 1 
hour. Cells were immunolabelled using antibodies targeting axon and myelin 
structures, detailed in Section 2.6. Imaging was performed as per Section 2.8.1.  
 Assessing the role of soluble factors in inducing white matter 
structure injury 
Cell culture supernatant was harvested from cells in Section 2.8.2, at 6 d p.i and 
infectious virus particles inactivated by exposure to UV-C light (8 W; 254 nm at a 
distance of 2 cm for 4 minutes, with shaking after 2 minutes) (Rezelj et al., 
2017). UV-treated supernatant was mixed with fresh media (75% UV-
supernatant, 25% fresh media). The mixture was transferred onto fresh DIV18 
CNS co-cultures; cells were incubated with UV-supernatant for 6 days with media 
replenishments taking place on days 2 and 4 (media replenishment mixture 
contained both UV-supernatant and fresh media in a ratio of 1:1). On day 6, cells 
were fixed by incubating in 4% formaldehyde at room temperature for 1 hour. 
Cells were immunolabelled using antibodies targeting axon and myelin structure, 
as well as ZIKV E to confirm the absence of active viral infection 
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(immunolabelling details can be found in Section 2.6. Imaging was performed as 
per Section 2.8.1. 
2.8.3 Transcriptomic analysis of mixed cell CNS cultures 
 Sample preparation 
 Infection of CNS cells  
Primary murine CNS cultures (described in Sections 2.1.2 and  4.2.2, kindly 
provided by V Schultz and J Barrie) were infected with ZIKV PE243 at MOI 1 (as 
described in section 2.2.3) on culture day 28 in vitro (DIV28). At 48- and 96-
hours post infection, cell culture supernatant was removed and discarded, and 1 
mL of Trizol reagent was applied to per 35 mm dish. Cells were incubated with 
Trizol reagent for 5 minutes at room temperature prior to resuspension and 
placement into a fresh 1.8mL cryotube and stored at -80 °C until required. 
 RNA extraction for RNAseq 
Trizol samples were defrosted at room temperature. Once thawed, 200 uL of 
chloroform was added per 1 mL of Trizol sample and vortexed for 15 seconds 
until thoroughly mixed. Samples were allowed to rest for 2 minutes at room 
temperature prior to centrifugation at 12,500 rpm (Eppendorf Centrifuge 5418, 
Rotor FA-45-18-11) at 4 °C . The upper water phase was then transferred to a 
sterile RNase free tube. RNA was further purified using the RNeasy Minkit 
(Qiagen) with on column DNase I digestion, according to the manufacturers 
protocol. The RNA was stored at -80 °C until required. Prior to library 
preparation, the quality and quantity of RNA was analysed using a High 
Sensitivity RNA ScreenTape ® (Agilent), and was performed by Natasha Johnson. 
  Library preparation and RNAseq 
Library preparation and sequencing (RNAseq) was performed using the TruSeq 
stranded mRNA library prep workflow (illumina), in accordance with 
manufacturers protocols. Library preparation and RNAseq was performed by 
Natasha Johnson of the Viral Genomics and Bioinformatic team of the MRC 
University of Glasgow Centre for Virus Research. 
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  Analysis of RNAseq data 
Read assembly, alignment, and identification of differentially expressed genes 
were performed by Dr Quan Gu. RNAseq read quality was assessed using FastQC 
software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). 
Sequence adaptors were then removed using TrimGalore 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Sequence 
reads were aligned to the Mus musculus genome (GRCm38.p6), which was 
downloaded via Ensembl (Ensembl genome browser 93) using HISAT2. 
After the alignment of sequencing reads, FeatureCount was used to count reads 
mapping to gene annotation files. The edgeR package was used to calculate the 
gene expression level and to analyse differentially expressed genes. False 
discovery rate (FDR) values were calculated using the Benjamini–Hochberg 
method using edgeR. The significant differential expression genes were selected 
based on FDR adjusted p-value (Q-value) < 0.05.  
The Ingenuity Pathway Analysis (IPA) tool (Qiagen) was used to interpret RNAseq 
data (analysis performed by Stephanie Cumberworth). RNAseq data were 
imported into IPA, which included: the list of identified DEGs at a given 
timepoint and their associated Log2 fold change (Log2FC) in expression value 
and Q-value (adjusted p-value which takes into account false discovery rate). A 
core expression analysis was performed by IPA using information from the 
uploaded dataset using the following conditions: reference set used was the 
Ingenuity Knowledge Base (genes only), species was defined as Mus musculus, 
initial analyses were conducted with ‘all’ tissues and cell lines and where 
indicated disease and function pathway analyses were restricted to only include 
tissues and cell lines of the central nervous system. All other values in the 
expression analysis wizard were set as default. IPA was used to predict the top 
canonical signalling pathways, in addition to disease and function pathways 
affected during ZIKV infection of CNS co-cultures at 96 h p.i. using input RNAseq 
data.     
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2.9 Software  
All figures were assembled using Inkscape software, unless stated otherwise. 
Where stated, some illustrations were created using BioRender. Graphs and 
statistical analyses were generated using GraphPad Prism version 6.07 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. 
Geneious 7.0 (https://www.geneious.com) software was used to perform 
multiple sequence alignments and verify Sanger sequencing results. 
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3 Results chapter 1: Establishing methods for 
ZIKV investigations 
3.1 Chapter specific acknowledgements 
The author would like to thank the following for their contributions which 
enabled investigations within this chapter to take place. 
Lindomar Pena and Rafael Freitas de Oliveira França (Fundação Oswaldo Cruz-
PE) for the initial isolation of the ZIKV strain PE243 used in this thesis and 
providing the Kohl group with this virus. 
Benjamin Brennan (MRC University of Glasgow Centre for Virus Research) for the 
preparation of master ZIKV PE243 stocks. 
Claire Donald (MRC University of Glasgow Centre for Virus Research) for 
establishing routine protocols for ZIKV propagation and titration. 
Jennifer Barrie and Verena Schultz (University of Glasgow) for the preparation of 
CNS and PNS co-cultures. 
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3.2 Introduction 
Upon commencement of this thesis, limited studies of ZIKV had been 
undertaken. Information such as propagation and detection methods, complete 
genome sequence information (with complete UTRs) and cellular tropism were 
not established and ill-defined. 
3.2.1 Host cell species origin in the study of arboviruses 
Following the 2015 ZIKV outbreak there was a rapid increase in the number of 
publications pertaining to ZIKV. As ZIKV study was in its infancy such 
investigations lacked methodical continuity. This made comparing investigative 
findings increasingly difficult. A range of virus propagation techniques were used 
to generate ZIKV stocks, including passage in a variety of mammalian and 
invertebrate cell lines. Depending on the nature of downstream 
experimentation, inappropriate virus propagation techniques may result in 
artefactual findings. 
Arboviruses, such as ZIKV, replicate in both their mammalian and invertebrate 
hosts. In the case of mosquito-borne viruses like ZIKV, the mosquito ingests the 
virus when taking a blood meal. The ingested virus must then infect cells of the 
mosquito midgut, replicate and disseminate throughout the mosquito, eventually 
reaching the salivary glands where it can then be transmitted through salivary 
secretions when the mosquito next takes a blood meal. 
Progeny virions adopt the membrane and protein glycosylation patterns of its 
host cell. Early studies of insect and mammalian glycosylation noted the 
heterogeneity of carbohydrate moieties which adorn DENV (Hsieh and Robbins, 
1984, Johnson et al., 1994). More recent studies of DENV originating from either 
mosquito or mammalian cells reveal that the E protein of progeny virions are 
differentially glycosylated dependent upon its host cell (Lei et al., 2015). The E 
protein of DENV originating from mosquito cells possesses high mannose type, 
complex type and fucosylated and sialylated N-glycans (Lei et al., 2015); high 
mannose type is the dominant moiety. Whereas in mammalian cells, it has been 
reported that complex type N-glycan is the dominant moiety, with some high 
mannose and hybrid structures detected (Lei et al., 2015). 
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Figure 3–1 N-linked glycan structures 
Examples of high mannose, hybrid and complex N-linked glycans. The dominant moiety in insect 
cells is high mannose-type N-linked glycans, whereas in mammalian cells complex-type moieties are 
dominant. Different carbohydrate structures are represented by coloured symbols, the direction of 
the connecting line indicates the position of the linkage between the backbones of differing 
carbohydrate molecules. Dashed lines indicate α glycosidic bonds, and solid lines indicate β 
glycosidic bonds. 
 
If one were to investigate arbovirus interactions with cells present at a bite-site, 
invertebrate propagated virus stocks would be appropriate, as this represents 
virus transmission from invertebrate to mammal. However, in principle, studies 
involving cells/tissue matter not implicated at the bite-site should adopt 
mammalian propagated virus stocks, as the virus in nature would have 
undergone several rounds of replication in mammalian host tissue during 
dissemination. 
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In the case of ZIKV investigations, some researchers have adopted invertebrate 
propagated virus stocks to study ZIKV interactions with the central and 
peripheral nervous system. Glycosylation of the Flavivirus envelope protein has 
been shown to affect virus entry, egress and pathogenicity (Shirato et al., 2004, 
Lee et al., 2010, Alen et al., 2012). In the interest of artefact prevention, it 
would seem prudent to study whether host cell species origin influences ZIKV 
infection. 
3.2.2 Protein interactions with 3’UTR-derived sfRNA 
Flaviviruses, including ZIKV, produce a highly structured, non-coding RNA 
product called sfRNA which is derived from the 3’ untranslated region (3’UTR) 
(Slonchak and Khromykh, 2018, Göertz et al., 2018). As detailed in Section 
1.1.14, numerous candidate interaction partners have been identified for the 
3’UTR of a range of flaviviruses, as summarised elsewhere (Roby et al., 2014). 
These candidates have varying roles in cellular translation, RNA processing and 
stability, and immune modulation. To date, only one protein, Musashi 1(MSI1), 
has been identified as an interaction partner with the ZIKV 3’UTR (Chavali et al., 
2017). 
MSI1 is a neural RNA binding protein implicated in the self-renewal of stem cells 
(Fox et al., 2015, Sakakibara et al., 1996). In the study by Chavali et al (2017), 
three consensus MSI binding sites were identified in stem loop structures within 
the ZIKV PE243 3’UTR, two of which were conserved in African lineage ZIKV 
strain, MR766. A combination of RNA pulldowns and UV cross-linking 
immunoprecipitation (CLIP) assays demonstrated that MSI1 but not MSI2 binds 
the ZIKV 3’UTR. Immunofluorescence analyses using confocal and super 
resolution microscopy illustrate that MSI1 co-localises with double stranded RNA 
(dsRNA; a replicative intermediate of positive sense virus replication) in ZIKV 
infected cells. Furthermore, infection of MSI1 KO cells resulted in a marked 
reduction of viral load in comparison to control cells. Additionally, a ‘dose 
dependent’ effect was observed between expression levels of MSI1 and the 
amount of viral RNA in infected cells Together these findings suggest an 
interaction between MSI1 and ZIKV, which is in part mediated by the ZIKV 3’UTR.  
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The sfRNA of DENV is produced in excess of genomic RNA during infection. It 
would therefore be interesting to have a robust understanding of the range of 
proteins that the 3’UTR RNA can interact with within the host cell, using ZIKV as 
a model virus. 
3.2.3 Chapter Aims 
 Characterise commercially available antibodies using western blot and 
immunofluorescence techniques 
 Identify biologically relevant cells and to study ZIKV infection in the 
central nervous system 
 Develop methods to study ZIKV 3’ UTR interactions with host proteins 
 Determine if the species of cell line used to propagate ZIKV influences 
viral fitness  
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3.3 Tools for ZIKV study 
3.3.1 Testing methods of molecular detection 
At the time of this investigation, there were limited tools available for the study 
of ZIKV. A repertoire of uncharacterised anti-ZIKV antibodies which targeted 
either the envelope or NS1 protein were obtained from Aalto Bio Reagents Ltd 
(Table 3–1 and Table 3–2). To assess the suitability of these antibodies, each was 
employed in the detection of ZIKV by western blot and immunofluorescence 
analysis. Vero E6 cells were infected with ZIKV at a MOI of 3.0 PFU/cell. After 48 
h p.i., cells were either fixed with 4% formaldehyde for immunofluorescence 
study, or cell lysates were harvested for western blot analysis. A starting 
antibody concentration of 10 µg/ mL was used to probe immunofluorescence 
coverslips and western blot membranes (Table 3–2).  
Antigen Product 
code 
Clone number Chosen 
Ab name 
Ig subclass (ug/ml) 
Zika envelope protein AZ1176 0302156 E_1 IgG1 5555.556 
Zika envelope protein AZ1176 0402166 E_2 IgG1 3846.154 
Zika envelope protein AZ1176 0502176 E_3 IgG1 10000       
Zika NS1 protein AZ1225 2701106 NS1_1 IgG1 2000 
Zika NS1 protein AZ1225 2801116 NS1_2 IgG1 2500 
Zika NS1 protein AZ1225 2901126 NS1_3 IgG1 3571.429 
Zika NS1 protein AZ1225 0102136 NS1_4 IgG2a 1515.152 
Zika NS1 protein AZ1225 0202146 NS1_5 IgG1 5000 
Table 3–1 Details of uncharacterised ZIKV antibodies targeting the envelope or NS1 protein 
(Aalto Bio Reagents). 
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Estimated ratio of Ab:buffer 
Ab Name Clone No. 10 ug/mL 100 ug/mL 
E_1 0302156 1:600 1:60 
E_2 0402166 1:400 1:40 
E_3 0502176 1:1000 1:100     
NS1_1 2701106 1:200 1:20 
NS1_2 2801116 1:250 1:25 
NS1_3 2901126 1:350 1:35 
NS1_4 0102136 1:150 1:15 
NS1_5 0202146 1:500 1:50 
Table 3–2 Table of estimated antibody:buffer ratios used for each antibody testing when 
used at a concentration of either 10 µg/mL or 100 µg/mL 
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Figure 3–2 Testing uncharacterised commercially available antibodies targeting the ZIKV 
envelope protein (ZIKV E) by western blot and immunofluorescence analysis. 
(A-C) Vero E6 cells were infected with ZIKV at a MOI of 1 PFU/cell. Cell lysates were harvested at 
48 h p.i. and subjected to western blot analysis. Membranes were probed with one of three antibodies 
targeting the ZIKV E protein (E_1, E_2 or E_3; mouse anti-ZIKV E protein).The membrane was also 
probed with an antibody raised against actin (rabbit anti- α-actin), which was used as a loading 
control. Secondary antibodies raised against mouse or rabbit IgG, conjugated to horseradish 
peroxidase, and ECL substrate were used to visualise protein bands on X-ray film. Arrows indicate 
positive ZIKV staining. (D) Vero E6 cells were infected with ZIKV at a MOI of 1 PFU/cell and fixed at 
48 h p.i. with 4% formaldehyde. Cells were reacted with one of three antibodies targeting the ZIKV 
E protein (mouse- anti ZIKV-E primary antibodies E_1, E_2 or E_3), followed by incubation with goat 
anti-mouse Alexa Fluor ® 488 secondary antibody. Nuclei were counterstained with DAPI. Cells were 
visualised using an EVOS Fl fluorescent microscope using the 20x objective. ZIKV E can be seen in 
green, and nuclei in blue.  
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All the anti-ZIKV envelope (ZIKV E) antibodies tested gave a specific signal for 
infected material compared to mock when tested by western blot and 
immunofluorescence analysis (Figure 3–2). In immunofluorescence images (Figure 
3–2B), the detected signal showed cytoplasmic, perinuclear distribution; as 
envelope protein is synthesised by the virus in the endoplasmic reticulum of 
infected cells, this staining pattern is consistent with envelope protein 
localisation during infection. 
By western blot analysis, in addition to a discreet band ~50 kDa in size 
(corresponding with the ZIKV E protein estimated size of ~52 kDa, predicted by 
ProtParam, ExPASY based upon sequence information based upon ZIKV PE243), 
the membranes probed with antibodies E_1 and E_3 displayed a second band ~45 
kDa in size (Figure 3–2A). 
The anti-NS1 antibodies also demonstrated specificity when used in 
immunofluorescence analysis, generating a signal only in infected cells (Figure 3–
3). The signal for NS1 was diffuse in the cytoplasm. The NS1_3 antibody had 
some non-specific speckles appearing both in the infected and uninfected 
samples. However, the presence of these speckles is more likely reflective of an 
insufficient washing protocol following the staining with a fluorescently labelled 
secondary antibody for this specific sample.  
Testing the anti-NS1 antibodies by western blot did yield some non-specific 
signals in mock infected lanes; this band was most prominent in membranes 
probed by NS1_1,2 and 5 antibodies. This band appeared in the mock infected 
lysate lane and is ~55 kDa in size. In the ZIKV infected lysate lane, all of the 
membranes displayed multiple bands; bands typically appeared ~62 kDa, ~55 kDa 
and <49 kDa (Figure 3–3, indicated by red arrows). The appearance of multiple 
signals in ZIKV lysate (and non-specific binding in mock infected lysate) was least 
prominent in the membrane probed with 10 µg/mL NS1_3.  
The flavivirus NS1 protein is between 41-55 kDa in its monomeric state; NS1 
proteins are post-translationally modified by glycosylation. Perhaps the range of 
signals detected by membranes probed by the anti-NS1 antibodies reflect the 
range of glycosylated NS1 proteins present in infected cells. To test this theory, 
lysate samples could be incubated with an enzyme to remove N-linked glycans, 
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such as PNGase F. These samples could be assayed by western blot probing the 
membrane with an antibody targeting NS1, alongside a sample which has been 
untreated; if a singular band appears in the enzyme treated sample and multiple 
appear in the untreated sample – it can be assumed that the multiple forms 
represent alternatively glycosylated forms. 
Owing to the lack of clarity when probing Western blot membranes with 
antibodies targeting NS1 (i.e. multiple band staining pattern), it was decided 
that such antibodies not be employed in the detection of ZIKV infection in vitro. 
Given the specificity of the envelope protein antibody E_2 by western blot and 
immunofluorescence analysis, this will be the chosen antibody for ZIKV detection 
in downstream analysis and shall simply be referred to herein as α-ZIKV-E. 
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Figure 3–3 Testing uncharacterised commercially available antibodies targeting the ZIKV 
NS1 protein by western blot and immunofluorescence analysis 
Each row corresponds to a different antibody clone which targets the ZIKV NS1 protein, labelled 1-
5. (A) Vero E6 cells were infected with ZIKV at a of MOI 1 PFU/cell. Cell lysates were harvested at 
48 h p.i. and subjected to western blot analysis. Membranes were probed with one of five antibodies 
targeting the ZIKV NS1 protein (mouse anti-ZIKV NS1 protein).The membrane was also probed with 
rabbit anti- α-actin antibodies, which was used as a loading control. Secondary antibodies raised 
against mouse or rabbit IgG, conjugated to horseradish peroxidase, and ECL substrate were used 
to visualise protein bands on X-ray film. Red arrows indicate bands of interest. (B) Vero E6 cells 
were infected with ZIKV at a MOI of 1 PFU/cell and fixed at 48 h p.i. with 4% formaldehyde. Cells 
were immunolabelled with one of five antibodies (10 µg/mL) targeting the ZIKV NS1 protein (mouse- 
anti NS1 primary antibody), followed by incubation with goat anti-mouse Alexa Fluor ® 488 
secondary antibody. Nuclei were counterstained with DAPI. Cells were visualised using an EVOS Fl 
fluorescent microscope (20x objective). ZIKV NS1 protein can be seen in green, and nuclei in blue.  
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3.3.2 Establishing neural cellular systems for ZIKV study 
One of the original intentions of this thesis was to conduct a transcriptomic 
analysis of ZIKV infection in a biologically relevant, CNS cell line at an ‘early’ 
and ‘late’ infectious timepoint. The aim of this approach was to decipher if the 
development of neurological complications could possibly be attributed to 
alterations in gene expression levels. Chapter 5 discusses an investigation by 
transcriptomics. Herein are some preliminary studies which were performed in 
order to try and assess the suitability of astrocyte cells for downstream 
investigations. 
Astrocytes are a highly prevalent cell type within the brain which exhibit diverse 
functionality including (but not limited to) blood-brain barrier function, CNS 
homeostasis and synapse formation (Miller, 2018). Astrocytes can be infected by 
other neurotropic flaviviruses such as Japanese encephalitis virus (JEV) and 
dengue virus (DENV). Upon infection, astrocytes become activated and a potent 
type I IFN response is elicited (van Marle et al., 2007, Lee et al., 2016, Lindqvist 
et al., 2016). Given that astrocytes are susceptible to infection with other 
related viruses, and may contribute to neurologic disease outcomes in JEV 
patients, they may represent an interesting cell type for the study of ZIKV 
infection (German et al., 2006).  
 Establishing SVGp12 seeding densities 
The astrocytic cell line SVGp12 (ATCC® CRL-8621™) is an immortal cell line 
derived from first trimester foetal brain tissue, as such it was selected as a 
candidate cell line for downstream experimentation. SVGp12 cells were new to 
the laboratory and required basic characterisation, including determining 
appropriate seeding densities, prior to experiments. 
Initially SVGp12 cells were seeded into 6 well tissue culture plates at either 0.5, 
1.0, 1.5 or 2.0 x 105 cells/mL. The cells were maintained at 37 °C overnight and 
observed the following day, in addition to 48 hours post-seeding (Figure 3–4). At 
one day post-seeding, wells containing 0.5 x 105 cells/mL were sparsely 
populated. Morphologically the cells appeared needle-like, which may be an 
indicator of ill health. At day 2 post-seeding, these cells displayed a marginal 
72 
 
increase in count, and still appeared spindle-like, indicating this density is too 
low for experiments. Wells seeded at a density of 2.0 x 105 cells/mL were almost 
confluent one day post-seeding and were overcrowded at day two. Wells seeded 
at 1.5 x 105 cells/mL were neither too sparse or dense at day one, yet densely 
populated at day two. Given that during infection of mammalian cells, ZIKV 
causes cytopathic effect by 48 h p.i., the seeding density of 1.5 x 105 cells/mL 
seems dense enough to withstand infection, without becoming too sparse or 
overcrowding. Therefore, 1.5 x 105 cells/mL was chosen as the appropriate 
seeding density for infection studies. 
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Figure 3–4 Seeding density test of SVGp12 cells in 6 well tissue culture plate  
The concentration of a homogenous cell suspension of SVGp12 cells was determined using a 
haemocytometer. The suspension was diluted in culture media to produce varying defined 
concentrations of SVGp12 cells. The cells were seeded into 6 well tissue culture plates and incubated 
overnight at 37 °C, after which they were imaged using an EVOS Fl microscope on the transmitted 
light setting using the 20x objective (day 1). Cells were maintained at 37 °C and imaged once more 
after a further 24 hours (day 2).  
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 Infection of SVGp12 cells 
SVGp12 cells were infected with ZIKV at two different MOIs, a low MOI (0.5 
PFU/cell) and a high MOI (5 PFU/cell), to increase the likelihood of establishing 
infection. Cell lysates were harvested at 24, 48 and 72 h p.i. and were subjected 
to analysis by western blot, using an α-ZIKV E antibody to detect infection 
(Figure 3–5A). ZIKV E could be detected at all timepoints in infected cell lysates 
pertaining to both MOI 0.5 and MOI 5, indicating SVGp12 cells are susceptible to 
infection with ZIKV. The 24 h p.i./MOI 0.5 lysate sample showed a faint band in 
comparison to the others, indicating that infection has progressed to a lesser 
degree than at other timepoints. By increasing the initial viral input to a MOI of 
5 PFU/cell, the band intensity at 24 h p.i. too increases. 
The positive control (lysate from Vero E6 cells infected with ZIKV at a MOI of 3 
PFU/cell) was faint at the band corresponding to ZIKV ~50 kDa but has two 
stronger bands both <17 kDa in size. As this lysate sample had previously been 
freeze-thawed, this may represent degraded ZIKV E protein. Furthermore, the 
actin bands for this sample was weaker in comparison to other timepoints; 
similarly, infected lysate (both MOI 0.5 and MOI 5) display weaker actin staining. 
In addition to western blot analysis, SVGp12 infected cells were fixed at 48 h p.i. 
and processed for immunofluorescence analysis. Cells were probed again with 
α-ZIKV E and nuclei were counterstained with DAPI (Figure 3–5B). The nuclei of 
ZIKV infected cells at both MOI 0.5 and MOI 5 displayed morphological changes. 
Cells infected with ZIKV at MOI 0.5 have misshapen nuclei, some of which 
appeared to be blebbing and/or sickling. Whereas at MOI 5, cell nuclei appeared 
much more sickled in appearance. This is in contrast with mock infected samples 
whereby nuclei appeared healthy in nature (oval/kidney shaped [reniform] and 
absent of condensed chromatin in non-dividing cells). 
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Figure 3–5 SVGp12 cells can be infected with the ZIKV 
(A) SVGp12 cells were infected with ZIKV at either a MOI 0.5 or 5 PFU/cell. At 24, 48 and 72 h p.i., 
cell lysates were harvested and subjected to analysis by western blot to detect the expression of the 
ZIKV envelope protein (ZIKV E [E_2]; indicated by red arrow). (B) SVp12 cells were infected with 
ZIKV with a MOI 0.5 or 5 PFU/cell. At 48 h p.i. cells were fixed in 4% formaldehyde for one hour prior 
to immunolabelling with an antibody targeting ZIKV E (green). Nuclei were counterstained with DAPI. 
Representative images from 2 biological replicates with 2 coverslips per condition, per replicate. 
Images were taken using a Zeiss LSM 710 confocal microscope using the 50x objective (with oil 
immersion). 
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 GFAP expression in SVGp12 cells 
Upon further characterisation of this cells line it was apparent that SVGp12 cells 
do not express the astrocytic marker glial fibrillary acidic protein (GFAP) (Figure 
3–6), as tested by western blot and immunofluorescence analysis. GFAP is an 
intermediate filament expressed in astrocytes; GFAP expression is used as a 
differential marker of astrocytes from other glial cell types present in the 
central nervous system (Eng et al., 2000). The lack of GFAP expression in SVGp12 
cells may indicate that the expression of other proteins may be altered in this 
cell line, raising the question of their relevance as a cell type for investigation 
by transcriptomics. It was therefore concluded that alternative cells be sought 
out for further investigation. 
 GFAP expression in primary Normal Human Astrocytes (NHA) 
The next cell line to be investigated were primary human astrocyte cells – 
normal human astrocytes (NHA; Lonza). As determined by western blot and 
immunofluorescence analysis, these cells do express the astrocytic marker GFAP 
(Figure 3–6). The calculated molecular weight of GFAP as determined using the 
ProtParam tool (ExPASY) is ~49.9 kDa. The antibody used to probe the western 
blot membrane was a polyclonal antibody (Rabbit anti-GFAP; Agilent, Dako). The 
GFAP positive band on the western blot which pertains to NHA cell lysate 
appears at ~40 kDa, with less prominent smear staining ranging between 38-49 
kDa. Whereas lysate from a mixed cell co-culture of central nervous system 
origin displays a discrete band ~49 kDa surrounded by a faint smear, with further 
faint discrete bands appearing at ~38 and ~40 kDa. The range in observed 
estimated molecular weights between NHA and CNS co-culture cells may be 
attributed to the fact that several isoforms of GFAP exist. The predominant 
splice form in CNS white matter is GFAP-α; CNS co-cultures are derived from 
murine spinal cord tissue (white matter) (Eng et al., 2000). Therefore, the 
discrete band ~50 kDa in CNS co-culture lysate may represent the GFAP-α 
isoform and the smear in NHA lysate representative of alternative isoforms. Both 
mouse and human GFAP has an estimated molecular weight of ~49.9 kDa. 
However, species-specific differences in splice variant expression may contribute 
to the differed staining patterns by western blot (Eng et al., 2000, Kamphuis et 
al., 2012).  
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Figure 3–6 The astrocytic cell line SVGp12 does has limited expression of the astrocyte 
marker glial fibrillary acidic protein (GFAP). 
Cell lines (A) SVGp12, (B) murine central nervous system co-cultures or (C) Primary human 
astrocyte cells, normal human astrocytes (NHA) were plated onto cover slips. (A) Cells were infected 
at a MOI of 5 PFU/cell for 24 h p.i (B&C) cells were uninfected. Samples were fixed in 4% 
formaldehyde and slides assayed for GFAP (Red) or ZIKV E (Green) and Nuclei were counterstained 
with DAPI (Blue). (D) Western blot testing for the expression of GFAP in cell cultures. SFTR cells are 
a cell line derived from sheep foetal thymus and were used as a negative control for GFAP 
expression. 
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 ZIKV infection in NHA cells 
As NHA cells were deemed GFAP positive, these cells were subsequently used in 
infection studies. Firstly, NHA cells were infected with ZIKV at a MOI of 0.1 
PFU/cell; cell culture supernatant and cellular lysates were harvested at 5, 10, 
24, 48 and 72 h p.i. Western blot analysis of NHA lysate probing for the 
expression of ZIKV E indicates that NHA cells are susceptible to ZIKV infection 
(Figure 3–7A). ZIKV E expression was detected from 48 h p.i onwards. Plaque 
assays were performed using the cell lysate to determine if infection was 
productive i.e. results in the creation of infectious progeny virions (Figure 3–7B). 
No virus replication was detected at 10 h p.i. with a 1-log increase detected by 
24 h p.i. At 48 h p.i. the virus titre 1.3 x104 PFU/ml. At 72 h p.i. the virus titre 
started to plateau at around 6 x104 PFU/ml. The limit of detection by western 
blot when probing for expression of E appeared to be 104 PFU/mL (the virus titre 
at 48 h.p.i). These data indicate that ZIKV can establish a productive infection in 
NHA cells.  
Figure 3–7 ZIKV can establish infection in primary normal human astrocytes (NHAs) 
NHA cells were infected with ZIKV using a MOI of 0.1 PFU/cell. At 5, 10, 24, 48 and 72 h p.i., cell 
culture supernatants were harvested and lysates of cell monolayers prepared. (A) Cell lysates were 
subjected to western blot analysis to test for the expression of the ZIKV envelope protein (ZIKV E; 
E_2). The membrane was also probed with an antibody raised against actin (rabbit anti- α-actin), 
which was used as a loading control. Secondary antibodies raised against mouse or rabbit IgG, 
conjugated to horseradish peroxidase, and ECL substrate were used to visualise protein bands on 
X-ray film (B) The infectious titres of cell culture supernatants were determined by plaque assay to 
produce a virus growth curve, n= 1.  
A. 
B. 
Hours post-infection (h p.i.) 
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As it was now established that ZIKV could infect NHA cells (Figure 3–7), the 
appropriate MOI and timepoints needed to be determined for transcriptomic 
analysis. The initial aim for transcriptomics experiments was to compare gene 
expression profiles of ‘early’ and ‘late’ infectious timepoints. For 
transcriptomics experiments it is ideal to have as many cells infected as 
possible. Therefore, to determine which MOI was appropriate to achieve this at 
an ‘early’ timepoint, immunofluorescence analyses were performed. As ZIKV E 
expression occured late in the virus infectious replicative cycle and failed to be 
detected by western blot at 10 h p.i. and 24 h p.i. (Figure 3–7), it was decided 
that an antibody targeting double stranded RNA (dsRNA; a replicative 
intermediate of virus infection) would be used to detect infection levels. NHA 
cells were infected at a MOI of either 3 or 5 PFU/cell and fixed with 4% 
formaldehyde at 10 and 24 h p.i. and immunostained with antibodies against 
dsRNA and GFAP (Figure 3–8). At 10 h p.i., detection of dsRNA was achieved only 
in cells infected at a MOI of 5 PFU/cell (Figure 3–8C inset image). However, at 24 
h p.i. dsRNA was detected in cells infected at a MOI of 3 PFU/cell, as well as in 
cells infected at a MOI of 5 PFU/cell (Figure 3–8B/C).  
At 24 h p.i. the morphology of the NHA cells had changed from larger cell bodies 
reminiscent of fibroblasts into cells with condensed GFAP, giving the appearance 
of smaller cell bodies, with long, thin projections emanating from the cell body 
(compare Figure 3–8A with Figure 3–8B/C). The morphology change was most 
striking in cells infected at a MOI of 5 PFU/cell. Furthermore cells infected at a 
MOI of 5 PFU/cell did not display these morphological changes at 12 h p.i., 
indicating this may be a viral load dependent effect (compare Figure 3–8B with 
1-7C and 1-7C with inset image). However, this experiment could only be 
performed once owing to culturing difficulties and further study would be 
required to confirm this finding. Owing to cell culturing difficulties such as 
failure to obtain high cell counts within the recommended passage timeframe 
(NHA cells were guaranteed for 10 population doublings per manufacturer 
guidelines; Lonza), NHA cells were therefore disregarded for future studies. 
Fortunately, a collaboration opportunity arose with neuroimmunology 
researchers at the University of Glasgow capable of culturing murine mixed cell, 
central and peripheral nervous system cultures (CNS and PNS respectively). Use 
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of these CNS and PNS cultures to model cell-cell interactions was well 
established within this research group, and could be tailored to reflect different 
developmental stages of human neural development (Thomson et al., 2006, 
Thomson et al., 2008). Furthermore, these cultures had also been used to study 
Semliki Forest virus interactions in the CNS (Unpublished, Dr Clive McKimmie, 
University of Leeds & Dr Julia Edgar, University of Glasgow). Therefore, the 
culture system seemed ideal to study ZIKV interactions within the CNS and PNS, 
and all future investigations were performed using these cells. More in depth 
introduction to these culture systems can be found in Chapter 4, Section 4.2.2.  
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Figure 3–8 Detection of ZIKV infection in NHA cells at early time points using double 
stranded RNA (dsRNA) as a marker of infection 
NHA cells were either mock infected (A) or infected with ZIKV at a MOI of either 3 (B) or 5 (C) 
PFU/cell. At 24 h p.i., cell monolayers were fixed with formaldehyde and immunolabelled for GFAP 
(red; goat anti-rabbit IgG Alexa Fluor ® 594 secondary antibody), dsRNA ( green; goat anti-mouse 
IgG Alexa Fluor ® 488) and DAPI (blue). The inset image in C displays NHA cells infected at a MOI 
of 5 PFU/cell fixed with formaldehyde at 10 h p.i., arrows indicate cells with positive staining for 
dsRNA. Images were taken using an EVOS Fl microscope using the 20x objective. Images are 
representative of 2 coverslips for one biological replicate. Scale bar: 50 µm.  
GFAP/dsRNA 
Mock 
ZIKV MOI 5 
ZIKV MOI 3 
50 µm 
A. 
B. 
C. 
82 
 
3.3.3 ZIKV 3’ UTR: protein interactions 
Given the capacity of the 3’UTR of related flaviviruses to interact with a range 
of host proteins, these candidate interaction partners may also function in the 
ZIKV life cycle. The only protein known to interact with the 3’UTR of ZIKV is 
MSI1. This was identified through a target study which primarily identified 
putative binding sites prior to downstream experimental studies which did not 
involve proteomic analysis (Chavali et al., 2017). It was therefore my aim to 
build upon this RNA pulldown protocol and develop methodology to conduct a 
proteomic study to assess a breadth of potential interaction partners of the ZIKV 
PE243 3’UTR. 
 Absolute quantitation of ZIKV genomic- and sfRNA by qPCR 
It has previously been found that DENV sfRNA is produced in higher amounts 
during infection in comparison to genomic RNA (gRNA) (Bidet et al., 2014). To 
quantify the amount of ZIKV sfRNA versus gRNA produced during infection, an 
infection time course was conducted to assay the levels of gRNA and sfRNA 
produced during infection by differential RT-qPCR. This protocol is based upon a 
previously described assay used to quantify DENV sfRNA (Bidet et al., 2014). The 
determination of a growth curve for sfRNA production was to inform timepoints 
for any downstream analyses. Briefly, forward qPCR primers were designed to 
specifically amplify regions of the ZIKV genome which pertained to either only 
the genome, or a region found in both the genome and the sfRNA (schematic 
representation can be found in Figure 3–9A). The same reverse primer was used 
for both reactions. The molar amounts of gRNA and gRNA+sfRNA were 
determined using the standard curve method (Figure 3–9B). By subtracting the 
molar amount of gRNA from the gRNA+sfRNA, the molar amount of sfRNA could 
be inferred. 
A549 cells were infected with ZIKV at a MOI of 0.1 PFU/mL. Cell culture 
supernatant and total cellular RNA was harvested at 8, 10, 24, 48 and 72 h.p.i. 
After extraction, total cellular RNA was reverse transcribed into cDNA and 
analysed by qPCR to determine the amount of gRNA and sfRNA. The results from 
the qPCR indicated that sfRNA was produced in excess of genomic RNA by 1 log 
(Figure 3–9C). At 24 hours post infection, the amount of genomic RNA increased 
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substantially, indicating that genome replication was active at this timepoint. 
However, the exponential phase of genome production appeared to plateau at 
48 h p.i. 
By comparing this data to a growth curve obtained by viral plaque assay, a 
comparison between genome replication (as determined by qPCR data) and virus 
release (plaque assay) was performed (Figure 3–9C). In comparison to the growth 
curve, at 24 h p.i. virus replication exceeded that of virus release, whereby the 
inverse occured after 48 h p.i. Therefore, the 48 h p.i. timepoint was too late a 
timepoint to capture the profile of infected cells undergoing virus genome 
replication.  
These data will inform the time point required to harvest infected cellular lysate 
to be used in a pulldown assay; this pulldown assay will employ ZIKV 3’UTR RNA 
as bait to explore 3’UTR-protein interactions. The intention to use infected cell 
lysate to perform the pulldown assay is two-fold. Firstly, the proteomic profile 
of the host cell alters during infection, and secondly, because prior studies 
indicate that the 3’UTR of flaviviruses can interact with viral proteins. 
Therefore, by using infected cell lysate the proteome is relevant to infection, in 
addition to being able to determine if any interactions occur with viral proteins. 
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Figure 3–9 Quantification of ZIKV gRNA and sfRNA 
(A) Schematic representation the NS5/3UTR region of the ZIKV genome which is amplified during 
the differential qPCR reaction for the absolute quantification of ZIKV sfRNA and gRNA. The red arrow 
(labelled G) indicates the position of the forward primer. G specifically amplifies a region in the NS5 
coding region, therefore will only be found in genomic RNA. The blue arrow (labelled GSF) indicates 
the position of the forward primer which is used to amplify a region of RNA which can be found both 
in genomic RNA and sfRNA. By subtracting the molar amount of product amplified (G) from the molar 
amount of products amplified from GSF; the molar amount of sfRNA can be determined (n(GSF)-
n(G)=n(SF). (B) The standard curve generated from qPCR of serial 10-fold dilutions of PCR products 
amplified from the pCCl-SP6-ZIKV* WT plasmid using the G/REV primers. (C) A growth curve of the 
production of sfRNA and genomic RNA generated from differential qPCR data. (D) A direct 
comparison of virus titre determined by plaque assay and gRNA production determined by qPCR of 
total cell RNA. Both sets of data were obtained from the same growth curve to allow direct 
comparisons to be made n=1.  
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 Production of biotinylated ZIKV 3’UTR RNA 
To elucidate potential 3’UTR:protein interactions, a pulldown assay was 
developed based upon a previously described protocol (Chavali et al., 2017). 
Briefly, the 3’UTR of ZIKV PE243 was cloned from the plasmid pCCl-SP6-ZIKV* WT 
(donated from Prof A. Merits, University of Tartu; contains 5’ and 3’ UTRs from 
ZIKV PE243) using a primer which inserted the SP6 promoter directly upstream of 
the 3’UTR start position (Figure 3–10). 3’UTR RNA was produced by in vitro 
transcription using the SP6 polymerase (Figure 3–10). Initially, exhaustive efforts 
were made to end label ZIKV 3’UTR RNA with desthiobiotin using the Pierce™ 
Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific). After numerous 
attempts to optimise this protocol, this direction was no longer pursued. 
Instead, biotinylated UTP was incorporated into ZIKV 3’UTR RNA during in vitro 
transcription as per (Chavali et al., 2017) (Figure 3–10). Figure 3–10 
demonstrates the successful production of RNA in addition to incorporation of 
biotinylated UTP, visible by the slightly higher position on the gel relative to the 
unlabelled equivalent.  
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Figure 3–10 Generation of biotinylated 3’UTR ZIKV RNA 
The ZIKV 3’UTR was cloned from the plasmid pCCl-SP6-ZIKV* WT (donated from Prof A. Merits, 
University of Tartu; contains 5’ and 3’ UTRs from ZIKV PE243), using a primer pair which inserted 
the SP6 promoter sequence immediately upstream of the 3’UTR start site. (A) Sanger sequencing 
demonstrating the successful insertion of the SP6 promoter sequence upstream of the ZIKV 3’UTR 
start site. (B) Agarose gel electrophoresis of template plasmid and subsequent products of cloning 
SP6-3’UTR. Lane 1: GeneRuler 1kb Plus DNA ladder. Lane 2: Template plasmid pCCl-SP6-ZIKV* 
WT. Lane 3: 3’UTR-SP6 product after insertion of SP6 site upstream of 3’UTR Lane 4: Products from 
lane 2 underwent a second round of amplification by PCR was subsequently purified by ethanol 
precipitation. (C). Agarose-formaldehyde gel of ZIKV 3’UTR RNA in vitro transcribed from SP6 
promoter either in the absence or presence of biotinylated UTP (lanes 2 and 3 respectively). Lane 1: 
RiboRuler LR, RNA ladder. Lane 2: 3’UTR RNA. Lane 3: Bio-16 UTP 3’UTR RNA. 
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 3’UTR RNA pulldown 
Two T250 flasks of A549 cells were infected with ZIKV at a MOI of 2 PFU/cell; 
cells were lysed at 24 h p.i and protein lysate pooled. ZIKV 3’UTR RNA was 
incubated with lysate at 4 °C. After 2 hours, 50 µL of MyOne Dynabeads 
conjugated with streptavidin were added to the RNA:protein mixture and 
incubated for a further 1 hour at 4 °C. RNA:protein complexes were then 
precipitated using a magnetic rack, washed and analysed staining for total 
protein composition (Figure 3–11A) and western blot for MSI1 (Figure 3–11B). 
The total protein composition of both lysate and RNA:protein:bead complexes 
were analysed by SDS-PAGE followed by staining with sypro orange (Figure 3–
11A). Whilst no visible differences appeared between lysates which had been 
incubated with or without 3’UTR RNA, the bead bound samples demonstrated 
some visible differences of protein composition as determined by protein 
molecular weight and density (indicated by * in Figure 3–11). These visible 
differences suggest that the pulldown assay functioned.  
To further validate if the assay functioned, these samples were analysed by 
western blot, whereby membranes were probed using the Musashi-1 (MSI1) 
antibody as a positive control for the pulldown (Figure 3–11). MSI1 is an RNA 
binding protein which can be found in a range of tissues, predominantly the 
brain and testis (Fagerberg et al., 2014); expression of MSI1 has also been 
detected in lungs, which is the origin of A549 cells used in these experiments. 
The interaction of ZIKV 3’UTR and MSI1 has previously been described (Chavali et 
al., 2017). Briefly, MSI1 binding sites were identified in the secondary structure 
of the 3’UTR of ZIKV PE243, and the protein interaction was confirmed using a 
similar method, with minor changes in RNA concentration used (20pmol) and 
lysate samples (uninfected human glioblastoma cell line U251) (Chavali et al., 
2017). Unfortunately, Figure 3–11 demonstrates that the 3’UTR was unable to 
pulldown MSI1, at least to sufficient quantities to be detected by Western blot.  
As determined by qPCR (section 823.3.3.1), sfRNA was expressed in higher 
quantities than genomic RNA during infection by almost 1-log difference (Figure 
3–9C). The excess of sfRNA produced during infection could be acting as a 
molecular sponge, sequestering endogenous MSI1 and therefore preventing 
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efficient pull down in this assay. To determine if this was a possibility, the 
pulldown assay was performed in tandem with uninfected A549 lysate. However, 
the staining pattern was the same for both infected and uninfected bead bound 
lysate samples (Figure 3–11B). 
An extremely faint staining the equivalent size of MSI1 was present in both 
infected and uninfected bead bound protein samples, which may be a positive 
band. The assay would require further optimisation to determine if this is the 
case. Consequently, this line of investigation was no longer pursued.  
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Figure 3–11 ZIKV 3’UTR RNA pulldown  
Cell lysate was harvested at 24 h.p.i from A549 cells that had been infected with ZIKV at a MOI of 2 
PFU/cell. The cell lysate was incubated either with ZIKV 3’UTR or alone for 2 hours at 4 °C, then 
with 50 µL of MyOne Dynabeads conjugated with streptavidin for a further hour. RNA:protein:bead 
complexes were precipitated using a magnetic rack, washed and subjected to SDS-PAGE. (A) The 
SDS-PAGE gel was stained using sypro orange to visualise the total protein composition of samples. 
Lysate: indicates samples of protein lysate taken after precipitation of RNA:protein:bead complexes. 
Bead bound: indicates samples which were precipitated using MyOne Dynabeads. Beads: indicates 
samples incubated only with MyOne Dynabeads. 3’UTR: indicates samples incubated first with ZIKV 
3’UTR RNA, then MyOne Dynabeads. (B) Lysates from both infected (I) and uninfected (U) cell lysate 
was used in the pulldown protocol and were run on an SDS-PAGE gel. The proteins were transferred 
from the SDS-PAGE gel by western blot, and the subsequent membrane probed with antibodies 
against α-tubulin (loading control), and Musashi-1 (positive control for the pulldown). In this instance 
labelled 3’UTR did not pull down Musashi 1. α-tubulin was used as a loading control for the lysate 
samples but also appears to bind MyOne Stepvavidin beads. Input lysate: indicates lysate pre-
incubation with or without RNA. Discard lysate: indicates lysate post-precipitation.  
* 
* 
* 
* 
* 
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3.3.4 Assessing importance of cellular origin in ZIKV infection 
To investigate the replicative capabilities of insect versus mammalian derived 
ZIKV, the strain PE243 was propagated in either mammalian-derived A549 Npro 
cells or mosquito-derived C6/36 cells. The A549 Npro cell line are a subclone of 
A549 cells which are derived from human lung epithelial tissue – the Npro sub 
clone expresses the bovine viral diarrhoeal N protein to render the type I IFN 
system ineffective; thus, making it a suitable cell line for viral propagation. The 
invertebrate cell line C6/36 is derived from Aedes albopictus, a commonly used 
cell line in ZIKV propagation. Virus was produced using the same elite stock of 
ZIKV, generating progeny virus of the same passage number and strain, the only 
difference being the propagation cell line. The resultant viruses are herein 
referred to as PE243 A549 Npro, and PE243 C6/36.  
Firstly, a plaque assay was performed to assess the plaque phenotype produced 
by PE243 A549 Npro and PE243 C6/36 viruses (Figure 3–12). There were no 
remarkable differences in the sizes of plaques produced between PE243 A549 
Npro and PE243 C6/36 produced viruses.  
 
Figure 3–12 Size comparison of plaques produced in A549 monolayer from PE243 A549 
Npro and PE243 C6/36 viruses. 
Serial dilutions of PE243 A549 Npro and PE243 C6/36 viruses were made in 2% FBS/PBS. The 
serial dilutions were used to infect monolayers of A549 cells for 1 hour prior to removal of infection 
media and replacement with 2x MEM 4% FBS diluted 1:1 with 1.2% Avicel. At 5 days post infection, 
the cell monolayers were fixed in 8% formaldehyde for 1 hour prior to staining with toluidine blue.  
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PE243 A549 Npro and PE243 C6/36, in addition to MR766 (propagated in A549 
Npro cells), were then used to infect central and peripheral nervous system (CNS 
and PNS respectively) mixed-cell co-cultures either WT or KO for the IFN α/β 
receptor (Ifnar1). CNS and PNS co-cultures are derived from embryonic day 13 
mouse spinal cord (CNS) or dorsal root ganglion (PNS), and possess all the major 
cell types of their respective nervous system (generated by Verena Schultz and 
Jennifer Barrie; detailed further in Section 4.2.2). Cultures were infected with 
the respective virus at a MOI of 1 PFU/cell. Cell culture supernatant was 
harvested, and total cellular RNA was extracted at 24 and 72 h p.i. Infectious 
virus in the cell culture supernatant was determined by plaque assay. Plaque 
assay data can be found in the right-hand column of Figure 3–13. Total cellular 
RNA was reverse transcribed and subjected to analysis by qPCR using primer 
pairs specific to ZIKV. Primer pairs specific for the house keeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were used as an internal 
control. The relative gene expression values for ZIKV RNA were determined using 
the 2-ΔΔCT method. Gene expression values are relative to an uninfected control 
sample, and data can be found in the left-hand column of Figure 3–13. 
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Figure 3–13 Quantitative comparison of virus replication and production of different ZIKV 
strains as determined by relative qPCR and virus titration 
Ifnar1 WT and KO CNS and PNS co-cultures were infected with ZIKV PE243 produced in either 
mammalian or invertebrate cells (PE243 A549 Npro, PE243 C6/36 respectively) or ZIKV strain 
MR766 (produced in A549 Npro cells), at a MOI of 1 PFU/cell. At 24 and 72 h p.i., culture supernatant 
and total cell RNA samples were harvested. A. KO CNS, B. KO PNS CNS, C. WT CNS, D. WT PNS. 
Left column: Total cellular RNA underwent analysis by qPCR using a ZIKV specific primer set using 
a two-step qPCR protocol. A primer pair specific to GAPDH was used as an internal control. Relative 
gene expression values were determined using the 2-ΔΔCT method. Gene expression values shown 
are relative to an uninfected control sample. Biological replicates: n=2 for KO PNS PE243 24 & 72 h 
p.i., KO CNS & WT PNS PE243 C6/36 24 h p.i., WT CNS all samples. All other samples n=3. Right 
column: Infectious virus titres in plaque forming units per mL (PFU/mL) was determined by viral 
plaque assay of cell culture supernatant harvested at 24 and 72 h p.i.. Virus titres were undetermined 
for WT PNS culture samples, as no plaques were produced. Biological replicates: WT PNS/CNS 
n=2, KO CNS n=3. Statistics: * p<0.05 ***p 0.0001, **** p<0.0001, determined by 2way ANOVA. 
Legend: 
A. 
B. 
C. 
D. 
RNA Titre 
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In all Ifnar1 KO and WT CNS and PNS cultures, it appeared that MR766 
consistently has high relative expression of ZIKV RNA and achieved higher titres 
compared to either PE243 or PE243 C6/36 at both 24 and 72 h p.i. All three ZIKV 
strains produced higher virus titres in KO CNS co-cultures compared with their 
WT CNS counterpart and KO PNS cultures (when right panels of Figure 3–13 A are 
compared with C/D). 
In Ifnar1 KO CNS cultures, all three ZIKV strains replicate and produce infectious 
virions as determined by qPCR and plaque assay, respectively (Figure 3–13A). 
MR766 displayed higher relative expression of ZIKV RNA and produced more 
infectious particles than either PE243 or PE243 C6/36 at both 24 and 72 h p.i. At 
72 h p.i., the difference in relative expression levels and virus titres between 
MR766 and either PE243 sample reached statistical significance as determined by 
2way ANOVA. MR766 produced titres almost 1.5-2 logs higher than PE243 at 24 
and 74 h p.i., compared with 1 log increase between MR766 and PE243 C6/36 at 
24 and 72 h p.i. PE243 C6/36 produced higher virus titres than PE243 at 24 and 
72 h p.i. (Figure 3–13A). At 24 h p.i., the mean virus titre was just under 1 log 
higher in PE243 C6/36 compared to PE243. At 72 h p.i. the difference in mean 
virus titre was around ½ a log. Differences in titres between PE243 and PE243 
C6/36 did not reach statistical significance. The difference in virus titres 
between PE243 samples was not reflected in the relative expression of ZIKV RNA. 
At both 24 and 72 h p.i., the relative expression of ZIKV RNA between PE243 and 
PE243 C6/36 was similar, though at 72 h p.i. the average RNA expression level 
was slightly higher in PE243 C6/36 than PE243.  
MR766 achieved high titres in KO PNS cultures, with a demonstrable increase in 
titre between 24 h p.i. and 72 h p.i. (right panel, Figure 3–13B). In contrast, 
PE243 did not appear to increase virus titre between 24 h p.i. and 72 h p.i. in KO 
PNS cultures (right panel, Figure 3–13B). Furthermore, the relative gene 
expression of ZIKV RNA in PE243 infected PNS KO cultures did not change 
between 24 and 72 h p.i. (left panel, Figure 3–13B). On the other hand, the virus 
titre of PE243 C6/36 appeared to increase slightly between 24 and 72 h p.i. 
(right hand, Figure 3–13B). The relative expression of ZIKV RNA does not 
corroborate the increase in virus titre when KO PNS cultures are infected with 
PE243 C6/36; the qPCR data indicated that neither PE243 or PE243 C6/36 
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replicates in KO PNS co-cultures. A further replicate of titration data could help 
resolve this discrepancy. 
In WT CNS cultures, the virus titre at 24 h p.i. and 72 h p.i. did not change for 
either PE243 or PE243 C6/36 (right panel, Figure 3–13C). The titre of MR766 
increased by less than half a log in WT CNS co-cultures between 24 and 72 h p.i. 
The relative RNA expression levels suggest that ZIKV RNA levels increase 
between 24 and 72 h p.i. for all three ZIKV strains. However, the large variation 
in data should be noted and further replicates will be required. 
Titration data could not be obtained for ZIKV infection of WT PNS co-cultures, as 
no visible plaques were produced. PE243 and PE243 C6/36 did not appear to 
replicate well in WT PNS co-cultures, as the relative ZIKV RNA expression levels 
did not change between 24 and 72 h p.i; whereas the relative ZIKV RNA 
expression levels increased slightly in MR766-infected WT PNS cultures. 
However, this difference is only marginal, and owing to the variation within the 
datasets, it may not reflect a genuine increase in viral RNA replication.  
In summary, Ifnar1 KO CNS and PNS cultures are more susceptible to ZIKV 
infection compared to their WT counterparts. MR766 consistently achieved 
higher infection levels in Ifnar1 KO and WT CNS and PNS cultures than either 
PE243 or PE243 C6/36 viruses as determined by qPCR, with exception of WT PNS 
co-cultures in which none of the sampled viruses demonstrated significant 
increases in viral replication. PE243 produced in mosquito cells (PE243 C6/36) 
achieved slightly higher infection levels in KO CNS co-cultures in comparison to 
PE243 produced in mammalian cells (PE243). 
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3.4 Discussion 
Upon the commencement of this thesis, relatively few reagents were available 
to study ZIKV infection, and standardised laboratory protocols were yet to be 
established. The primary aim of this chapter was to identify suitable reagents 
and methodology for studying aspects of ZIKV infection and identify areas of 
investigation. 
3.4.1 Antibodies 
A range of uncharacterised antibodies were obtained from Aalto Bio Reagents, 
targeting either ZIKV envelope or NS1. These were subsequently tested using 
western blot and immunofluorescence analyses (Section 3.3.1). 
All the antibodies targeting ZIKV envelope were used successfully to detect ZIKV-
positive infected samples, with no detectable non-specific binding ZIKV-negative 
samples (both western blot and immunofluorescence) (Figure 3–2). One of the E 
antibodies (clone number 0402166) produced a discrete, single band at the 
correct approximate size (~50 kDa; E = 52 kDa). However, the other two clones 
produced two bands ~50 kDa and ~45 kDa. ZIKV E possesses an N-linked 
glycosylation motif (N-X-S/T) at amino acid position 154 (Haddow et al., 2012); 
the two bands observed by western blot may be attributable to alternate 
glycosylation statuses of E present in lysate samples. Detection of E in fixed cells 
by immunofluorescence techniques demonstrate no cross-reactivity in mock 
infected cells (Figure 3–2). 
Antibodies targeting NS1 yielded differing results (Figure 3–3). Detection of ZIKV 
infection by western blot did not result in a singular discrete band; most of the 
NS1 antibodies detected multiple bands approximately ~62 kDa, ~45 kDa and <49 
kDa (Flavivirus NS1 = 46-55 kDa). NS1 undergoes various post-translation 
modifications during the Flavivirus life cycle, resulting in distinct functional 
properties (Pryor and Wright, 1994). The multiple bands detected by western 
blot could reflect the range of glycosylation patterns of NS1. In most of the 
membranes probed with NS1 antibodies, a band ~55 kDa was present in ZIKV-
negative samples. A band of this size was also present in ZIKV-positive samples, 
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but to differing intensities. Whether this reflected inherent cross-reactivity of 
the antibodies, or a lack of optimisation, would require further investigation.  
Detection of NS1 in ZIKV-infected cells by immunofluorescence demonstrated no-
cross reactivity in mock infected cells (Figure 3–3). One clone, 2901126, had 
speckles present in the uninfected sample, however these speckles did not 
adhere to the staining characteristic of ZIKV-positive samples (perinuclear), nor 
did they appear to be specific to a cell. Therefore, this could reflect an 
inadequate washing procedure during the staining protocol and the signal may 
pertain to residual fluorescent secondary antibodies. A control experiment in 
which cells were incubated with secondary antibody alone would determine if 
inadequate washing procedures would result in the non-specific signal observed. 
This control experiment was not performed initially as the secondary antibody in 
use (goat anti-mouse IgG Alexa Fluor ® 488) had been used extensively within 
the Kohl laboratory in combination with the cells in question (Vero E6) without 
issues of non-specific binding.   
Downstream detection of ZIKV infection by western blot and 
immunofluorescence techniques will be performed using antibodies targeting E, 
specifically clone 0402166, given the target specificity of this antibody. 
Throughout the remainder of this thesis, this antibody clone shall only be 
referred to as ZIKV E.  
3.4.2 Cells 
The cell lines Vero E6 and A549/A549 Npro, commonly used in the study of other 
viruses, have been used to propagate and study ZIKV within the Kohl laboratory 
(Donald et al., 2016). The emergent neurological symptoms associated with ZIKV 
infection during the 2015/16 outbreak prompted study in a more biologically 
relevant cell line or primary cells. Other studies have focused on the role of 
ZIKV-mediated depletion of neural progenitors using neurospheres and organoid 
models of the developing brain; such studies highlighted differing region specific 
progenitor cells as a target for infection and contribute towards microcephaly 
(Bayless et al., 2016, Dang et al., 2016, Garcez et al., 2016, Onorati et al., 
2016, Li et al., 2016a). Another study highlighted human foetal microglia as 
target for ZIKV infection, and a source of inflammation (Lum et al., 2017). 
97 
 
However, not all foetal ZIKV infections result in microcephaly, and the long-term 
effects of ‘asymptomatic’ foetal ZIKV infection are yet to be observed. It is 
therefore prudent to explore ZIKV infection in other cell types within the brain 
to determine populations which may contribute towards ambiguous pathologies 
(i.e. those which may not present until later-life), identify cells in which 
persistent infection may be established, and identify cells which contribute 
neuroprotective roles in ZIKV infection. 
Astrocytes are one of the most abundant cell types within the brain, contributing 
to numerous supportive CNS functions including: blood-brain barrier 
maintenance, CNS homeostasis, synaptic pruning and immunological regulation 
(Miller, 2018). Astrogliosis has been demonstrated during infection with other 
neurotropic flaviviruses such as TBEV, JEV and WNV (German et al., 2006, van 
Marle et al., 2007, Gelpi et al., 2005). Astrogliosis refers to reactive astrocytes 
undergoing morphological, and probable molecular changes in response to CNS 
insult (Sofroniew, 2014); the nature of the insult influences such changes. 
Furthermore, it has been demonstrated that despite initial infection with 
flaviviruses such as TBEV, astrocytes are refractory to virus-induced cell death 
(Lindqvist et al., 2016). Instead, astrocytes contribute to Flavivirus restriction 
within the CNS via fast-acting type-I IFN responses (Lindqvist et al., 2016). 
Therefore, astrocytes represent an interesting cell population to study ZIKV 
interactions. 
In this chapter, it has been demonstrated that ZIKV can establish productive 
infection within the transformed cell line SVGp12 (Figure 3–5), in addition to 
primary human astrocytes (Figure 3–7 and Figure 3–8). Owing to various culturing 
issues such as lack of expression of the astrocytic cell marker GFAP SVGp12 cells, 
and incompatibility of plasticware with NHA cells (to grow high quantity of 
cells), both these cell types were deemed unfit to pursue further study. It was 
instead decided that mouse-derived multi-cell type co-cultures which model the 
CNS and PNS, generated by a collaborating laboratory, would be a better suited 
model (Thomson et al., 2006). The brain is a complex organ with numerous cell 
types, all interacting with one another – with the expression of certain genes 
being dependent on such interactions. Therefore, pursuing a transcriptomic 
study using these co-cultures may be more indicative of what is occurring 
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globally with CNS during ZIKV infection. Chapter 4 explores initial studies 
conducted with CNS and PNS co-cultures and the results of transcriptomic 
analyses in CNS co-cultures can be found in Chapter 5. 
3.4.3 ZIKV 3’UTR pulldown 
The focus of this chapter was to produce methods to study ZIKV-host 
interactions. Few interactions have been described between 3’UTR and host 
proteins. Therefore, the aim of this line of research was to establish 
methodology to pursue research to delineate ZIKV 3’UTR interactions with host 
proteins, with the potential to expand to other members of the Flaviviridae 
family. Initial qPCR data demonstrate that like DENV, ZIKV sfRNA is produced in 
higher quantities than genomic RNA during infection.  
Despite exhaustive efforts to adapt the protocol described by Chavali et al., 
2017 (Section 3.3.3), there was insufficient data to suggest the successful use of 
biotinylated ZIKV 3’UTR as bait in a pulldown assay in the studies carried out in 
this chapter (Figure 3–11). Therefore, further proteomic analyses were not 
pursued. Numerous factors may have influenced this result. For example, 
Musashi-1 expression in A549 cells could be lower than in the U-251 cells used in 
Chavali et al., 2017 – which may influence the ‘control’ for pulldown efficiency 
in this dataset. Furthermore, Chavali et al., 2017 use a predetermined quantity 
of protein lysate in the pulldown assay, whereas data in this thesis the total 
protein concentration has not been quantified; cell count was used as a measure 
in place of protein concentration. This may mean that the amount of cell lysate 
used in the pulldown may have been insufficient to detect Musashi-1 within the 
‘control’ pulldown.  
Secondary structure formation is critical for some sfRNA functionality, such as 
XRN1 resistance. Whilst efforts were made to relax and refold biotinylated bait 
3’UTR RNA, perhaps the RNA remained improperly folded – failing to bind 
Musashi-1. Additionally, incorporation of biotinylated UTP itself may alter 
secondary structure formation and hence influence the binding capacity of the 
bait 3’UTR RNA. However, this method was employed by Chavali et al 2017 and 
therefore may not be an influential factor in this study.  
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3.4.4 ZIKV strain comparison 
The 2015/16 ZIKV outbreak lead to a rapid increase in ZIKV studies being 
published. The lack of established and standardised protocols resulted in an 
increase in varying methodologies being employed to study ZIKV. The use of 
differing viral strains and propagation methods could lead to the generation of 
artefactual data. The key difference in propagation method was the species 
origin of the employed cell line; many used an insect derived cell-line (C6/36), 
and others a mammalian (typically Vero E6, some used A549/A549 Npro). The 
primary difference in ZIKV strain was studies which used MR766 as a model ZIKV 
MR766 has an extensive passage history and is of African lineage, not Asian-
lineage (the lineage of contemporary ZIKV outbreak isolates). One of the aims of 
this chapter was to determine if any of these confounding factors influence viral 
replication (determined by qPCR) and production (determined by viral plaque 
assay). 
These data (Figure 3–13) showed that ZIKV PE243 propagated in insect cells 
(C6/36) may afford some reproductive advantage over PE243 propagated in 
mammalian cells (A549 Npro) within Ifnar1 KO CNS co-cultures. ZIKV PE243 
C6/36 produced higher titres of virus compared with ZIKV PE243 Npro, though 
this did not reach statistical significance. However, when examined by qPCR, 
both viruses produced similar quantities of viral RNA. Furthermore, in KO and 
WT PNS and WT CNS co-cultures, there was no significant difference between 
either PE243 virus. Overall, these results suggest that the species used to 
propagate PE243 virus does not affect virus replication in WT CNS and WT and 
KO PNS co-cultures.  
In contrast, it is clear from these data that using MR766 produces markedly 
increased levels of infection within both WT and KO CNS and PNS co-cultures 
compared to either PE243 virus (Figure 3–12). MR766 historically has undergone 
just under 150 passages in the brains of suckling mice, in addition to various cell 
culture passages (Haddow et al., 2012). Whether the differences observed 
between MR766 and PE243 is a result of adaptation to mammalian cells or more 
specifically murine cells, neuro-adaptation or lineage-specific adaptation is 
unknown.  
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It has recently come to light that multiple variations of MR766 are in laboratory 
use, which differ in sequence (Carbaugh et al., 2019). Some variations possess 
the N154 glycosylation site, others have a single amino acid mutation which 
ablates the glycosylation site or a 4 amino acid deletion removing the 
glycosylation site altogether. Absent of N154 glycosylation, MR766 infection is 
attenuated in mice (Carbaugh et al., 2019). Many African-lineage ZIKV isolates 
lack N154 glycosylation, whereas all Asian-lineage ZIKV strains possess the N154 
glycosylation signal. The N153/N154 glycosylation sequence is conserved 
amongst flaviviruses, contributing to pathogenicity and neuro-invasive properties 
in WNV (Shirato et al., 2004, Beasley et al., 2005). Interestingly, the MR766 
isolate used in these studies does not have an intact N154 glycosylation site 
(GenBank accession number: AY632535). Absent N154 glycosylation, it may be 
that host adaption is the main contributor to the increased fitness of MR766 
compared with either PE243 virus. However, this virus has not been 
re-sequenced since its acquisition. It would be intriguing to determine whether 
the inclusion of N154 glycosylation would be further advantageous to MR766 
replication within the CNS and PNS co-cultures to corroborate findings of 
Carbaugh et al., 2019 which state that N154 glycosylation mediates ZIKV 
pathogenesis. 
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3.5 Summary 
 The anti-ZIKV envelope antibody clone 0402166 from Aalto Biosciences 
can be used successfully in western blot and immunofluorescence 
protocols to detect ZIKV infection. 
 ZIKV readily infects astrocytes. However, owing to a combination of 
functional and technical issues neither the astrocyte cell line SVGp12 or 
NHA will be used in downstream analyses in this thesis. 
 The species origin of cell lines used to propagate ZIKV PE243 did not 
significantly affect viral replication in Ifnar1 KO and WT CNS and PNS co-
cultures. 
 ZIKV MR766 (GenBank accession number: AY632535) has significantly 
increased replicative capacity compared with ZIKV PE243 (produced in 
either mammalian or insect cells) in both Ifnar1 KO/WT CNS and Ifnar1 
PNS co-cultures. 
 CNS and PNS co-cultures represent a biologically relevant, complex model 
to investigate ZIKV interactions in the nervous system. Further 
characterisation of ZIKV infection in these systems can be found in Results 
Chapter 2. 
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4 Results chapter 2: ZIKV infection of the central 
and peripheral nervous systems 
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103 
 
4.2 Introduction 
4.2.1 ZIKV and nervous system disorders 
The 2015/16 ZIKV epidemic in South and Central America was characterised by 
an unprecedented rise in neurological disease complications affecting the 
central and peripheral nervous systems (CNS and PNS respectively) (Campos et 
al., 2015, Zanluca et al., 2015). Prior to this outbreak, documented symptoms of 
ZIKV included fever, maculopapular rash, myalgia, headache and arthralgia - 
symptoms also consistent with co-circulating arboviruses, DENV and chikungunya 
virus, also endemic in regions of ZIKV transmission (SIMPSON, 1964, Filipe et al., 
1973, Dupont-Rouzeyrol et al., 2015, Villamil-Gómez et al., 2016).  
Retrospective analyses of the 2013 outbreak of ZIKV in French Polynesia linked 
ZIKV infection with the increased incidence of GBS; a complication that has also 
been associated with the 2015/16 outbreak (Cao-Lormeau et al., 2016, Oehler et 
al., 2014). GBS is an acute paralysing neuropathy caused by aberrant immune 
responses targeting peripheral nerves, typically following infection. In addition 
to ZIKV, other infectious agents associated with GBS include bacteria such as 
Campylobacter jejuni, Mycoplasma pneumoniae and Haemophilus influenzae, 
and viruses such as cytomegalovirus, Epstein Barr virus, influenza A virus (Jacobs 
et al., 1998, Mori et al., 2000). A spectrum of pathological phenotypes exist, 
which are primarily dependent on nerve component involvement (reviewed in 
(Willison et al., 2016)). ‘Acute inflammatory demyelinating polyneuropathy’ 
denotes GBS syndromes where immune-related injury involves Schwann cells and 
the myelin sheath (see section 4.2.2.2 for description of nervous system cell 
types). Whereas, ‘acute motor axonal neuropathy’ describes GBS syndromes 
where the target of autoimmune injury are axons themselves (Willison et al., 
2016). GBS is primarily managed by the administration of intravenous 
immunoglobulins. The aetiology of ZIKV-associated GBS remains to be 
determined; whether ZIKV-GBS reflects a post-infectious immune disorder or a 
consequence of direct viral infection of the PNS is currently unknown. 
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Novel sequelae of ZIKV infection affecting the CNS were a serious concern during 
the 2015/16 outbreak; this included an expanding spectrum of 
neurodevelopmental disorders predominantly affecting the CNS of neonates - 
now termed ‘congenital ZIKV syndrome’. (Mlakar et al., 2016, Schuler-Faccini et 
al., 2016, Melo et al., 2016, Moura da Silva et al., 2016). A notable 
developmental disorder that arose during the 2015/16 outbreak is microcephaly 
(Section 1.3.4). Microcephaly is characteristically associated with a reduction in 
head circumference which is below the third percentile for age and sex (Mlakar 
et al., 2016). Pathological findings of ZIKV-infected infants report further 
malformations including extensive cerebral calcifications, ventriculomegaly 
(enlarged ventricles [fluid filled spaces] in the brain) and arthrogryposis 
(congenital joint contracture) (Chimelli et al., 2017). The spectrum of 
neurological manifestations associated with congenital ZIKV infection are 
collectively known as congenital ZIKV syndrome (CZS). Auditory and ocular 
impairments, fine motor delay, behavioural abnormalities, below average 
cognitive performance and expressive language delays have also been associated 
with congenital ZIKV infection (de Paula Freitas et al., 2016, Leal et al., 2016, 
Muller and Mulkey, 2019).  
At the time of study, the pathobiology underlying the neurological 
manifestations of ZIKV were poorly characterised, and a comprehensive 
understanding of the cellular tropism within CNS and PNS tissue were lacking. 
Efforts were made to try and determine ZIKV entry receptors, highlighting Axl – a 
cell surface receptor tyrosine kinase - as a potential candidate; the importance 
of this molecule in facilitating virus entry is still debated (Nowakowski et al., 
2016, Hastings et al., 2017, Li et al., 2017, Wang et al., 2017, Ojha et al., 2019). 
Studies involving neurospheres, organoids and induced pluripotent stem cells 
were used to investigate the potential causes of microcephaly, demonstrating 
that neural progenitor cells and radial glia were susceptible to ZIKV infection 
(Qian et al., 2017). Numerous studies involving mouse models were used to study 
ZIKV mediated birth defects and neuropathogenesis, amongst other effects such 
as testicular infection (Cugola et al., 2016, Li et al., 2016a, Fernandes et al., 
2017, Govero et al., 2016). Previous studies in one-day-old Webster Swiss, AG129 
and new-born Swiss mice, suggested that neurons and astrocytes may be 
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susceptible to ZIKV infection (Fernandes et al., 2017, Bell et al., 1971, Aliota et 
al., 2016). 
Despite these findings, at the time of experimentation for this thesis no attempt 
had been made to examine the relative vulnerability of all the principle cell 
types within the CNS. Furthermore, no investigation of ZIKV infection within the 
PNS had been conducted.  
4.2.2 Overview of CNS and PNS co-cultures 
 Co-culture generation 
CNS and PNS co-cultures were kindly generated by J Barrie and V Schultz for 
downstream experimentation documented within this chapter, using techniques 
adapted from previous work (Thomson et al., 2006, Thomson et al., 2008).  
CNS cultures were generated from the spinal cords of Ifnar1 knockout (KO) and 
wildtype (WT) embryonic day 13 (E13) mouse embryos. The Ifnar1 gene encodes 
IFN α/β receptor subunit 1; mice homozygous negative (-/-) for Ifnar1 are 
rendered unable to respond to exogenous type I IFNs (IFN α/β) and typically have 
an increased susceptibility to viral infection (Müller et al., 1994). Briefly, a 
homogenous cell suspension of spinal cord tissue was generated and plated on 
top of coverslips and maintained until day 28 in vitro (DIV28). DIV28 CNS co-
cultures are reflective of more mature CNS systems such as that of the adult 
brain, as axons are extended and fully myelinated (see Figure 4–12 for a 
schematic overview of neural developmental processes). CNS co-culture 
development can be tailored to reflect different stages of the developing brain, 
as described in section 4.3.4. 
‘Sister’ peripheral nervous system cultures (PNS) were also generated from the 
same embryos, by harvesting dorsal root ganglia (DRG) and plating one DRG per 
coverslip. PNS cultures were maintained for the same length of time as CNS 
cultures.  
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Figure 4–1 Light microscope image and schematic of central nervous system (CNS). 
(A) Light microscope image of CNS co-culture imaged at DIV28. Neuronal cell bodies cluster to form 
nuclei, making connections with other nuclei via extensions (axons/dendrites). (B) Schematic 
representation of principle cell types present within CNS co-culture. Principle cell types include 
neurons, astrocytes, microglia, oligodendrocytes and oligodendrocyte precursors (OPCs). 
Oligodendrocytes are the myelin forming cell type of the CNS and wrap around the axons of neurons 
to enable saltatory conduction to take place. Myelinated axons form the white matter of the brain.  
400 µm 
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 Co-culture composition 
To examine ZIKV tropism within the CNS and PNS, mixed cell co-cultures were 
employed in these studies. These co-cultures contain all principle cell types of 
their respective nervous system but lack secondary immune responses, for 
example those provided by T cells. Grown in semi-monolayer conditions atop of 
glass coverslips, they recapitulate complex cell-cell interactions of intact 
nervous systems – allowing for molecular studies of such interactions to be 
conducted.
 
Figure 4–2 Schematic representation of CNS myelin sheath produced by an oligodendrocyte 
Oligodendrocytes are the myelinating cell type of the central nervous system. One oligodendrocyte 
(purple) can form the myelin sheath for many axons. Oligodendrocytes extend processes which wrap 
a lipid-rich, specialised membrane around the axons of neurons (blue). (A) Transverse section of 
myelinated axon. (B) Longitudinal cross-section of myelinated axon. This image was produced using 
BioRender.  
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The CNS is composed of five principle cell types: neurons, astrocytes, microglia, 
oligodendrocytes and oligodendrocyte precursor cells (OPCs) (Figure 4–1). A brief 
overview of each cell type is summarised herein. Neurons communicate signals, 
via electrical impulses and neurotransmitters, from the CNS (and within) to the 
rest of the body to affect a response. Astrocytes are the most abundant cell type 
in the central nervous system and possess diverse functionality, reflected in the 
increased recognition of astroglia subpopulations (Miller, 2018). Astrocyte 
function includes but is not limited to the maintenance of CNS homeostasis, 
blood brain barrier function, neuron synaptogenesis, and immunological 
regulation (Miller, 2018). Oligodendrocytes are the myelin-producing cell type of 
the CNS. Myelin is a specialised cell membrane that wraps around axons, 
insulating them and enabling rapid conduction action potentials to take place; 
one oligodendrocyte can insulate multiple axons within the CNS (Figure 4–1B and 
Figure 4–2) (Snaidero and Simons, 2017). Oligodendrocyte precursor cells are a 
class of stem cell that can differentiate into mature oligodendrocytes. Microglia 
are the tissue resident macrophages of the CNS, implicated in the regulation of 
immune/inflammatory effects and CNS maintenance (Nayak et al., 2014).  
The principle cell types of the PNS include neurons, macrophages and Schwann 
cells (Figure 4–3). Schwann cells are the cell type responsible for myelinating 
axons of the peripheral nervous system. The myelin sheath of the periphery 
differs to that of the CNS, as many Schwann cells are required to myelinate a 
singular axon in the PNS (Salzer, 2015). The cell body of the Schwann cell is in 
close proximity to PNS axons, whereas CNS oligodendrocyte cell bodies may 
reside in a distant location to a CNS axon (compare Figure 4–1B with Figure 4–
3B). 
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Figure 4–3 Light microscope image and schematic of peripheral nervous system (PNS) cells. 
(A) Light microscope image of PNS co-culture, imaged at DIV28. PNS neurons organise to form 
parallel bundles, extending out from DRGs (DRG not shown in this image). (B) Schematic 
representation of the principle cell types present within PNS co-culture. The principle cell types of 
the PNS include neurons, macrophages and Schwann cells. Schwann cells are the myelinating cell 
type of the PNS. Numerous Schwann cells are required to form the myelin sheath of a singular axon. 
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4.2.3 Chapter aims 
Determining ZIKV tropism on a cell type specific level is essential in 
understanding ZIKV-associated neuro-pathologies. Therefore, the primary aim of 
this chapter was to determine the cellular targets and pathophysiological 
responses of ZIKV infection within the CNS and PNS using murine ‘myelinating’ 
co-cultures (see section 4.2.2.2 for co-culture composition and generation). 
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4.3 Results 
4.3.1 CNS co-cultures are more susceptible to ZIKV infection than 
their PNS counterpart, even in the absence of type I IFN 
responses 
To investigate ZIKV tropism within the CNS and PNS, Ifnar1 KO and WT (herein 
referred to as KO and WT) co-cultures were infected with ZIKV for either 24 or 
72 h p.i. at a MOI of 0.3 or 3.0 PFU/cell, respectively. The two differing MOIs 
and timepoints were used to examine different aspects of ZIKV tropism within 
the CNS and PNS co-cultures. The lower infectious dose coupled with the shorter 
timepoint (MOI 0.3/24 h p.i.) was used to investigate the initial infectious 
targets for ZIKV infection. Whereas the longer timepoint coupled with the higher 
infectious dose (MOI 3/72 h p.i.) was used to try to identify all possible 
infectious targets of ZIKV infection.  
Cultures were fixed at the timepoints indicated, immunolabelled with an 
antibody targeting the ZIKV envelope protein (ZIKV E) and nuclei were 
counterstained with DAPI. ZIKV E positive and negative cells within an area of 
interest were quantified (rectangular area of interest [AOI] of 148,427 µm or 
20,000 µm – see chapter Section 2.8.1 for details) (Figure 4–4 and Figure 4–7). 
ZIKV E positive cells were identified by observing characteristic staining patterns 
for the ZIKV E protein i.e. intense staining in cytoplasmic perinuclear 
distribution, or diffuse cytoplasmic staining with distinct association with a 
nucleus (Section 3.3.1, Figure 3–2)(Donald et al., 2016). 
Overall, infection levels were lower in PNS cultures compared to CNS cultures, 
even in the absence of type I IFN responses (Figure 4–4). When infected at a MOI 
of 3.0 PFU/cell and fixed at 72 h p.i., 19% of the cells were infected in the KO 
CNS co-cultures, whereas the percentage of cells infected in the PNS equivalent 
for these conditions is only 1%. The lack of PNS infection is best exemplified 
visually when comparing KO cultures of CNS and PNS cultures (1st Column of data 
in Figure 4–4A/B). 
At 24 h p.i., 4% of the cells in the KO CNS culture were infected as indicated by 
positive staining for ZIKV E, whereas only 2% of the cells were infected in the 
equivalent WT culture. The disparity in infection levels between WT and KO co-
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cultures was most apparent when observing MOI 3.0/ 72 h p.i. co-cultures; KO 
cultures were 19% infected and WT, 4%. This demonstrates that the presence of 
type I IFN responses plays a protective role within CNS co-cultures during ZIKV 
infection. However, in PNS co-cultures overall infection levels were much lower 
than CNS co-cultures; infection levels with KO and WT co-cultures at either 
MOI/timepoint combination were around 1-2% (Figure 4–4B). This suggests that 
cells of the PNS co-cultures are intrinsically refractory to ZIKV infection; owing 
to such low levels of ZIKV infection, it is unclear from this study if type I IFN 
plays a critical protective role against ZIKV infection in PNS co-cultures, as it 
appears to do so in the CNS co-cultures.  
Absent of type I IFN responses, high ZIKV infection levels can be achieved, and is 
advantageous for studying intrinsic cell type specific susceptibility to ZIKV 
infection. Therefore, the remainder of the studies in this chapter were 
subsequently performed using Ifnar1 KO CNS co-cultures only. 
113 
 
 
Figure 4–4 Characterisation of ZIKV infection in Ifnar1 KO and WT CNS and PNS co-cultures. 
CNS and PNS co-cultures were infected with ZIKV with either MOI of 0.3 or 3 PFU/cell for and 
assayed at the time points indicated. ZIKV infection was quantified by a manual count of ZIKV 
envelope positive cells (using mouse anti-ZIKV E and goat anti-mouse IgG Alexa Fluor ® 488; green) 
vs total DAPI positive cells. Overview immunofluorescence images are displayed in the top panel. 
White bars represent total cell density whereas black bars indicate the infected cell density. The total 
percentage of infected cells (green) is displayed above the bars in the bottom panel.   
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 PNS maintenance media does not inhibit ZIKV infection 
The maintenance media for CNS and PNS cultures differ in their composition. 
Notably, CNS media are serum-free whereas PNS media contain horse serum. To 
ensure that the apparent lack of ZIKV infection in PNS co-cultures is not an 
artefact of culture conditions, a series of infections were performed in a ZIKV 
permissible cell line to test PNS media components. 
A549 cells, a cell line permissive to ZIKV infection (Donald et al., 2016), were 
infected with ZIKV at a MOI of 0.3 PFU/cell for 72 h. Cells were maintained in 
one of the following combinations of media post infection: DMEM supplemented 
with 10% FBS (normal A549 media), DMEM supplemented with 10% horse serum 
(HS), whole PNS maintenance media (10% HS), PNS maintenance media 
supplemented with 10% FBS. ZIKV infection was assessed qualitatively by 
immunostaining cells for ZIKV E and DAPI (representative images are shown in 
Figure 4–5).  
Upon observation, infection levels remained consistent between the differing 
media conditions and it was decided that this qualitative assessment was 
sufficient in this investigation. Results show that horse serum does not inhibit 
ZIKV infection in either DMEM or PNS maintenance media. In fact, it seems that 
PNS maintenance media enhanced infection when supplemented with 10% FBS. 
In these conditions, it appeared that cells were clustered together with large 
blank spaces on coverslips and few cells remain uninfected, presumably as a 
result of enhanced cytopathic effect taking place (CPE).  
Owing to the reduced infection within PNS co-cultures it appears unlikely that 
Guillain-Barré syndrome or other disorders affecting the periphery are a result of 
direct ZIKV infection of the PNS. 
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Figure 4–5 PNS maintenance media do not inhibit ZIKV infection in A549 cells. 
A549 cells were infected with ZIKV at a MOI of 0.3 PFU/cell for 72 h. Following the adsorption period, 
cells were either maintained in complete PNS maintenance media (PNS 10% horse serum (HS)), 
PNS maintenance media supplemented with FBS (PNS 10% FBS), normal A549 maintenance media 
(DMEM 10% FBS) or A549 media supplemented with 10% horse serum (DMEM 10% HS). Scale 
bar: 100 µm Blue: DAPI Green: ZIKV envelope protein (mouse anti-ZIKV E [primary antibody], goat 
anti-rabbit IgG Alexa Fluor ® 488 [secondary antibody]). 
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4.3.2 Principle CNS cell types have varying susceptibility to 
infection with ZIKV 
As ZIKV infection levels were greatest in Ifnar1 KO CNS cultures, these cultures 
were used to investigate ZIKV tropism on a cell type specific level. As described 
previously in section 4.3.1, cultures were infected at MOI of 0.3 PFU/cell for 
24 h or a MOI of 3.0 PFU/cell for 72 h to determine: 
I) The initial cell types infected by ZIKV within the CNS 
II) The range of cell types infected by ZIKV within the CNS 
Post-fixation, cells were immunolabelled using cell type specific markers. 
Neurons were labelled with α-NeuN; NeuN is a transcription factor present in 
nucleus of neurons. Astrocytes were labelled with α-GFAP; GFAP - glial fibrillary 
acidic protein - is an intermediate filament. Oligodendrocytes were labelled 
with α-PLP/DM20; PLP (proteolipid protein) and DM20 are two abundant proteins 
found in myelin. Oligodendrocyte precursor cells (OPCs) were immunolabelled 
with α-NG2; NG2 is chondroitin sulphate proteoglycan and differentiates 
between OPCs and mature oligodendrocytes. Microglia were immunolabelled 
with α-F480; F480 is a surface glycoprotein found on macrophages. Cells were 
also immunolabelled with α-ZIKV E and nuclei were counterstained with DAPI. 
Cells that stained positive for a specific cell type marker were enumerated, in 
addition to cells with double positive staining (positive for cell type specific 
marker and ZIKV E). Representative images of each cell type can be found in 
Figure 4–6. 
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Figure 4–6 Confocal microscopy of ZIKV infected CNS cells.  
Cell type specific immunofluorescence analysis of ZIKV infected cells in Ifnar1 KO CNS co-cultures. 
(A) Neuron stained for NeuN, also known of Fox-3, a transcription factor which primarily resides in 
neuronal nuclei but can also exist within the cytoplasm of neurons. (B) Astrocyte stained for GFAP, 
an intermediate filament found within this star-shaped cell. (C) Oligodendrocyte stained for 
PLP/DM20, a component of myelin; this stain highlights oligodendrocyte cells bodies and myelin 
sheaths, which are long, thin, extensions of lipid-rich membranes that wrap around axons (D) 
Oligodendrocyte precursor cell (OPC) stained for NG2, which is an integral membrane proteoglycan. 
OPC’s have several projections emanating from the cell body, which are immature myelin 
sheaths.(E) Microglial cell stained for F4/80, a macrophage-specific adhesion g-protein coupled 
receptor; projections from the cell body allow microglia to move and scavenge cellular debris and 
eliminate infected/damaged cells.Green: ZIKV envelope protein (mouse anti-ZIKV E [primary 
antibody], goat anti-rabbit IgG Alexa Fluor ® 488 [secondary antibody]), Blue: DAPI, red: cell- type 
specific marker (A  Rabbit anti-NeuN [primary antibody]; B  Rabbit anti-GFAP [primary antibody]; C  
Rat anti-PLP/DM20 [clone AA3; primary antibody]; D  Rabbit anti-NG2 [primary antibody]; E - rat anti-
F480 [primary antibody]). Secondary antibodies used to visualise cell specific markers were either 
goat anti-rabbit IgG or goat anti-rat IgG conjugated with Alexa Fluor ® 594. Scale bar: 10um. 
A B 
C D 
E 
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The overall culture composition did not alter markedly between each of the 
infection conditions (MOI 0.3/24 h p.i., MOI 3/72 h p.i. and mock) when 
observing the profile of total cell type densities, measured in cells/mm2 
(compare white bars of Figure 4–7 A/B/C). This highlights the reproducible 
nature of co-culture generation, in addition to demonstrating that ZIKV 
infection, at least within these time frames, did not alter the proportions of 
cell-type specific populations in this culture. However, cultures infected at MOI 
3/ 72 h p.i. showed a slight reduction in oligodendrocyte populations; the mean 
total cell density (cells/mm2) was 90.1, 60.1 and 33.6 for mock, MOI 0.3/24 h p.i 
and MOI 3/72 h.p.i. respectively (Table 4–1,Table 4–2,Table 4–3).  
 Total cell density 
Infected cell 
density 
(MOI 0.3/24 h.p.i) 
% Infected 
considering 
the relative 
abundance of 
cell type 
Cell Type 
Mean 
(cells / mm2) 
SD 
Mean 
(cells / mm2) 
SD 
Oligodendrocytes 60.1 7.9 19.9 9.2 24% 
OPCs 215.7 73.3 30.1 23.0 12% 
Microglia 97.8 38.0 5.3 6.5 6% 
Astrocytes 316.2 44.3 11.6 4.3 3% 
Neurons 309.2 76.8 9.4 12.1 3% 
Table 4–1 Quantification cell-type specific ZIKV infection in CNS co-cultures: MOI 0.3  
Ifnar1 CNS co-cultures were infected with ZIKV at a MOI of 0.3 and fixed with 4% formaldehyde at 
24 h.p.i. Coverslips were immunostained for ZIKV in addition to cell-type specific markers. The 
number of infected and uninfected cells was enumerated, and percentage of infection calculated, 
taking into account the relative abundance of each cell type. SD: standard deviation.  
The proportion of ZIKV-positive cell types are summarised in Table 4–1, Table 4–
2 and Figure 4–7. Oligodendrocytes were the predominant cell type infected by 
ZIKV at both multiplicities of infection and time points. These data indicate that 
oligodendrocytes may be more permissive to ZIKV replication than other CNS cell 
types and may represent a key target during infection of the CNS with ZIKV. 
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 Total cell density 
Infected cell 
density 
(MOI 3/72 h.p.i) 
% Infected 
considering the 
relative 
abundance of 
cell type 
Cell Type 
Mean 
(cells / mm2) 
SD 
Mean 
(cells / mm2) 
SD 
Oligodendrocytes 33.6 10.3 27.2 11.2 45% 
OPCs 260.2 37.0 30.7 23.3 11% 
Microglia 106.4 34.2 54.2 16.5 34% 
Astrocytes 253.3 104.6 83.5 28.4 26% 
Neurons 347.9 166.4 33.0 20.2 9% 
Table 4–2 Quantification cell-type specific ZIKV infection in CNS co-cultures: MOI 3 
Ifnar1 CNS co-cultures were infected with ZIKV at a MOI of 3 and fixed with 4% formaldehyde at 
72 h.p.i. Coverslips were immunostained for ZIKV in addition to cell-type specific markers. The 
number of infected and uninfected cells was enumerated, and percentage of infection calculated, 
taking into account the relative abundance of each cell type.  SD: standard deviation.  
Alternatively, neurons appeared less permissive to ZIKV infection, as evidenced 
by infection rates of 3 or 9% within the cell type population. In summary, these 
data demonstrate that each principle CNS cell type is susceptible to ZIKV 
infection, albeit to varying degrees of susceptibility; ranging from 
oligodendrocytes (most permissive) to neurons (least permissive). 
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 Total cell density 
Infected cell 
density 
(MOCK) 
% Infected 
(considering 
relative 
abundance of 
cell type) 
Cell Type 
Mean 
(cells / mm2) 
SD 
Mean 
(cells / mm2) 
SD 
Oligodendrocytes 90.1 34.6 3.4 2.3 3% 
OPCs 270.5 45.3 0.3 0.4 <1% 
Microglia 85.6 29.6 1.1 1.4 2% 
Astrocytes 346.6 69.1 8.5 10.2 4% 
Neurons 372.0 114.8 3.0 4.0 <1% 
Table 4–3 Quantification cell-type specific ZIKV infection in CNS co-cultures: MOCK 
Ifnar1 CNS co-cultures were mock infected with “% FBS/PBS and fixed with 4% formaldehyde at 
72 h.p.i. Coverslips were immunostained for ZIKV in addition to cell-type specific markers. The 
number of infected and uninfected cells was enumerated and percentage of infection calculated, 
taking into account the relative abundance of each cell type.  SD: standard deviation.  
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Figure 4–7 Quantitation of cell type specific infection ZIKV within Ifnar1KO CNS co-cultures. 
Cell type densities of CNS cultures were enumerated in the CNS cultures and presented as cells/mm2 
(white bars). The number of infected cells of each cell type is overlaid (black bars). The relative 
percentage of infection of each cell type is displayed above the corresponding bar. (A) Data from 
cultures infected at MOI 0.3 for 24 h p.i. (B) Data from cultures infect at a MOI of 3 PFU/cell for 72 
h. (C) Enumeration of mock infected cultures. Bars represent mean ± SD; n=3. 
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4.3.3 ZIKV infection of the CNS and cell death 
In addition to quantifying levels of ZIKV infection in different cell populations of 
the CNS, pyknotic nuclei were also counted as a marker for unhealthy and/or 
dying cells present in cultures (Figure 4–9). Pyknotic nuclei were distinguished 
from healthy nuclei based upon the intensity and homogeneity of DAPI labelling, 
and size. Pyknotic nuclei appeared very small and rounded with uniform, intense 
DAPI staining, whereas healthy nuclei varied in size and were heterogeneous in 
the uptake of DAPI stain - presenting intensely stained puncta within a lesser 
stained oval (Figure 4–8). 
 
Figure 4–8 Representative images of healthy and pyknotic nuclei 
CNS co-cultures (DIV28) were mock-infected by incubating with PBS supplemented with 2% FBS 
for one hour at 37 °C, prior to replacing with fresh CNS media. After 72 h p.i., cells were fixed in 4% 
formaldehyde. Nuclei within the CNS co-culture were stained using DAPI. (A) Image of healthy nuclei 
within a CNS co-culture (B) Image of unhealthy/pyknotic nuclei within a CNS co-culture. Images were 
taken at 20x magnification.  
At 72 h p.i. (MOI 3), ZIKV infection appeared to cause injury to most cell types as 
determined by pyknotic nuclei counts - with exception of neurons. There was 
degree of variation in pyknotic nuclei counts across most cell types and 
conditions. However, this was most pronounced for data relating to 
oligodendrocytes. Oligodendrocyte cell bodies are quite small and may be easily 
confused for pyknotic nuclei in some cases, particularly given the resolution of 
some nuclei in images used to quantification. This is owed to the fact that CNS 
co-cultures are not true monolayer cultures, as such they have many different 
focal planes. Therefore, in any given image some nuclei were out of focus, 
should this be an oligodendrocyte nucleus it may appear pyknotic given its size. 
This might also account for the higher percentage of pyknotic oligodendrocyte 
A B 
10 µm 
123 
 
nuclei in mock infected cultures (Figure 4–9). Therefore, this large degree of 
variation in this dataset may be attributed to human error in addition to 
protocol methodology. Despite issues pertaining to variation, there was a 
significant increase in pyknotic nuclei belonging to astrocytes and microglia. 
 
Figure 4–9 Exploration of cell death within Ifnar1 KO CNS co-cultures, as determined by 
pyknotic nuclei counts.  
Data from mock infected cultures are represented in white bars, MOI 0.3/24 h p.i. data are displayed 
in grey bars, and black bars represent data from MOI 3.0/72 h p.i. cultures. Bars represent mean ± 
SD; *p <0.05, n=3 
To address the issues that arose due to the subjective nature of counting 
pyknotic nuclei, a chemical assay was employed to investigate the global health 
of infected CNS cultures. The ApoTox-Glo™ Triplex Assay (Promega) was used to 
assess cell viability, cytotoxicity and apoptosis. To perform this assay, CNS co-
cultures were plated into 96 well plates instead of normal co-culture conditions. 
Cultures were infected with ZIKV at a MOI of 0.3 or 3 PFU/cell, and the assay 
was performed in accordance with manufacturer specifications at the time 
points indicated. Staurosporine, an inducer of apoptosis was used as a positive 
control of increasing cytotoxicity and apoptosis activation within this assay, and 
a negative control for cell viability. As staurosporine was solubilised in DMSO, 
DMSO was also used as a control and samples were assayed at 72 h post 
treatment. 
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The initial results (n=2) indicate there was relatively little change in cell 
viability between the different conditions (Figure 4–10A). Cultures at 24 h p.i. 
appeared to have a slight reduction in cell viability in comparison with 72 h p.i. 
and mock infected samples, with no considerable difference in GF-AFC intensity 
observed between cultures infected at the differing multiplicities of infection. 
When investigating cytotoxicity (Figure 4–10B), it appeared there was slightly 
more variation present between replicates 1 and 2, particularly at 72 h p.i. 
Overall, at 24 h p.i. cultures displayed similar levels of detected cytotoxicity to 
mock treated cultures. Whereas, at 72 h p.i. cultures displayed increased bis-
AFF-R110 activity, with cultures infected at the higher MOI demonstrating the 
highest increase in cytotoxicity in comparison to the other cultures. When 
measuring apoptosis there was a slight increase in apoptosis in cells infected at a 
MOI of 3.0 PFU/cell at 72 h p.i. cultures in comparison to mock infected cultures 
(Figure 4–10C). However, this fold change is negligible and owing to high 
variability is not considered significant. 
Overall, the initial observations of this experiment did not inspire further 
investigation, as the observed effects of ZIKV infection on global culture health 
at these timepoints were marginal. Therefore, further experimentation involving 
cell death using these conditions ceased. 
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Figure 4–10 Cell death analyses of IFN KO CNS co-cultures using ApoTox-Glo™ (Promega).  
Ifnar-1 CNS co-cultures grown in wells of a 96 well-plate were infected in triplicate with ZIKV at a 
MOI of either 0.3 or 3 PFU/cell. Samples were assayed at 24 h p.i. (white bars) and 72 h p.i. (black 
bars) using the ApoTox-Glo™ Triplex Assay and measured using a GloMax® 20/20 Luminometer 
(Promega). (A) Cells were treated with a cell-permeable GF-AFC substrate, and viability was 
measured using a luminometer with a fluorescence filter (400 nm wavelength excitation/ 505 nm 
wavelength emission). (B) Cells were treated with a cell-impermeable bis-AAF substrate, and 
cytotoxicity was measured using a luminometer with a fluorescence filter (485 nm wavelength 
excitation/ 520 nm wavelength emission). (C) Cells were lysed with the Caspase-Glo® 3/7 reagent 
and markers of apoptosis (caspase 3/7 activation) were measured via luminescence using a 
luminometer. Staurosporine, a known inducer of apoptosis, was used as a positive control for cell 
death/apoptosis. Biological repeats n=2, drug controls n= 1.   
Staurosporine 
Staurosporine 
Staurosporine 
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4.3.4 ZIKV infection of CNS co-cultures induces injury to white 
matter structures 
Oligodendrocytes were found to have the highest percentage of ZIKV infection of 
all principle CNS cell types present in our murine co-cultures (section 4.3.2). It 
became apparent during the quantification stages of earlier investigations of cell 
type specific levels of infection, that the PLP/DM20 (oligodendrocyte cell body 
and myelin) staining pattern in ZIKV infected cultures was slightly different 
compared to that of mock infected cultures. This was most pronounced in MOI 
3/72 h p.i. infected cultures. Oligodendrocytes extend processes (extensions) 
which wrap axons within the CNS with layers of specialised cell membrane to 
form myelin sheaths (Snaidero and Simons, 2014). Myelin sheaths when stained 
with PLP/DM20 should appear as relatively smooth long strands, with some 
larger rounded patches (oligodendrocyte cell bodies); sometimes small bumps 
might appear on the surface of the long strands - however, this can vary 
between cultures (Thomson et al., 2008). In ZIKV infected samples, the myelin 
staining appears fragmented and strands appeared thinner, with a more 
‘bubbled’ appearance in comparison to mock infected cultures (compare Figure 
4–11A with Figure 4–11B). See Figure 4–11C for a closer, direct comparison of 
healthy (indicated by a smooth arrow and unhealthy (indicated by a dashed 
arrow) myelin.  
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Figure 4–11 Myelin damage during ZIKV infection.  
Cultures were infected with ZIKV at a MOI of 3.0 PFU/cell. At 72 h p.i. cells were fixed in 4% 
formaldehyde, stained for ZIKV E (mouse anti-ZIKV E [primary antibody], goat anti-rabbit IgG Alexa 
Fluor ® 488 [secondary antibody]; green), myelin (rabbit anti-PLP/DM20 [primary antibody], goat 
anti-rabbit IgG Alexa Fluor ® 594; red) and DAPI (blue) and analysed by confocal microscopy. (A) 
Mock-infected CNS co-culture stained for myelin. (B) ZIKV-infected CNS co-culture at 72 h p.i, 
stained for myelin (C) Close up of a ZIKV-infected oligodendrocyte, stained for ZIKV-E, myelin and 
DAPI. Dashed arrow points towards fragmented myelin sheath of an infected oligodendrocyte. The 
solid arrow points towards healthy myelin, which is smooth in appearance. 
Myelination of neurons in the human brain occurs late in gestation and is not 
complete until early adulthood (a timeline of different neural development 
processes can be found in Figure 4–12) (Fields, 2008, Giedd, 2004). Previous 
experiments within this chapter utilised cultures which were relatively mature 
(DIV28) and are more reflective of an adult human brain (sections 4.3.1 to 
4.3.3). This was because other studies at the time focused on predominantly 
immature CNS systems to model microcephaly as the highest risk for developing 
this condition was thought to be the first trimester. Our study aimed to 
understand ZIKV tropism in both the CNS and PNS; as GBS typically affects a 
more mature nervous system, and the effects of ZIKV infection within the CNS of 
10 µm 
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more mature brains e.g. infants remained unexplored. This led to using the later 
culture developmental time point to explore novel aspects of ZIKV infection. 
This was done in the knowledge that the stages of co-culture development were 
well established, and that we could tailor infection to reflect earlier time points 
of human foetal development (Thomson et al., 2006, Thomson et al., 2008).  
 
Figure 4–12 Schematic representation of developmental processes within the human CNS 
from conception to adulthood.  
The grey bar indicates timepoints throughout life, with a large focus on the gestation period. 
Myelination occurs late in gestation period (red) and occurs throughout childhood into early 
adulthood. Figure adapted from (Tau and Peterson, 2010). 
Therefore, to test if the process of myelination was affected by ZIKV infection, 
murine CNS co-cultures were infected at a developmental timepoint that 
reflected late foetal life when myelination was just starting to take place e.g. at 
28 weeks post-conception (Figure 4–12 for overview of gestational timeline; top 
row Figure 4–13 for image co-culture equivalent, DIV18). Cultures were infected 
at a MOI of 0.3 PFU/cell in order to try and increase the longevity of the 
experiment, as myelination within CNS co-cultures was complete at DIV28 
(reflective of post-natal life). The aim was to allow co-cultures to mature until 
DIV28 to observe if myelination was affected by infection with ZIKV from early 
stages of development. However, owing to culture deterioration in infected 
samples, experiments were halted at DIV24 (6 d p.i.). Cultures were maintained 
until DIV24 with media replenishments taking place 2 and 4 d p.i. (see Section 
2.8.1 for details). Cultures were subsequently fixed and immunolabelled to 
depict white matter structures; myelin was immunolabelled with α-MBP (myelin 
basic protein) and axons with α-SMI31 (phosphorylated neurofilament). The 
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presence or absence of ZIKV infection was confirmed through separate 
immunostaining for ZIKV E (Figure 4–14).  
In ZIKV-infected cultures, at DIV24 (6 d p.i.) there was a near complete loss of 
myelin (bottom row, first column -Figure 4–13), in comparison to mock cultures 
which had extensive myelin sheath formation (middle row, first column - Figure 
4–13).
 
Figure 4–13 Extensive loss of myelin and axons is observed during ZIKV infection of CNS co-
cultures. 
Murine co-cultures were infected with ZIKV at a MOI of 0.3 PFU/cell. Ifnar1 KO CNS co-cultures 
were infected when they reached DIV18, a developmental stage where myelination had just begun. 
Cells were maintained until DIV24 (6 d p.i.) when myelination should be extensive. Column 1: Myelin 
staining (rat anti-MBP [primary antibody], goat anti-rat IgG Alexa Fluor ® 594 [secondary antibody]); 
Column 2: Axons (mouse anti-SMI31 [primary antibody], goat anti-mouse IgG Alexa Fluor ® 488 
[secondary antibody]); Column 3: merged image. myelin is shown in green, and axons are shown in 
red (false coloured for clarity). Arrows indicate prominent example of where phosphorylated 
neurofilament has retreated from the axons, to the neuron cell body – an indicator of axonal damage. 
Scale bar: 50 µm. Representative images from a minimum of three independent biological replicates, 
for which at least two coverslips were analysed.  
‘late foetal’ 
‘post-natal’ 
‘post-natal’ 
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Figure 4–14 ZIKV infection induces loss of myelin sheath in CNS co-cultures at 6 d p.i 
Ifnar1 CNS co-cultures were infected on DIV18 with ZIKV at a MOI of 0.3 and maintained until 6 d p.i 
when cultures were fixed with 4% formaldehyde. Cells were immunolabelled with antibodies targeting 
ZIKV E (mouse anti-ZIKV E [primary antibody], goat anti-mouse IgG Alexa Fluor ® 488; green) and 
the myelin sheath/oligodendrocyte cell bodies (rabbit anti-PLP/DM20 [primary antibody], goat anti-
rabbit IgG Alexa Fluor ® 594; red), and counterstained with DAPI (blue). (A) Mock-infected CNS co-
culture with healthy myelin sheath development (red) absent of ZIKV-positive cells (green). (B) ZIKV-
infected CNS co-culture with unhealthy, fragmented myelin sheaths (red), with many ZIKV-positive 
cells (green).  Images taken by Dr Verena Schultz, a collaborator of the project. Representative 
images from a minimum of three independent biological replicates, for which at least two coverslips 
were analysed.  
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Additionally, axons appeared injured in ZIKV infected cultures at DIV24 (6 d p.i.) 
(Figure 4–13, second column). Immunolabelling with anti-SMI31 should reveal a 
dense network of axons in healthy samples (Figure 4–15A). However, during ZIKV 
infection SMI31 appeared to have retreated into neuron cell bodies – an indicator 
of axonal injury (Figure 4–15B). This axonal injury appeared to occur in absence 
of apparent neuronal injury, as indicated by the presence of relatively healthy 
neuronal nuclei (Figure 4–15Bi and Bii). 
 
Figure 4–15 Axonal injury occurs in absence of injury to neuronal cell bodies and nuclei. 
Our data show that phosphorylated neurofilament retreats into the cell bodies of neurons in CNS co- 
cultures infected with ZIKV (MOI 0.3/6 d p.i.). (A) mock-infected CNS co-culture with typical SMI31 
staining displaying a dense axonal network. (B) ZIKV-infected CNS co-culture demonstrating a loss 
of axonal network. Red boxes indicate neurons with abnormal SMI31 staining, which has retreated 
from the axons and in towards neuronal cell bodies. Images A and B were taken at 20x magnification. 
(Bi/Bii) Healthy neuronal nuclei belonging to neurons with axonal injury (enlarged from image B), 
displaying SMI31 staining within the cell body. Grey: DAPI stained nuclei, Blue (false coloured for 
clarity): SMI31 stained axons and/or neuronal cell body (mouse anti-SMI31 [primary antibody], goat 
anti-mouse IgG Alexa Fluor ® 488 [secondary antibody]. Representative images from a minimum of 
three independent biological replicates, for which at least two coverslips were analysed.
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Figure 4–16 Examining injury and cell death as determined by pyknotic nuclei count.  
Ifnar1 KO CNS co-cultures were infected at DIV18 at a MOI of 0.3 and fixed with 4% formaldehyde 
at 6 d.p.i. Coverslips were immunolabelled against ZIKV-E (mouse anti-ZIKV E [primary antibody], 
goat anti-mouse IgG Alexa Fluor ® 488), a cell-type specific marker (neurons: rabbit anti-NeuN; 
astrocytes: rabbit anti-GFAP; oligodendrocytes: rat anti-PLP/DM20; OPCs: rabbit anti-NG2; 
microglia: rat anti-F4/80. Secondary antibodies: goat anti-rat IgG or goat anti-rabbit IgG conjugated 
with Alexa Fluor ® 594) and were counterstained with DAPI.Images were taken at 20x magnification 
and cells enumerated for total number of DAPI nuclei, and ‘dying’ DAPI nuclei (i.e. pyknotic nuclei) 
for each condition and per cell type. A) light blue bars are healthy DAPI nuclei in comparison to 
pyknotic nuclei in dark blue – this is measured in cells per mm2 B) Percentage pyknotic nuclei per 
cell type. Black bars indicate MOI 0.3/d d.p.i and white bars indicate Mock infected cultures. * 
indicates p< 0.05 and ** p< 0.005 , bars represent mean ± SD. n=3 
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To investigate the possible causes of injury to myelin and axons, cell type 
specific pyknotic nuclei counts were performed. Cultures were infected at a MOI 
of 0.3 PFU/cell or mock infected and incubated at 37 oC for 6 days until DIV24. 
There was a significant increase in the number of pyknotic nuclei per mm2 at 6 
d p.i. when cultures are infected with ZIKV at a MOI of 0.3, compared to mock 
infected cultures. Significant increases in the percentage of pyknotic nuclei 
pertaining to oligodendrocytes, OPCs and microglia were observed, with over 
25% of total oligodendrocyte nuclei appearing pyknotic. As mentioned 
previously, oligodendrocyte nuclei can appear quite small and condensed in 
images taken for enumeration purposes. However, the rise in oligodendrocyte 
injury and/or cell death indicated by pyknotic nuclei counts may help explain 
the extensive myelin loss observed in ZIKV infected cultures at this timepoint. It 
is noteworthy that the percentage of pyknotic nuclei pertaining to neurons 
increased only slightly – suggesting that axonal injury occurs in absence of 
apparent neuronal cell death.  
In summary, white matter structures are injured when CNS co-cultures are 
infected with ZIKV at a developmental stage reflective of late foetal/early post-
natal life.  
 Soluble factors alone are insufficient to induce injury to white matter 
components of the CNS 
Results in section 4.3.4 (Figure 4–13) demonstrated that myelin was obliterated 
when co-cultures were infected with ZIKV at a MOI of 0.3 PFU/cell for 6 days. An 
increase in the percentage of pyknotic nuclei cell counts suggested that the loss 
of myelin could be a result of increased oligodendrocyte cell death. To rule out 
the possibility that myelin injury could be caused by inflammatory molecules 
produced by the culture during infection, culture media from infected and 
uninfected co-cultures were examined. 
CNS co-cultures were infected with ZIKV at a MOI of 0.3 PFU/cell (or mock 
infected) and culture supernatants were harvested at 6 d p.i. The supernatant 
from infected and uninfected CNS co-cultures were exposed to a UV lamp to 
inactivate ZIKV virus (refer to Section 2.8.2.1 for full methodology). Conditioned 
media (UV inactivated supernatant) were mixed with fresh media to negate any 
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effects that might be observed due to nutrient deficits. The subsequent mixtures 
were  transferred onto fresh DIV18 cultures (when myelination is starting to take 
place). These cultures were maintained until DIV 24 (when extensive myelin loss 
is observed in ZIKV infected cultures - Figure 4–14), with refeeds taking place 
every 48 h with 1:1 conditioned:fresh media. On DIV24, samples were fixed in 
formaldehyde and immunolabelled against SMI31 and MBP  (axons and myelin, as 
in Figure 4–13- Figure 4–17A), in addition to PLP/DM20 (myelin) and ZIKV E 
protein (Figure 4–17B). 
There was no apparent difference in overall myelin quality and axonal health 
between media which originated from infected or mock-infected cultures (Figure 
4–17A). There was no positive staining for ZIKV E protein in Figure 4–17B, 
indicating that the UV inactivation of ZIKV was successful (see Figure 4–17B inset 
for staining pattern of supernatant which was not inactivated by UV). These 
results indicate that injury to white matter structures is unlikely the result of 
soluble factors alone.  
  
135 
 
 
Figure 4–17 UV inactivated, ZIKV infection conditioned media does not cause injury to white 
matter structures.  
CNS co-cultures were infected with ZIKV at a MOI of 0.3 PFU/cell and incubated at 37 oC for 6 days. 
The supernatant was subjected to UV-inactivation before being transferred onto fresh DIV18 CNS 
co-cultures. These cultures were maintained until DIV24 (6 days post-transfer) and were subjected 
to immunofluorescence analyses. (A) CNS co-culture imaged at 6 days post-transfer, stained for 
axons (mouse anti-SMI31 [primary antibody], goat anti-mouse Alexa Fluor ® 488 [secondary 
antibody]; shown in red [false coloured]) and myelin (rat anti-MBP [primary antibody], goat anti-rat 
IgG Alexa Fluor ® 594 [secondary antibody]; shown in green [false coloured]). Inset image depicts 
MOI 0.3/ 6 d p.i. culture also stained for axons (red) and myelin (green) – demonstrating extensive 
myelin and axonal injury. (B) CNS co-culture images at 6 days post-transfer, stained for ZIKV-E 
(mouse anti-ZIKV E [primary antibody], goat anti-mouse IgG Alexa Fluor ® 488 [secondary antibody] 
green) and myelin (rabbit anti-PLP/DM20 [primary antibody], goat anti-rabbit IgG Alexa Fluor ® 594 
[secondary antibody[; red) Inset image depicts MOI 0.3/ 6 d p.i. culture positive for ZIKV E staining 
(green) and abnormal myelin staining (red). Scale bar: 100 µm. Representative images are displayed 
from three individual biological replicates, for which a minimum of two coverslips were analysed per 
condition.   
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4.3.5 Supporting glial cells are required for ZIKV infection of 
mature neurons 
Previous results in this chapter have established that neurons are less 
susceptible to ZIKV infection, compared with other principle CNS cell types, in 
Ifnar1 KO CNS co-cultures (Section 4.3.2, Figure 4–7). However, axonal pathology 
is observed during prolonged ZIKV infection; a phenotype which appears to 
accompany myelin loss and cannot be recapitulated by the transference of UV 
inactivated ZIKV conditioned media (Section 4.3.4, Figure 4–13 and Figure 4–17). 
To determine if axonal injury is induced by direct ZIKV infection of neurons, 
‘pure’ neuronal cultures were generated from spinal cord tissue. Two types of 
neuronal cultures were generated. One culture had been depleted of a moderate 
amount of contaminating glial cell types during preparation and was maintained 
only in neurobasal medium (NBM). The other culture had been supplemented 
with 5-Fluoro- 2’deoxyuridine (NBM + FUDR). FUDR is an anti-mitotic drug, which 
depletes the culture of proliferating cell types such as contaminating glial cells, 
whilst sparing mature post-mitotic neurons. The purity of neuronal cultures was 
assessed by V.Schultz prior to use and is demonstrated in Figure 4–18. Culture 
purity was assessed by taking cell type specific DAPI counts of principle CNS cell 
types, as previously described in section 4.3.2. Cultures maintained in NBM alone 
contain more contaminating glial cell types than those supplemented with FUDR. 
The predominant contaminating cell types were Olig2+ cells (Oligodendrocytes 
and OPCs).  
Neuronal cultures were infected with ZIKV (MOI of 0.3 PFU/cell) and were fixed 
in 4% formaldehyde for 1 hour at 6 d p.i. Cultures were then immunolabelled 
against varying targets to examine: I) culture purity (Figure 4–19), II) axonal 
injury (Figure 4–20) and III) ZIKV infection (Figure 4–21, Figure 4–22). Under these 
conditions, whole CNS co-cultures possessed a decimated myelin sheath and 
axonal processes were injured (Cumberworth, Barrie et al. 2017). However, in 
both types of neuronal cultures (+/- FUDR), axonal networks remained intact 
(Figure 4–20). At 6 d p.i. neuronal cultures supplemented with FUDR did possess 
few contaminating glial cells, though this was a marked reduction in comparison 
to cultures maintained in NBM alone (Figure 4–19). 
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Figure 4–18 Purity testing of neuronal cultures grown in the presence or absence of FUDR  
Culture generation, purity testing and figure components were kindly provided by V Schultz. Neuronal 
cultures were grown in neurobasal medium (NBM) in the presence or absence of mitotic inhibitor, 
FUDR (5-fluorodeoxyuridine). FUDR is used to curtail the growth of proliferative cell types within 
neuronal cultures (i.e. contaminating glial cell types) whilst sparing post-mitotic neurons (Oorschot, 
1989). (A) A graph detailing the percentage of each cell type present in cultures grown in NBM alone 
or NBM+FUDR. NeuN: neurons, Olig2: oligodendroglia (oligodendrocytes and OPCs), GFAP: 
astrocytes, Iba1: microglia. Bars represent mean ± SD. (B) representative images of neuronal 
cultures grown in NBM or NBM+FUDR. Top row: cultures are immunolabelled against 
oligodendroglia (mouse anti-Olig2 [primary antibody], goat anti-mouse IgG Alexa Fluor ® 488 
[secondary antibody]; green) and astrocytes (rabbit anti-GFAP [primary antibody], goat anti-rabbit 
IgG Alexa Fluor ® 594 [secondary antibody] ;red). Bottom row: cultures are immunolabelled against 
neuronal components – axons (mouse anti-SMI31, goat anti-mouse IgG Alexa Fluor ® 488 
[secondary antibody]; green) and neuronal nuclei (rabbit anti-NeuN [primary antibody], goat anti-
rabbit IgG Alexa Fluor ® 594 [secondary antibody];red). Nuclei were counterstained with DAPI (blue). 
Scale bar: 100 µm.  
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Figure 4–19 Purity testing at 6 d p.i. of neuronal cultures maintained in neurobasal media 
alone or supplemented with FUDR.  
Neuronal cultures were grown in neurobasal medium (NBM) in the presence or absence of mitotic 
inhibitor, FUDR (5-fluorodeoxyuridine). Neuronal cultures were infected with ZIKV (MOI 0.3) or mock 
infected for 6 d p.i., with media replenishments taking place at 2 and 4 days post infection. At 6 d p.i. 
cultures were fixed and immunolabelled with antibodies raised against contaminating glial cell types; 
oligodendrocytes and OPCS (mouse anti-Olig2 [primary antibody], goat anti-mouse IgG Alexa Fluor 
® 488 [secondary antibody]; green) and astrocytes (rabbit anti-GFAP [primary antibody], goat anti-
rabbit IgG Alexa Fluor ® 594 [secondary antibody]; red).. Nuclei were counterstained with DAPI 
(blue). White arrows indicate oligodendroglia and red arrows indicate astrocytes.Inset image (NBM, 
top right), demonstrates astrocyte presence in ZIKV infected cultures in addition to Olig2+ cell types. 
Scale bar: 100 µm. Representative images are shown for 2 biological replicates, with 3 coverslips 
examined per replicate. 
In the majority of cultures assayed by immunofluorescence analysis, there were 
no visible signs of ZIKV infection , except for one area of interest in neuronal 
cultures maintained in NBM only (n=2 biological replicates, 2 coverslips per 
condition per replicate) (Figure 4–21). The one focus of ZIKV infection occurred 
in a mixture of neuronal and non-neuronal cell types within this culture (Figure 
4–22). It is therefore reasonable to suggest that for neurons to become infected, 
a high local concentration of virus is required, which may be provided by 
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infected non-neuronal cell types interacting with neuronal processes (Figure 4–
22iii). Positive staining for the ZIKV envelope protein was also seen in neuronal 
processes emanating from NeuN positive cell bodies (Figure 4–22i/ii). It may be 
possible that neuronal infection is mediated by neuronal cell-cell contacts; if 
neurons were intrinsically susceptible to ZIKV infection, more neurons would 
appear positive for ZIKV E staining in distant regions.  
The rarity of neuronal ZIKV infection within these cultures could be attributed in 
part to the type of neurons present in these cultures. Neuronal cultures are 
derived from murine Ifnar1 KO spinal cords. These dissociated cell cultures lack 
region specific expression of genes that might typically be found in vivo 
(Cumberworth et al., 2017a). Additionally, a mixture of interneurons and 
‘motor’ neurons are present within these cultures. The ‘motor’ neurons in these 
cultures do not innervate muscle – exemplifying alternative gene expression and 
subsequent functional phenotypes of culture vs in vivo cells. It has been 
demonstrated that cortical neurons can be infected with ZIKV (van den Pol et 
al., 2017, Olmo et al., 2017). It is therefore possible that ZIKV simply does not 
target the predominant neuronal cell type within this culture system.  
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Figure 4–20 ZIKV infection does not induced axonal damage in neuronal cultures maintained 
in the presence or absence FUDR.  
Neuronal cultures were grown in neurobasal medium either in the presence or absence of FUDR (5-
fluorodeoxyuridine). Neuronal cultures were infected with ZIKV at a MOI of 0.3 PFU/cell for 6 days, 
with maintenance culture media replenishments taking place at 2 and 4 d p.i. Cultures were fixed at 
6 d p.i. and immunolabelled with antibodies targeting a component of axons (mouse anti-SMI31, goat 
anti-mouse IgG Alexa Fluor ® 488 [secondary antibody]; green) and neuronal nuclei (rabbit anti-
NeuN [primary antibody], goat anti-rabbit IgG Alexa Fluor ® 594 [secondary antibody];red). . Nuclei 
were counterstained with DAPI (blue). Scale bar: 100 µm. Representative images are shown for 2 
biological replicates, with 3 coverslips examined per replicate. 
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Figure 4–21 ‘Pure’ neuronal cultures are extremely resistant to ZIKV infection.  
Neuronal cultures were grown in neurobasal media (NBM) with or without FUDR (5-
fluorodeoxyuridine). Neuronal cultures were infected with ZIKV at a MOI of 0.3 PFU/cell for 6 days, 
with maintenance culture media replenishments taking place at 2 and 4 d p.i. Cultures were fixed at 
6 d p.i. and immunolabelled with antibodies against ZIKV E (mouse anti-ZIKV E [primary antibody], 
goat anti-mouse IgG Alexa Fluor ® 488 [secondary antibody]; green) and neuronal nuclei (rabbit anti-
NeuN [primary antibody], goat anti-rabbit IgG Alexa Fluor ® 594 [secondary antibody]; red). Nuclei 
were counterstained with DAPI (blue). Representative images are shown for 2 biological replicates, 
with 3 coverslips examined per replicate.  
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Figure 4–22 Foci of ZIKV infected cells , including neruons, in ‘impure’ neuronal culture 
Neuronal cultures were maintained in neurobasal media alone, and were infected with ZIKV at a MOI 
of 0.3 PFU/cell for 6 days, with maintenance culture media replenishments taking place at 2 and 4 d 
p.i. Cultures were fixed at 6 d p.i. and immunolabelled with antibodies against ZIKV E ZIKV E (mouse 
anti-ZIKV E [primary antibody], goat anti-mouse IgG Alexa Fluor ® 488 [secondary antibody]; green) 
and neuronal nuclei (rabbit anti-NeuN [primary antibody], goat anti-rabbit IgG Alexa Fluor ® 594 
[secondary antibody]; red). .Cell nuclei were counterstained with DAPI (blue). In the absence of the 
mitotic inhibitor FUDR, higher quantities of contaminating glial cells are present in neuronal cultures. 
This image represents the only focus of infection detected throughout experimentation using ‘purified’ 
neuronal cultures (biological replicates n=2, 3 coverslips per replicate). Neurons are indicated by the 
characteristic red stain for NeuN, found in the nuclei and cell bodies of neurons. Other glial cells are 
indicated by the presence of blue DAPI nuclei, which are not positive for NeuN staining. (*) Indicates 
an infected glial cell (i.e. perinuclear green staining, blue nucleus, no red NeuN stain), (I/II) Highlights 
infected neurons (i.e. perinuclear green staining, blue nucleus, red NeuN stain in nucleus/cell body).  
In this image, the green ZIKV E staining extends the length of the neuronal process (III) 
Demonstrates uninfected neurons in the presence of infected glial cell types.  
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4.4 Discussion 
Identifying the infectious targets of ZIKV within the CNS and PNS is paramount in 
understanding the pathogenesis of ZIKV infection. The primary aim of this 
chapter was to determine the susceptibility of cells within the CNS and PNS to 
ZIKV infection and observe the consequences of ZIKV infection within these 
systems. Mixed mouse-embryo derived cell co-cultures which replicate several 
aspects of intact central and peripheral nervous systems were used in these 
studies (kindly generated by either J Barrie or V Schultz). Such cultures were 
generated from E13 embryonic mouse spinal cord or dorsal root ganglion to give 
rise to CNS and PNS cultures respectively (in the background of mouse strains 
A129, Ifnar1 KO or WT).  
4.4.1 PNS cells are highly resistant to ZIKV infection in 
comparison to CNS cells 
The pathobiology surround ZIKV-associated GBS, a peripheral neuropathy, is 
unknown. Therefore, to determine whether ZIKV-GBS could be attributed to 
direct infection of the PNS, this study infected PNS co-cultures with ZIKV PE243 
and quantified levels of ZIKV positive cells. These data demonstrate that PNS 
cells are less susceptible to ZIKV infection than their CNS counterpart generated 
from the same embryo, even if the absence of type I IFN responses (Figure 4–4). 
The apparent lack of infection within PNS cultures was found not to be a result 
of potential inhibitory factors within PNS maintenance media (Figure 4–5).  
Contrary to these findings, is the work of Oh et al,. 2017 whereby A129 Ifnar1 
KO mice were infected with ZIKV (ZIKV strain SZ01 [GenBank 
accession:KU866423], propagated in C6/36 cells) by intraperitoneal injection and 
immunofluorescence analysis revealed infection of PNS DRG neurons (Oh et al., 
2017). Furthermore, this study demonstrates infection and injury of peripheral 
neurons derived from human neural crest stem cells. However, Oh et al. made 
no efforts in the way of quantifying levels of ZIKV infection. The representative 
images shown are of very small area and display only 1-2 infected neurons in a 
given space. The study claims that ZIKV positive DRG neurons are also positive 
for cleaved caspase 3 – an indicator of apoptosis- and suggest ZIKV infection 
induces apoptosis in DRG neurons. Given the small sample area, it is not possible 
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to ascertain the extent of, nor the effect of, ZIKV infection within DRG neurons 
from this study alone. 
Another study (Volpi et al., 2018) also claimed to contradict the findings within 
this chapter. However, upon further investigation it seems that they report 
similar findings as described here in terms of levels of infection within the PNS. 
Volpi et al., employs DRG explant cultures (aka PNS co-cultures – background 
strain C57BL/6 Ifnar1 KO) to investigate ZIKV infection in the PNS, using ZIKV 
strains MR766 and PRVABC59 (a strain isolated during the 2015/16 outbreak). 
The study infects PNS co-cultures with 7 x 105 PFU of MR766 or 1.2 x 106 PFU of 
PRVABC59 with an infection time of 4 hours. This is in contrast to studies 
conducted in this chapter which utilises ZIKV PE243 infecting PNS co-cultures 
with the equivalent of 1.2 x 105 PFU (MOI 0.3) or 1.2 x 106 PFU (MOI 3) with a 
virus exposure time of 1 hour. Virus propagation methods were not disclosed in 
this paper.  
Volpi et al., 2018 also makes no attempt to quantify the level of infection within 
PNS cultures and refers only to qualitative immunofluorescence studies. The 
images displayed in this paper primarily focus in on the DRG cell body cluster 
when attempting to identify ZIKV infection, instead of neurons extending out-
with the DRG. In MR766 infected cultures, higher levels of infection are present, 
a finding consistent with data reported in this thesis (Chapter 3 Section 3.3.4). 
MR766 is a ZIKV strain first isolated in Uganda but has since undergone over 100 
passages in a mixture of the brains of suckling mice and cell culture. Therefore, 
MR766 could represent a highly adapted ZIKV strain to mammalian cells, and 
perhaps even cells of neural origin. As demonstrated in Section 3.3.4, MR766 
displays higher levels of infection in Ifnar1 KO CNS cultures in comparison to 
infection with ZIKV PE243 produced in either insect or mammalian cells. It is 
therefore unsurprising that there are higher levels of infection in the studies of 
the PNS conducted by Volpi et al which utilise a similar infection model system.  
The infection levels of ZIKV strain PRVABC59 in the paper by Volpi et al are 
markedly less than that of MR766 samples. At 3 d p.i, the representative image 
displays only one cell infected with PRVABC59. Despite infecting cultures for a 
longer time period (1.2 x 106 PFU/4 hours compared with 1.2 x 106 PFU/1 hour) 
this finding does not appear too dissimilar to those in this chapter (ZIKV PE243 
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infection of Ifnar1 KO PNS co-cultures at 72 h p.i. are 1%). Given that no 
attempts at quantification were made, it is difficult to ascertain any differences 
in infection levels without a direct comparison of data obtained by equivalent 
methods. However, the data presented by Volpi et al., 2018 do not appear to 
demonstrate markedly increased infection levels despite differences in ZIKV 
strains, infection timeframe and mouse background strain to produce cultures.  
Volpi et al. also demonstrate a slight visual decline in myelin staining at 10 d p.i. 
in PNS co-cultures infected with either MR766 or PRVABC59. This is not a line of 
investigation pursued in this chapter; PNS co-culture infections in this chapter 
only explore PNS infection up to 72 h p.i. (3 d p.i) with MOI 3 (equivalent of 1.2 
x 106 PFU). Despite low infection levels within PNS cultures in this chapter 
(section 4.3.1), cell type specific analyses revealed the myelinating cell type of 
the PNS, Schwann cells, can be infected with ZIKV (Cumberworth et al., 2017a). 
In Volpi et al. virus titre in culture supernatant of PNS cultures increases over 
time indicating active viral reproduction. This is a finding not replicated by our 
own studies which indicate that virus titres decrease over time in PNS culture 
supernatant. Perhaps the infection in the cultures described by Volpi et al.  
targeted Schwann cells. Follow up studies would need to confirm viral 
replication within PNS cultures, and the apparent loss of myelin observed in 
studies by Volpi et al. However, pathological findings demonstrate that the DRG 
is unaffected in case reports of ZIKV infected infants (Chimelli et al., 2017). 
Further studies are required to clarify the infection status of PNS cells both by in 
vitro and in vivo methods. Given the apparent lack of infection in vitro and 
clinical findings and that GBS is typically regarded as a post infectious auto-
antibody mediated disorder, it might seem more prudent to identify gangliosides 
implicated in PNS injury that may contribute to the development of GBS.  
4.4.2 ZIKV infection in CNS injures white matter structures 
In the most recent ZIKV outbreak, striking complications of the CNS were 
observed in neonates born to mothers infected with ZIKV during pregnancy. The 
underlying cause of the associated neurodevelopmental disorders, and the true 
extent of the damage is still relatively unknown. At the time of investigation, 
little was understood regarding the tropism of ZIKV within the CNS, or indeed if 
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the neurological complications of ZIKV were strain specific. Findings within this 
chapter indicate that all principle cell types within the CNS can be infected with 
a strain of ZIKV isolated from a patient with no reported neurological symptoms 
(ZIKV/H.sapiens/Brazil/PE243/2015 Genbank accession number KX197192 
(Donald et al., 2016) – referred to as ZIKV or ZIKV PE243) (Figure 4–6 and Figure 
4–7). Type I IFN responses play a protective role in ZIKV infection of CNS co-
cultures, reducing infection levels from 19% to 4% in Ifnar1 WT cultures (MOI 
3/72 h p.i.). ZIKV infection of Ifnar1 KO cultures lead to an increase in pyknotic 
nuclei, an indicator of injury and cell death (Figure 4–9). These data imply that 
this strain of ZIKV is capable of inflicting CNS injury, despite not being 
associated with a patient exhibiting neurological disease. This might indicate 
that infection of neural cell types is not strain specific and may be dependent on 
alternative factors such as the immunological status of the patient, amongst 
other factors. 
Myelin damage in ZIKV infected Ifnar1 KO CNS co-cultures was first observed at 
72 h p.i. (MOI 3), when broken myelin sheaths were increasing in abundance 
(Figure 4–11). Axons and myelin were substantially depleted when challenging 
CNS co-cultures at a developmental stage reflective of late foetal development, 
when myelination was first beginning, and allowing cultures to progress to a 
stage when myelination should be nearing completion (post-natal life) (Figure 4–
13). Whether the loss of myelin represents a de- or a dys-myelinating phenotype 
is unclear. Demyelination is the destruction of pre-existing myelin whereas 
dysmyelination describes impaired myelin development. Oligodendrocytes are 
the leading target for ZIKV infection in CNS co-cultures presenting the highest 
percentage level of infection at 24 (MOI 0.3) and 72 h p.i. (MOI 3) (Figure 4–7). 
The lower infectious dose and shorter timepoint was used to ascertain the initial 
infectious targets of ZIKV infection; these data reflect that oligodendrocytes are 
a particularly vulnerable cell type for ZIKV infection. Moreover, at 6 d p.i. (when 
myelin loss is observed), there was a significant increase in the percentage of 
pyknotic nuclei pertaining to oligodendrocytes (Figure 4–9). Therefore, this may 
be indicative of a demyelinating phenotype that is secondary to oligodendrocyte 
cell death as opposed to impaired myelin development. Though this does not 
explain the observed axonal injury (Figure 4–15). 
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Data presented in this chapter suggest neuronal infection within CNS co-cultures 
is relatively rare; neurons possessed the lowest percentage of infection at 72 h 
p.i. with ZIKV at MOI 3 (9%) (Figure 4–7). Furthermore, no infection was observed 
in ‘pure’ neuronal cultures derived from spinal cord - except for in the presence 
of contaminating glia (Figure 4–21 and Figure 4–22). However, this observation 
was only made in one area of a singular coverslip of one biological replicate 
(biological replicates n=2, 3 coverslips per biological replicate) (Figure 4–22). 
This suggests that neurons derived from the spinal cord may be intrinsically 
resistant to ZIKV infection, requiring supporting glial cells to become infected. It 
is unlikely that neurons in CNS co-cultures express the entire complement of 
gene products which are produced in vivo, as a result of absent or mis-localised 
CNS region-specific cell fate determinants (Cumberworth et al., 2017a). Neurons 
present in the CNS co-culture are a mixture of neuronal subtypes. Neurons 
derived from the cortex are susceptible to ZIKV infection (van den Pol et al., 
2017, Azouz et al., 2019). Therefore, it may be interesting to conduct studies to 
determine the susceptibility of various neuronal types. 
Complementary to the in vitro data presented in this chapter, it was shown that 
neuronal infection in a variety of CNS regions occurred secondary to infection of 
glial cells, primarily astrocytes, in the brains of mice infected with ZIKV on the 
day of birth by intraperitoneal injection (van den Pol et al., 2017). Whether 
these data implies neurons become infected via cell-cell spread or they just 
require a high local concentration of virus in order to become infected requires 
further investigation.  
Axonal injury occurred in absence of substantial neuron infection and cell death 
(Figure 4–15). The transfer of UV inactivated ZIKV-conditioned media did not 
induce injury to myelin or axonal structures, suggesting that the damage 
incurred is not mediated by soluble factors alone (Figure 4–17). The only 
substance which causes demonstrable axonal injury in vitro is nitric oxide (Smith 
et al., 2001). Nitric oxide is important for synaptic plasticity in the CNS,and 
involved in neurotransmission; however, if nitric oxide is produced in excess it 
becomes noxious (Calabrese et al., 2007).Given the short half-life of nitric 
oxide, if present in UV-ZIKV conditioned media it is unlikely to have substantial 
effects unless replenished often (i.e. by a producer of nitric oxide) (Hakim et 
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al., 1996). Both astrocytes and microglia are producers of nitric oxide in the 
central nervous system; production of nitric oxide can be induced by viral 
infection. It would be interesting to know whether there is increased production 
of this molecule in ZIKV-infected co-cultures, and if this may be a cause of white 
matter injury in CNS co-cultures.  
The injury to white matter structures (myelinated axons) observed in CNS co-
cultures is consistent with pathological findings in clinical case studies, whereby 
a reduction in CNS white matter is demonstrated (Chimelli et al., 2017, Chimelli 
and Avvad-Portari, 2018). In these cases, the spinal cord was unharmed by ZIKV 
infection. In this chapter, white matter injury was modelled in cultures of spinal 
cord origin, these findings suggest that other determinants factor in the 
exclusion of spinal cord injury in these cases. 
CNS co-cultures infected at a developmental timepoint reflective of late foetal 
life displayed extensive myelin loss when observed at a timepoint modelling 
infancy/childhood (Figure 4–13). Myelin is required for optimal cognitive function 
in addition to learning and memory. It is prudent that follow up studies be 
conducted with babies born with inapparent symptoms of ZIKV congenital 
syndrome, as more subtle neurodevelopmental defects may be present e.g. 
learning disorders (Fields, 2008, Stanelle-Bertram et al., 2018). This is 
exemplified by a report from a prospective cohort study completed with babies 
born to mothers who had PCR confirmed ZIKV infection during pregnancy during 
the 2015/16 ZIKV outbreak in Brazil (Nielsen-Saines et al., 2019). The study 
involved the clinical and neurological assessment of 216 infants with a median 
age of 18 months (range 7-32 months). Notably, 35% of infants in this study had 
below average for age language function, and 31.5% had other 
neurodevelopmental/ophthalmic/auditory impairments. Interestingly this follow-
up study demonstrated that normal assessments at birth did not guarantee 
normal results in subsequent neurological assessments; 25% (17/68) of children 
with normal early assessments had below-average neurodevelopmental 
assessments at follow-up. Three infants in the cohort were diagnosed with 
autism spectrum disorder (ASD); further investigations are required to 
investigate this potential link between ZIKV and ASD (Vianna et al., 2018).  
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It is therefore essential that follow-up analyses of children born to mothers with 
confirmed ZIKV infection continue, in order to understand the full complement 
of neurodevelopmental sequalae.  
150 
 
4.5 Summary 
 Type I IFN plays a protective role in ZIKV infection of CNS co-cultures. 
 PNS cells are less susceptible to ZIKV infection than CNS cells, even in the 
absence of type I IFN. Given the lack of PNS infection, it is unlikely that 
ZIKV associated GBS is a result of direct viral infection of the PNS. 
 Of the principle CNS cell types, oligodendroglia (oligodendrocytes and 
OPCs) are particularly vulnerable to ZIKV infection and injury. 
 White matter structures are injured during ZIKV infection of Ifnar1 KO 
CNS co-cultures, resulting in substantial myelin and axon loss– this injury 
is not caused by soluble factors alone but may be directly due to virus 
infection. 
 CNS neurons derived from Ifnar1 KO spinal cord are particularly resistant 
to ZIKV infection in the absence of supporting glial cells – suggesting that 
axonal injury is unlikely to be a result of direct neuronal infection and 
instead secondary to the production of inflammatory molecules by cells 
within inCNS co-cultures. 
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5 Results Chapter 3: Transcriptomic analysis of 
Zika virus infected Central Nervous System 
(CNS) co-cultures 
5.1 Introduction 
CNS co-cultures derived from embryonic mice possess all the principle cell types 
of the CNS: neurons, astrocytes, oligodendrocytes, oligodendrocyte precursor 
cells and microglia (see Chapter 4 Section 4.2.2 for further details of the roles of 
individual cell types). CNS co-cultures recapitulate many of the neuro-glial 
interactions observed in the CNS; furthermore, if matured until 28 days in vitro, 
neurons are fully extended and myelinated (white matter structures) (Thomson 
et al., 2006). This culture system can be manipulated to represent different 
developmental timeframes. Data presented in Chapter 4 demonstrated that 
when infected with ZIKV at a developmental timeframe which crossed late 
foetal/post-natal stages, much of the white matter structures in CNS co-cultures 
(Ifnar1 KO) were destroyed (6 d p.i./144 h p.i.[Section 4.3.4]). Specifically, the 
myelin sheath is destroyed in addition to substantial axonal damage. 
Importantly, many neurons presenting axonal injury within the co-cultures did 
not show signs of infection with ZIKV and appeared to have intact, healthy 
nuclei, despite neuronal cell bodies swelling and becoming filled with 
phosphorylated neurofilament (an indicator of neuronal damage (Yuan et al., 
2017)). Results in Chapter 4 (Section 4.3.4.1) indicated that this pathology was 
unlikely to be the result of the action of soluble factors alone. However, it is 
undetermined whether the loss of myelin associated with ZIKV infection is a 
result of the death of oligodendrocytes, or a distinct dys- or de-myelination 
process determined by altered mRNA transcript expression during infection. 
De-myelination refers to the deterioration of pre-established myelin, whereas 
dys-myelination is the impaired production of myelin. Therefore, we decided to 
investigate the transcriptomic profiles of ZIKV-infected CNS co-cultures. 
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5.2 Aims 
The aim of this chapter is to compare the transcriptome of early and late stage 
infected CNS co-cultures in order to identify differentially expressed genes 
(DEGs) induced by ZIKV infection. These data may highlight candidate transcripts 
associated with ZIKV-induced white matter injury in CNS co-cultures. 
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5.3 Results 
5.3.1 Preparation of samples for RNAseq 
CNS co-cultures (Ifnar1 KO) were prepared as previously described (Chapter 4, 
Section 4.2.2). The cultures were maintained until matured to DIV18 (+/- 
2 days), at which time they were mock-infected (i.e. treated with 2% FBS diluted 
in PBS) or infected with ZIKV at a MOI of 0.3 PFU/cell. At 48 h p.i. and 96 h p.i. 
cell culture media were aspirated, cells washed once with PBS, and total cellular 
RNA was harvested from the co-cultures using TRIzol reagent. These timepoints 
were selected as they preceded the destruction of myelin. It was noted in 
Chapter 4 Section 4.3.1 that at 24 h p.i ZIKV infection of CNS co-cultures was 
limited, and at 72 h p.i infection was well established; therefore, 48 h p.i. was 
selected as the early infectious timepoint. The later timepoint, 96 h p.i., was 
selected as it appeared that cultures looked unhealthy, but many cell bodies 
remained when visualised under a light microscope (Figure 5–1). Therefore, this 
may be a suitable timepoint to highlight any potential damage associated 
transcripts.  
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Figure 5–1 Light microscopy images of CNS co-cultures infected with ZIKV. 
Ifnar1 KO CNS co-cultures were infected with ZIKV at a MOI of 0.3 PFU/cell or were mock infected. 
Cultures were imaged using an EVOS FL microscope using the transmitted light setting at 0 h p.i. 
and 96 h p.i. Examples of fibrous strands, likely white matter structures (myelinated axons), are 
indicated by white boxes. The black box indicates injured fibrous structures at 96 h p.i.   
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The quality of extracted RNA was analysed using a High Sensitivity RNA 
ScreenTape® (Agilent; Table 5–1; performed by Natasha Johnson, MRC University 
of Glasgow Centre for Virus Research). RNA samples were initially assessed using 
RINe (RNA Integrity Number equivalent) score, in addition to appearance of 28S 
and 16S rRNA bands separated through gel electrophoresis. RINe scores above 
8.5 are typically considered high enough quality for library preparation to take 
place (Schroeder et al., 2006, Agilent, 2012). RNA sequencing libraries were 
prepared by Natasha Johnson using the TruSeq stranded mRNA library prep 
workflow (illumina). Following the PCR stage of library preparation, a further 
quality control check of the RNA was performed by RNA screen tape analysis 
prior to sequencing. Next generation sequencing was performed using the 
NextSeq® Sequencing System using NextSeq® 500/550 High Output Kit v2 
Cartridges.  
Sample RINe 
R1_48h p.i. 9.1 
R1_48h_mock 8.8 
R1_96h p.i. 9.2 
R1_96h_mock 9.2 
R3_48h p.i. 9.3 
R3_48h_mock 9.1 
R3_96h p.i. 9.5 
R3_96h_mock 9.4 
R4_48h p.i. 9.3 
R4_48h_mock 9.4 
R4_96h p.i. 9.6 
R4_96h_mock 9.6 
 
Table 5–1 RNA integrity numbers of initial RNA samples used to generate libraries for RNAseq 
analyses.  
RNA quality control was performed using the High Sensitivity RNA ScreenTape®. R1,3,4 indicates 
to which biological replicate group the sample belonged to. 
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5.3.2 Assessing sample set variation 
To assess biological replicate and sample set variation, data were analysed using 
a multidimensional scaling (MDS) plot (kindly generated by Dr Quan Gu, MRC 
University of Glasgow Centre for Virus Research) (Figure 5–2). MDS plots assess 
the degree of similarity between data. In this plot, the transcriptomic profile of 
a single biological replicate is represented by a sample set name (e.g. virus96h). 
Samples which are most similar, will cluster together closely, meanwhile 
dissimilar samples will be distanced further apart.  
One biological replicate for all 4 sample sets (virus 96h, virus48h mock96h and 
mock48h; top half of the MDS plot, Figure 5–2) was disparate from the other 2 
biological replicates, which cluster relatively close together with their 
corresponding sample set counterparts (bottom half of the MDS plot, Figure 5–2). 
Typically, it would be expected that biological replicates have slight 
dissimilarities but not to the extent observed in these data. However, RNA from 
these samples were taken from primary mixed cell cultures. Each biological 
replicate is representative of cultures taken from embryos pertaining to 
different litters. Whilst the generation of CNS co-cultures is reproducible and 
biological effects are robust and reproducible in previous experiments, 
expression data may vary depending upon the biological composition of cell 
types present in these cultures. As co-cultures were infected +/- two days, this 
may have had a greater effect on gene expression than anticipated. Further 
analyses of the expression data will reveal more information about this 
dissimilarity. 
Samples mock48h, mock96h and virus48h cluster closely together (bottom right 
hand corner of MDS plot, Figure 5–2) indicating that these groups have similar 
RNA expression data. Meanwhile the sample set ‘virus96h’ groups further away 
from this cluster (bottom left hand corner of MDS plot, Figure 5–2) indicating 
gene expression at the later timepoint with ZIKV infected cells differs 
substantially from early and mock infected cultures.  
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Figure 5–2 Multidimensional scaling (MDS) plot comparing datasets obtained from mock or 
infected samples at 48 h p.i. and 96h p.i.   
Variation between timepoints, infected and uninfected samples and biological replicates were 
analysed using an MDS plot. This MDS plot was generated using the LogFC method; this method 
calculates distances between samples based on log2 fold changes (Log2FC). The x- and y- axes 
are representative of Euclidean distances between samples. The greater the distance between 
datapoints, the less related the datapoints are. CNS co-cultures were either infected with ZIKV at a 
MOI of 0.3 PFU/cell (virus- yellow/blue) or mock-infected (mock- red/green). RNA was harvested at 
either 48 h p.i. (48h – red/blue) or 96 h p.i. (96h – yellow/green). The MDS plot was kindly provided 
by Dr Quan Gu. 
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5.3.3 Differentially expressed gene comparison between grouped 
analyses 
Differentially expressed genes (DEGs) were identified using RNAseq expression 
data. Only statistically significant DEGs with a Q value of <0.05 were included in 
these analyses. The q-value is an adjusted p-value which takes into account the 
false discovery rate (Storey and Tibshirani, 2003). DEGs were identified for the 
following datasets: 48 h p.i. V 48 h mock, 96 h p.i. V 96 h mock, and 48 h mock 
V 96 h mock. To assess the number of shared DEGs between different groups of 
paired analyses, a Venn diagram was produced (Figure 5–3). 
 
Figure 5–3 Venn diagram displaying the number of shared differentially expressed genes 
(DEGs).  
DEG lists were obtained by comparing RNAseq data between ZIKV infected and mock infected 
samples from 48 and 96 h p.i., in addition to comparing RNAseq data between 48 h mock and 96 h 
mock samples. Only DEGs with a Q-value <0.05 were included in these analyses. 
To determine differentially expressed genes which may be associated with 
normal culture function and/or development as opposed to virus infection, 48h 
mock V 96 mock DEGS were compared with data from other grouped analyses 
(Figure 5–3).  
A total of 27 significant DEGs were identified between 48 h mock V 96 h mock 
datasets. Comparing this with DEGs from other analyses, 19 DEGs were unique to 
48 h mock V 96h mock, and 8 hits were also found at 96 h p.i. (Figure 5–3). To 
determine whether these 8 DEGs were involved in normal culture development, 
or if they represent genes whose expression are altered by ZIKV infection, a 
heatmap was generated using the raw expression values for each DEG in the 48 h 
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mock, 96 h mock and 96 h p.i. dataset (Figure 5–4). As the expression of these 8 
DEGs are altered between both mock and infected samples sets, it can be 
assumed that the expression of these genes may be altered by ZIKV infection and 
therefore do not represent genes implicated in normal culture function and 
development.  
 
Figure 5–4 A heatmap indicating DEGs which were shared between 48 h Mock V 96 h Mock, 
and 96 h Mock V 96 h p.i. dataset comparisons are not involved in normal CNS co-culture 
development.  
DEG lists were obtained by comparing RNAseq data between ZIKV infected and mock infected CNS 
co-culture samples from 48 and 96 h p.i., in addition to comparing RNAseq data between 48 h mock 
and 96 h mock samples. In total, 8 DEGs were found to be shared between 48 h Mock V 96 h Mock, 
and 96 h Mock V 96 h p.i. comparisons. Raw expression values for each condition (n=3; 48 h mock, 
96 h mock, 96 h p.i.) were subsequently used to generate a heatmap. The row Z-score (the number 
of standard deviations an observation is from the mean) is indicated by a colour scale representing 
values from -2 to 2; this visually represents how different data are between comparator 
datasets.Each sub-column is representative of a single biological replicate. N=3 biological replicates 
per experimental condition underwent RNAseq and subsequent analyses to identify DEGs. Heatmap 
generated using Heatmapper (Babicki et al., 2016) 
The 19 DEGs which are unique to the 48 h mock vs 96 h mock dataset are 
summarised in Table 5–2. As these DEGs differ between the mock cultures of 
differing timepoints (48 h p.i./DIV20, 96 h p.i./DIV22), they may be involved in 
culture function/development. 
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Gene Description Log2FC Q-value 
5430419D17Rik RIKEN cDNA 5430419D17 gene 1.349822632 0.013727 
Ptgds 
Prostaglandin D2 
synthase which is highly 
expressed in mouse brain 
tissue 1.159369699 6.11E-13 
Dcd dopa 
decarboxylase Dcd dopa decarboxylase 0.798480908 0.001119 
Prdm16os 
Prdm16 opposite strand 
transcript 0.783089832 0.047293 
C1s1 
Complement component 1, 
subcomponent 1 0.781542798 0.032348 
Sult1a1 
Sulfotransferase family 1A, 
phenol-preferring, member 1 0.735819031 0.039275 
Lyz2 Lysozyme C-2 precursor 0.67208358 0.000261 
Abca9 
ATP-binding cassette, sub-
family A (ABC1), member 9 0.624110509 0.032074 
Lrriq1 
Leucine-rich repeats and IQ 
motif containing 1 0.548544221 0.040768 
Aldh6a1 
Aldehyde dehydrogenase 
family 6, subfamily A1 0.504553732 0.013727 
Hacd4 
3-hydroxyacyl-CoA 
dehydratase 4 0.479419852 0.040768 
Prom1 Prominin 1 0.47554711 0.042655 
Ccdc3 
Coiled-coil domain containing 
3 0.453373011 0.04515 
Lims2 
LIM zinc finger domain 
containing 2 -0.474966406 0.029954 
Dbx2 Developing brain homeobox 2 -0.589232159 0.001985 
Tubb6 tubulin, beta 6 class V -0.718924133 0.028927 
Cited1 
Cbp/p300-interacting 
transactivator with Glu/Asp-
rich carboxy-terminal domain 
1 -0.823628338 0.032684 
Kif23 Kinesin family member 23 -0.961728063 0.040768 
Gm35455 Uncharacterised -1.272445743 0.042655 
 
Table 5–2 Table summarising DEGs unique to 48 h mock V 96 h mock analysis. 
A brief summary of gene function and expression data (expressed as Log2 fold change [Log2FC]) 
are shown. Q-values <0.05 are considered significant. 
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5.3.4 DEGs associated with ‘early’ ZIKV infection 
As indicated by the MDS plot (Figure 5–2), it is evident that the expression 
profiles of ZIKV infected samples at 48 h p.i. were not dissimilar to their mock 
counterparts. The ZIKV infected sample had only 4 DEGs that reached the 
significance value cut off (Q value <0.05). These genes were: Ifit1, Cxcl10, Ccl5 
and Tpd52-ps. In contrast, the 96 h p.i. timepoint had 340 significant DEGs when 
compared to the 96h mock dataset; 3 DEGs of which are also differentially 
expressed at 48 h p. I (Ifit1, Cxcl10 and Ccl5). Despite sharing DEG hits, these 3 
genes have disparate expression levels in both datasets. Details of which, 
including gene function, can be found in Table 5–3. 
Gene Function Log2FC 
48 h p.i. V 
48h mock 
Log2FC 
96 h p.i. V 
96h mock 
Ifit1 Encodes a protein which has been 
demonstrated to have antiviral effects in 
response to type I IFN. May inhibit viral 
replication and translation initiation. 
2.19792935 5.1699853 
Cxcl10 Immune modulatory role stimulation of 
monocytes, natural killer and T-cell 
migration, and modulation of adhesion 
molecule expression. 
2.15402709 6.7479685 
Ccl5 Immunoregulatory molecule, acts as 
member of the CC subfamily, functions as 
a chemoattractant for blood monocytes, 
memory T helper cells and eosinophils. 
1.52118905 7.4386244 
 
Table 5–3 DEGs shared between datasets comparing 48 h p.i. V 48h mock data with that of 96 
h p.i. V 96h mock data. 
A brief summary of gene function and expression data (expressed as Log2FC) are shown.  
All the genes listed in Table 5–3 (Ifit1, Cxcl10 and Ccl5), have been described to 
coordinate the mammalian immune responses to viral infection (Trifilo et al., 
2004, Hosking and Lane, 2010, Diamond, 2014). Ccxl10 and Ccl5 are typically 
secreted cytokines involved in chemotaxis of immune cells; expression of these 
cytokines has been associated with both neuroprotective and neuropathological 
roles in the CNS (Glass et al., 2004, Hosking and Lane, 2010). Whereas Ifit1 is an 
interferon stimulated gene (ISG) that exerts its function intracellularly within 
the cytoplasm, restricting foreign messenger RNA molecules, such as viral RNA 
genomes (Diamond, 2014). Given that the co-cultures had been infected with 
ZIKV, it is unsurprising that molecules with immunomodulatory roles were 
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upregulated at this timepoint, as it would be assumed that cells were starting to 
mount a response to virus infection. These CNS co-cultures are generated from 
embryonic mice which lack to type I IFN receptor (Ifnar1). Loss of this receptor 
renders cells incapable of responding to type I IFNs, though cells can still 
produce them. However, cells can produce antiviral transcripts via alternative 
routes such as NF-κB signalling, though should not necessarily be able to produce 
transcripts from the ISRE promoter. Furthermore, the expression values of all 
three genes increase between 48 h p.i and 96 h p. I (Ifit1 >2-fold, Cxcl10 >3-fold, 
Ccl5 >4-fold increase in Log2FC from 48 h to 96 h. p. i [Table 5–3]), indicating 
that these genes were being upregulated in response to ZIKV infection. 
Despite 48 h p.i. being a relatively early stage of ZIKV infection within CNS co-
cultures, the identification of only 4 significant DEGs is somewhat perplexing. 
ZIKV infection in Ifnar1 CNS co-cultures was detected by qPCR, plaque assay and 
immunofluorescence staining as early as 24 h p.i.(Chapters 3 and 4, Sections 
3.3.4 and 4.3.1). Furthermore, the upregulation of immune related transcripts, 
albeit a minor selection that reached statistical significance, indicated the 
presence of infection. Perhaps at this timepoint the level of infection is too low 
to incur a large shift in expression profile, and any transcripts that may be 
altered due to ZIKV infection were subsequently discounted from analyses due to 
restrictions of statistical significance (Q-value of <0.5).  
Imposing a restriction of Q value <1 returned only an additional 2 DEGs 
compared to the original analysis: Eln (encodes the protein elastin which is a 
component of the extracellular matrix) and Rsad2 (in humans encodes the 
antiviral protein, viperin).Upon further investigation, discounting any Q-value 
restrictions, over 15,000 DEGs were identified at 48 h.p.i. The top 10 most up- 
and down-regulated genes (as determined by Log2FC values) are summarised in 
Table 5–4.  
A mixture of gene functions can be found within the top 10 up and down 
regulated gene lists including genes implicated in immune regulation, cellular 
recruitment and trafficking, antiviral genes, undescribed genes and a few genes 
out width these categories. Lhx5, a gene implicated in neural cell differentiation 
and the development of several structures in the CNS, was downregulated at 48 
h.p.i compared to mock (Zhao et al., 1999, Peng and Westerfield, 2006, Lui et 
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al., 2017). Lhx5 is not significantly differentially expressed at 96 h.p.i (Log2FC 
0.01221; Q value 1). Whilst the downregulation of Lhx5 by ZIKV infection would 
be an interesting prospect, without further validation using methods such as 
qRT-PCR, no conclusion can be drawn yet from this finding. 
Another gene of interest highlighted in this list is kazn; a gene with roles in 
cellular adhesion and cytoskeletal organisation. The dataset suggests at 48 h.p.i 
kazn is downregulated, which would imply cells are more motile, given that this 
gene is involved in cell adhesion. This wouldn’t be unreasonable to suggest as 
phagocytic cells in the CNS culture will need to adopt a more motile phenotype 
in order to target infected cells and clear cellular debris generated as a result of 
any lytic ZIKV infection. Many of the DEGs identified at 96 h.p.i also have 
reported functions in chemotaxis and cellular migration and were upregulated 
following ZIKV infection (Section 5.3.5). However, Kazn was not significantly 
differentially expressed at 96 h.p.i, nor was it differentially expressed in 
absence of Q-value restrictions; further validation is required to determine if 
this gene is differentially expressed at 48 h.p.i.  
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Table 5–4 Top 10 up- and down-regulated DEGs at 48 h.p.i, minus Q value restrictions. 
A brief summary of gene function and expression data (expressed as Log2FC) are shown. The Q-
value is also shown as an indicator of significance of expression data. Downregulated DEGs are 
shaded in grey. 
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To determine whether any other DEGs found in the unrestricted 48 h.p.i DEG list 
could be supported by differential expression at 96 h.p.i, a comparison between 
the two datasets was performed. Genes from the unrestricted list of DEGs 
identified at 48 h.p.i with a Log2FC value >0.5 (either up- or down-regulated) 
were extracted – this yielded a smaller list of 187 DEGs. This list was then 
compared with significant DEGs identified at 96 h p.i. (Q value <0.05) in order to 
identify shared molecules. A summary of the shared DEGs and their Log2FC 
values at 48 h p.i. and 96 h p.i. can be found in Table 5–5. 
Again, the analysis returned genes which can primarily be connected to immune 
and inflammatory responses. One gene of interest consistently returned in the 
analyses is Rsad2; also known as viperin. This is one of the top 10 upregulated 
genes at 48 h p.i., possessing a Log2FC value of 1.1306 - though its Q- value does 
not reach the significance threshold of <0.05 (Q-value = 0.666863). Despite not 
reaching statistical significance at 48 h p.i., it is differentially expressed at 96 h 
p.i. At 96 h p.i., it becomes one of the top 25 upregulated DEGs, possessing a 
log2FC value of 4.979172, and reaches statistical significance with a Q-value of 
8.02E-32. Recent studies suggest that viperin is important in the restriction of 
flaviviruses such as WNV, DENV, TBEV and HCV, with ZIKV being the most recent 
addition to this list (Lindqvist et al., 2018, Van der Hoek et al., 2017).Viperin 
exerts its antiviral activity using numerous mechanisms which can vary between 
members of the same family; in the case of ZIKV, data suggests viperin imposes 
restriction at the level of RNA replication (Van der Hoek et al., 2017). 
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Gene 
48 h p.i. 96 h p.i. 
Log2FC  
Q-value 
(unrestricted) Log2FC  
Q-value 
(<0.05) 
Ifit1 2.19792935 7.29E-09 5.169985341 1.86E-73 
Cxcl10 2.154027086 7.29E-09 6.747968503 3.44E-89 
Ccl5 1.521189045 0.0269 7.438624412 1.58E-41 
Rsad2 1.130599647 0.66686 4.979171573 8.02E-32 
Ccl2 0.924277083 0.92428 6.209304557 1.04E-69 
Tnfaip2 0.580833818 1 3.428105096 5.12E-28 
Steap4 0.578902358 1 3.796855457 1.18E-30 
Lcn2 0.570631425 1 3.5666967 1.12E-21 
Saa3 0.569793506 1 2.911601427 0.009854 
Gbp9 0.551932227 1 2.522424279 3.29E-12 
Ptx3 0.537151005 1 2.718479723 3.45E-06 
Mir6236 -0.683920338 1 0.980588 0.006554 
Gm23935 -0.691106922 1 1.082937375 0.000334 
 
Table 5–5 List of DEGs that appear at both 48 h p.i. and 96 h p.i. and their associated Log2FC 
expression values. 
Expression data (expressed as Log2FC) are shown for DEGs which appear at both 48 h p.i. and 96 
h p.i. The Q-value is also shown as an indicator of significance of expression data; statistically 
significant Q value <0.05. 
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5.3.5 Initial analyses of 96 h p.i. vs mock dataset 
Herein the DEG dataset in use is 96 h p.i. vs 96 h mock, as this provided the most 
significant DEGs (48 h p.i. vs 48 h p.i. had only 4 DEGs which were above the Q-
value threshold of <0.5). In total 340 significant DEGs were identified at 96 h p.i. 
in comparison to the equivalent mock dataset; of which, 303 genes were up-
regulated, and 37 genes were down-regulated. A summary of which can found in 
Figure 5–5.  
Next, the top 10 most up- and down-regulated molecules were identified within 
the dataset (Table 5–6). The 10 most upregulated genes have a median Log2FC 
of 7.659 (range: 6.748 — 10.982) and their functions broadly categorise into 
genes involved in cell-cell signalling and recruitment, and type I IFN responses. 
The top 10 most up regulated genes, in descending order of expression include: 
IFNB1, OVOL1, HEATR9, OASL, Cxcl11, Cxcl2, Ccl5, IL6, GBP5 and CXCL10. IFNB1, 
which encodes IFN-β (a type I IFN), was the most up-regulated gene in response 
to ZIKV infection at 96 h p.i.  Type I IFN plays a protective role in ZIKV infection, 
as demonstrated in Chapter 4 Section 4.3.1, whereby CNS co-cultures which 
possessed WT Ifnar1 were less susceptible to ZIKV infection. A recent study 
highlights that astrocyte mount a rapid type I IFN response which protects cells 
against cytopathic effects of ZIKV infection (Lindqvist et al., 2016). 
The 10 most downregulated genes have a median Log2FC of -0.817 (range: 
- 0.667 — -7.858). In descending order of expression, the 10 most downregulated 
genes include: PTGS1, SLCO2B1, ADAMTS16, PPP1R1B, TPRKβ, TP73, TLR8, 
TMEM52, MRC1, IL11RA (Table 5–6). IL11RA was the most downregulated gene in 
response to ZIKV infection at 96 h p.i.; IL11RA encodes the interleukin 11 
receptor subunit alpha and is a member of the hematopoietic cytokine receptor 
family. 
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Figure 5–5 DEGs between mock and infected samples at 96 h p.i.   
A total list of significant DEGs were identified by isolating expression data possessing a Q-value 
<0.05. (A) A heatmap representing DEGs across 3 independent experiments comparing mock and 
infected samples at 96 h p.i.  Each column represents a biological replicate. Heatmap generated 
using Heatmapper (Babicki et al., 2016). (B) A plot representing the total number of DEGs up (red 
arrow) and downregulated (green arrow) at 96 h p.i.    
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Gene Description Log2FC Q-value 
IFNB1 Interferon beta 1 10.982 1.57E-48 
OVOL1 
Ovo like zink finger 1- transcription factor involved in the development 
and differentiation of numerous tissues.(Kagawa et al., 2019) 
10.006 
2.20E-25 
HEATR9 
HEAT repeat containing 9 – uncharacterised function, suggested role in 
haematopeotic stem cell differentiation. Also upregulated in influenza 
infection of alveolar epithelial cells (Stairiker et al., 2018). 
9.840 
1.57E-27 
OASL 
2’-5’-oligoadenylate synthetase like – IFN inducible enzyme which has 
antiviral activity. Senses exogenous nucleic acid and induces its 
degradation via RNase L. 
8.517 
7.85E-42 
Cxcl11 Chemokine which binds the CXCR3 receptor.  8.202 7.24E-34 
CxCl2 Produced by activated monocytes, expressed at sites of inflammation. 7.659 6.30E-75 
CCL5 
Chemoattractant for blood monocytes, memory T helper cells and 
eosinophils 
7.439 
1.58E-41 
IL6 Interleukin 6 - involved in inflammatory response 7.349 2.98E-29 
GBP5 
Guanylate binding protein 5 - Activator of NLRP3 inflammasome with 
roles in innate immunity and inflammation. 
6.880 
9.54E-42 
CXCL10 
Immunoregulatory molecule - functions as a chemoattractant for blood 
monocytes, memory T helper cells and eosinophils. 
6.748 
3.44E-89 
PTGS1 Prostaglandin G/H synthase 1 precursor -0.667 0.002376 
SLCO2B1 
Solute carrier organic anion transporter family member 2B1 – modules 
Na+ independent transport of organic anions e.g. prostaglandins 
-0.679 
0.014771 
ADAMTS1
6 
ADAM Metallopeptidase with thrombospondin type 1 motif 16 - 
-0.683 
0.033574 
PPP1R1B 
Protein phosphatase 1 regulatory inhibitor subunit 1B – signal 
transduction molecule involved in dopaminergic and glutaminergic 
signalling.  
-0.725 
0.000103 
TPRKB TP53RK binding protein  -0.817 0.000471 
TP73 
Tumour protein P73 – member of the p53 family of transcription 
factors. It is located on chromosome 1p36 in humans, that is frequently 
deleted in neuroblastoma and other tumours. 
-0.885 
0.02568 
TLR8 Toll like receptor 8  -0.962 0.011103 
TMEM52 Transmembrane protein 52 -1.059 0.029592 
MRC1 
Mannose receptor C-Type 1 – mediates endocytosis of glycoproteins by 
macrophages. Involved in antiviral immune responses to HIV-1 
(Sukegawa et al., 2018) and DENV entry (Miller et al., 2008, Lo et al., 
2016) 
-1.114 
0.003129 
IL11RA Interleukin 11 receptor subunit alpha -7.858 9.82E-17 
 
Table 5–6 Top 10 up- and down- regulated significant DEGs at 96 h p.i. 
Expression data (expressed as Log2FC) are shown for genes which are differentially expressed at 
96 h p.i. compared to 96 h mock. The Q-value is also shown as an indicator of significance of 
expression data. Downregulated genes are highlighted in grey and upregulated genes are white.  
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It is noteworthy that Table 5–6 only details 20/340 DEGs found at 96 h p.i. with 
ZIKV; the remainder can be found in the Appendix. This is a microscopic view of 
the expression profile found at 96 h p.i., furthermore individual genes expressed 
in response to ZIKV infection in a mixed-cell co-culture provides little context as 
to what is occurring on a more global scale in the CNS. Therefore, further 
analyses using the Ingenuity Pathway Analysis (IPA) software was used to 
examine canonical signalling pathways affected in the dataset (section 5.3.6), in 
addition to disease and function analyses (section 5.3.7). 
5.3.6 Top canonical signalling pathways affected at 96 h p.i. 
DEGs identified at 96 h p.i. were imported into the ingenuity pathway analysis 
(IPA) tool. IPA was then used to predict biological functions associated with the 
DEG dataset. A summary of the top 20 canonical signalling pathways identified 
by IPA can be found in Figure 5–6. 
 
Figure 5–6 Top 20 significant canonical pathways affected at 96 h p.i. vs mock infected CNS 
samples, determined by p-value, as identified by IPA.  
Bars are measured against -log(p-values). The bigger the bar, the smaller the p value, indicating that 
the activity in this pathway from the dataset is statistically significant. The intensity of the colour red 
correlates with z-score positivity. Positive z-scores indicate upregulated pathways, whereas negative 
z-scores are indicative of downregulation. Grey bars indicate that although a pathway is affected, the 
resulting activity (activation or repression) is unknown. The ratio reflects the number of molecules 
presented in the dataset that are involved in a given pathway, against the known total of pathway 
components.  
  
171 
 
Many of the top canonical pathways identified by IPA are implicated in immune 
and inflammatory responses. This is to be expected as infection of mammalian 
cells with any microbe elicits an immune response; viral infection of mammalian 
cells potentiates innate immune responses (Brubaker et al., 2015). At 96 h p.i. 
with ZIKV, the two most significantly affected canonical pathways involve the 
detection of pathogens by pattern recognition receptors (PRRs), including ‘IRF 
activation by cytosolic PRRs and ‘Role of PRRs in recognition of bacteria and 
viruses’ (Figure 5–6). ZIKV replicates within the cytoplasm and possesses non-self 
motifs which can be detected by PRRs; examples of PRRs implicated in detecting 
ZIKV infection include RIG-I-like receptors (RLRs), MDA-5, cGMP-AMP synthase 
(cGAS) and TLR3.  
Whilst canonical pathways involved in PRR activation are the most significantly 
affected pathways, other pathways correlate with stronger activation (as 
determined by z-score). The canonical pathways with the most positive z-scores 
include: ‘role of PRRs of bacteria and viruses’, ‘neuroinflammation signalling 
pathway’, ‘dendritic cell maturation’ and 'production of nitric oxide and reactive 
oxygen species in macrophages’ (Figure 5–6). Genes implicated in 
neuroinflammation, and their associated expression levels are summarised in 
Figure 5–7. 
For some pathways which were significantly affected by ZIKV infection at 96 h 
p.i., no activity patterns were available to assign a positive or negative z-score, 
these include: ‘IL-17A signalling in fibroblasts’, ‘granulocyte adhesion and 
diapedesis’, ‘role of PKR in IFN induction and antiviral response’, 
‘communications between innate and adaptive immune cells’, ‘agranulocyte 
adhesion and diapedesis’, ‘IL-10 signalling’, and ‘cross-talk between dendritic 
cells and natural killer cells’.  
Another factor implicated in the assessment of canonical pathway activation is 
the number of molecules found to be differentially expressed which pertain to a 
particular pathway, expressed as a ratio (Figure 5–6). The higher the ratio, the 
more molecules in a pathway are differentially expressed in the dataset. At 96 h 
p.i. with ZIKV, the canonical pathways with the most DEGs involved include: ‘IL-
17A signalling in fibroblasts’, ‘TNFR2 signalling’, ‘role of RIG-I like receptors in 
antiviral immunity’, and ‘role of PKR in IFN induction and antiviral response’.   
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Figure 5–7 DEGs implicated in neuroinflammatory pathways. 
Expression analyses were performed using IPA (Ingenuity pathway analysis) and filtered to only 
include nervous system tissues, CNS cell lines and neuroblastoma cell lines. The displayed DEGS 
were grouped and categorised using the canonical pathways tool. The heatmap displays expression 
values from 3 independent experiments for mock and infected samples at 96 h p.i.  Log2FC: Log2 
Fold change expression value. Heatmap generated using Heatmapper (Babicki et al., 2016).  
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Only seven canonical pathways had a negative z-score, indicating that they are 
down regulated at 96 h p.i. following ZIKV infection. In order of increasing p-
value, pathways with negative z-scores include: ‘Angiopoeitin signalling’, 
‘LXR/RXR activation’, ‘Apoptosis signalling’, ‘PPAR signalling’, ‘PPARα/RXRα 
activation’, ‘antioxidant action of vitamin C’, and ‘PTEN signalling’. These 
pathways are broadly implicated in lipid metabolism, cell survival and 
proliferation, as well as angiogenesis. 
5.3.7 Disease and Function analyses of CNS co-cultures at 96 h 
p.i. with ZIKV 
The top 5 disease pathways related to ZIKV infection at 96 h p.i. identified using 
the disease and functions tools in IPA included: ‘inflammatory response’, 
‘organismal injury and abnormalities’, ‘infectious disease’, ‘immunological 
disease’, and ‘gastrointestinal disease’. Upon further exploration of the dataset, 
it was found that 194 disease/function annotations were predicated to have 
increased activity with ZIKV infection at 96 h p.i.  These broadly categorised 
into: cellular movement/recruitment (33.5%), cell survival/proliferation (25.3%), 
cell death (13.4%), activation of cells (7.2%), immune responses (7.2%), 
differentiation of cells (6.7%), and other functions (6.7%). Nine disease/function 
annotations were predicted to be decreased with ZIKV infection at 96 h p.i., 
including: replication of RNA virus, replication of virus, replication of 
Herpesviridae, infection of mammalia, atrophy of lymphoid organ, nephritis, 
weight loss, morbidity or mortalitiy, and organismal death. Upon further 
investigation, a number of molecules were upregulated at 96 h p.i. infection 
with ZIKV which were associated with the decrease in viral replication (
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Figure 5–8). This is indicative of the elicitation of a potent anti-viral response 
within CNS co-cultures in response to infection with ZIKV.  
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These disease/function categories provide little insight into the injury observed 
in CNS co-cultures when infected with ZIKV, this could be due to the complex 
nature of using a multi-cell type model system. Therefore, subsequent 
disease/function analyses were performed with a filter to only include results 
pertaining to cells of neurological origin, in order to yield more specific 
disease/function categories.  
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Figure 5–8 DEGs implicated in the reduction of viral replication. 
Expression analyses were performed using IPA (Ingenuity pathway analysis); expression data was 
not filtered to exclude cell types in this analysis. The displayed DEGS were grouped and categorised 
using the disease and function tool. The heatmap displays expression values from 3 independent 
experiments for mock and infected samples at 96 h p.i. Log2FC: Log2 Fold change expression. 
Heatmap generated using Heatmapper (Babicki et al., 2016). 
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With a filter to exclude cell types which are not of neurological origin, the top 5 
disease/functions were: neurological disease, organismal injury and 
abnormalities, inflammatory response, cardiovascular disease and psychological 
disorders. Further exploration of the disease and function analyses revealed 
groupings of molecules pertaining to disease/functions predicted to have 
increased activity at 96 h p.i. with ZIKV. The IPA tool highlighted these 
predictions as ‘biased’; however, because the mixed cell co-culture used in this 
study is of CNS origin, these analyses were pursued. A list of the 
disease/function annotations, together with their p-value, activation score and 
associated molecules identified within the dataset can be found in Table 5–7. 
Positive activation z-scores indicate that the pathway is predicted to be 
activated; the closer the activation z-score is to 0, the less activated the 
pathway. The 22 annotations which are predicated to be activated at 96 h p.i. 
with ZIKV broadly categorise into one or more of the following functions: 
activation of cells (22.7%), cell movement/migration (31.8%), lipid metabolism 
(13.6%), neuron/neurite morphology (27.3%) and cell viability (4.5%). 
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Table 5–7 Predicated increased disease/functions as determined by IPA analysis at 96 h p.i., 
using a filter for neurological cell types. (1/2)  
Ordered in decreasing order of Activation Z-score, which is indicative of the level of activation of a 
pathway; scores above 0 are upregulated. 
179 
 
M
o
le
c
u
le
s 
EG
R
1
,I
L6
,N
O
S2
,P
TG
ES
,P
TG
S2
,T
N
F 
A
TF
3
,C
3
,C
D
K
N
1
A
,C
H
L1
,E
IF
4
EB
P
1
,F
G
F2
,F
O
S,
IG
SF
9
,IL
6
,L
C
N
2
,N
FK
B
1
,P
TG
S2
,R
A
LB
,R
EL
B
,R
N
D
1
,T
G
FB
1
,T
N
F,
TP
5
3
,T
R
P
C
1
,V
A
SP
 
A
TF
3
,C
3
,C
D
K
N
1
A
,E
IF
4
EB
P
1
,F
G
F2
,F
O
S,
IG
SF
9
,I
L6
,L
C
N
2
,N
FK
B
1
,P
T
G
S2
,R
A
LB
,R
EL
B
,R
N
D
1
,T
G
FB
1
,T
N
F,
TP
53
,T
R
P
C
1
,V
A
SP
 
C
C
L5
,C
X
C
L3
,C
YB
B
,E
G
R
1
,F
G
F2
,F
O
S,
H
B
EG
F,
H
LA
-
A
,I
L1
1
R
A
,IL
6
,J
U
N
,L
C
N
2
,L
IF
,N
FK
B
IA
,N
FK
B
IB
,P
TG
S2
,R
EL
,R
IP
K
2
,S
IR
T1
,S
P
H
K
1
,T
G
FB
1
,T
N
F,
TP
5
3
,T
P
73
 
A
TF
3
,B
TG
2
,C
3
,C
D
44
,C
D
K
N
1
A
,C
H
L1
,C
YB
B
,E
G
R
1
,E
IF
4
EB
P
1
,F
G
F2
,F
O
S,
G
EM
,IC
A
M
1
,I
G
S
F9
,I
L1
1
R
A
,IL
6
,J
U
N
,L
C
N
2
,M
IC
A
LL
2
,N
FK
B
1
,N
FK
B
IA
,P
LX
N
D
1
,P
TG
S2
,R
A
LB
,R
EL
B
,R
N
D
1
,T
G
FB
1
,T
H
B
S2
,T
N
F,
TP
5
3
,T
R
P
C
1
,V
A
SP
 
C
3
,C
C
L2
,C
cl
2
,C
C
L4
,C
C
L5
,C
D
4
4
,C
X
C
L1
0
,I
L1
1
R
A
,T
N
F 
IL
6
,N
O
S2
,P
TG
ES
,P
TG
S2
,T
N
F 
A
TF
3
,C
H
L1
,F
G
F2
,F
O
S,
TG
FB
1
,T
P
5
3
 
A
TF
3
,F
G
F2
,F
O
S,
TG
FB
1
,T
P
5
3
 
C
3
,C
C
L2
,C
cl
2
,C
C
L4
,C
C
L5
,C
D
4
4
,C
X
C
L1
0
,F
A
S,
IL
11
R
A
,T
N
F,
V
C
A
M
1
 
A
TF
3
,C
D
K
N
1
A
,E
P
H
A
2
,G
EM
,I
FR
D
1
,R
R
A
D
,S
ER
P
IN
E1
,T
N
FR
SF
1
2
A
 
A
c
ti
v
a
ti
o
n
 
z
-s
c
o
re
 
2
.3
9
1
 
2
.3
8
6
 
2
.3
8
6
 
2
.3
7
 
2
.2
1
5
 
2
.2
0
3
 
2
.2
0
1
 
2
.1
8
3
 
2
.1
8
3
 
2
.1
8
 
2
.1
5
7
 
p
-v
a
lu
e
 
3
.3
9
E
-0
6
 
4
.4
3
E
-0
5
 
9
.4
1
E
0
5
 
9
.3
6
E
-0
9
 
0
.0
0
0
8
4
6
 
6
.3
9
E
-0
9
 
3
.2
6
E
-0
6
 
0
.0
1
0
5
 
0
.0
2
2
6
 
1
.2
4
E
-0
8
 
0
.0
1
5
3
 
A
n
n
o
ta
ti
o
n
 
S
y
n
th
e
si
s 
o
f 
fa
tt
y
 
a
c
id
s 
S
h
a
p
e
 c
h
a
n
g
e
 o
f 
n
e
u
ri
te
s 
B
ra
n
c
h
in
g
 o
f 
N
e
u
ri
te
s 
C
e
ll
 v
ia
b
il
it
y
 
D
e
v
e
lo
p
m
e
n
t 
o
f 
n
e
u
ro
n
s 
C
e
ll
 m
o
v
e
m
e
n
t 
o
f 
m
o
n
o
n
u
c
le
a
r 
le
u
k
o
c
y
te
s 
S
y
n
th
e
si
s 
o
f 
p
ro
st
a
g
la
n
d
in
 E
2
 
S
h
a
p
e
 c
h
a
n
g
e
 o
f 
a
x
o
n
s 
B
ra
n
c
h
in
g
 o
f 
a
x
o
n
s 
C
e
ll
 m
o
v
e
m
e
n
t 
o
f 
le
u
k
o
c
y
te
s 
E
x
te
n
si
o
n
 o
f 
n
e
u
ri
te
s 
Table 5-7 Continued - Predicated increased disease/functions as determined by IPA analysis 
at 96 h p.i., using a filter for neurological cell types. (2/2). Ordered in decreasing order of 
Activation Z-score, which is indicative of the level of activation of a pathway; scores above 0 
are upregulated.   
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5.4 Discussion 
The aim of this chapter was to conduct a transcriptomic analysis of ZIKV-
infected CNS co-cultures which were derived from the spinal cords of Ifnar1 KO 
embryonic day 13 mice. CNS co-cultures possess all of the major cell types of 
the CNS, which include astrocytes, neurons, oligodendrocytes, oligodendrocyte 
precursors and microglia. Cultures were infected with ZIKV PE243 and RNAseq 
performed on RNA harvested at early and late infectious timepoints (48 and 
96 h p.i, respectively) from co-cultures derived from three different litters (i.e. 
3 independent biological replicates).  
At 48 h p.i only 4 significant DEGs (Q value <0.05) were identified in ZIKV-
infected co-cultures, comprising Ifit1, Cxcxl10, Ccl5 and Tpd52-ps – all of which 
were upregulated. Whereas at 96 h p.i 340 significant DEGs were identified; 303 
DEGs were upregulated, and 37 downregulated. Numerous upregulated 
significant DEGs had immunomodulatory roles, the majority of which were 
involved in the recruitment of immune cells; this observation was made not only 
by examining individual upregulated transcripts, but also using the IPA gene 
function and pathway analysis tools.  
An upregulated gene of note is Ovol1; it is the second most upregulated gene in 
cells infected with ZIKV at 96 h p.i, possessing a Log2FC value of 10.006. 
Interestingly, Ovol1 has also been found to be upregulated during influenza 
infection of mouse airway epithelial cells (Ioannidis et al., 2012), though its role 
in infection is unknown. Ovol1 is a transcription factor that acts downstream of 
Wnt/β-catenin and TGF-β signalling pathways. Ovol1 is expressed in a variety of 
tissues and is involved in the terminal differentiation of progenitor cells. A 
recent study of cellular programming in induced pluripotent stem cell production 
suggests that Ovol1 acts to repress the proliferation of cells that do not 
reprogram to acquire pluripotency i.e. transition into iPSCs (Kagawa et al., 
2019). This study highlights that whilst Ovol1 is not directly involved in the 
acquisition of pluripotency it aids the reprogramming process in iPSC generation. 
Another molecule KLF4 (Kruppel-like factor 4), is implicated in reprogramming 
somatic cells into iPSCs (Qin and Zhang, 2012). Moreover, KLF4 was found to 
significantly upregulated during ZIKV infection at 96 h p.i. (Log2FC 1.023976, Q-
value 0.004668). Oct3/4 Sox2 and c-Myc are also key contributors to iPSC 
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generation (Takahashi and Yamanaka, 2006). However, only Sox2 was found in 
the 96 h p.i. dataset, with marginal differential expression in ZIKV infected 
cultures (Log2fc 0.01341, Q-value 1). It is well documented that ZIKV replicates 
efficiently in iPSCs and progenitor cells (Dang et al., 2016, Russo et al., 2017, 
Tang et al., 2016) . It would be interesting to determine if ZIKV influences cell 
type populations within CNS co-cultures in order to render a favourable cellular 
niche, by increasing progenitor cell populations to confer a replicative 
advantage. In Chapter 4 Section 4.3.2, cell type specific populations of CNS co-
cultures were quantified; however, oligodendrocyte progenitor cells were the 
only progenitor cell population analysed in this culture. Re-analysing these co-
cultures using a stain for pluripotent cell types would be of interest. However, 
ZIKV also induces cytopathic responses within neural progenitor cells, therefore 
this may be difficult to determine by quantification of progenitor cell 
populations alone (Tang et al., 2016, Dang et al., 2016).To determine if Ovol1 
and KLF4 aid viral replication, siRNA knockdown of these genes in cell lines or 
knockout cell lines could be generated.  
Interestingly, aside from its roles in maintaining pluripotency, studies 
demonstrate the KLF4 is an regulator of axonal development; enhanced 
expression of KLF4 abolishes neurite outgrowth (processes extending from 
neurons) and impedes neuronal migration in vitro and in vivo (Moore et al., 
2009, Qin and Zhang, 2012). Further roles of KLF4 as a transcription factor 
include cell cycle arrest and augmentation of pro-inflammatory responses; in 
particular, it has been demonstrated that KLF4 activates microglia, upregulating 
iNOS and pro-inflammatory cytokines such as TNF-a MCP-1 and IL-6 (Kaushik et 
al., 2010). iNOS is the only known agent that causes axonal injury in vitro (Smith 
et al., 2001, Kapoor et al., 2003). In Chapter 4 Section 4.3.4, it was found that 
CNS co-cultures infected with ZIKV are dramatically depleted of axons, whilst 
maintaining healthy neuron populations which consisted primarily of neuronal 
cell bodies possessing no neurite extensions. Whilst KLF4 expression may not 
contribute to axon loss, it may play roles in inhibiting axonal regeneration once 
damaged (Moore et al., 2009). Furthermore, KLF4 may indirectly exacerbate 
neuroinflammation which may drive axon loss in ZIKV-infected mixed-cell CNS 
co-cultures as a result of iNOS upregulation. Given the relatively low-level 
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upregulation of KLF4 (Log2FC 1.023976), it is likely several factors act 
cooperatively to cause the white matter pathology observed in CNS co-cultures.  
A significantly downregulated gene of interested is the Mannose Receptor C Type 
1 (MRC1; Log2FC -1.114). MRC1 is expressed on the surface of tissue 
macrophages and dendritic cells as well as some endothelial cells and can act as 
an entry receptor for numerous invading pathogens, including DENV (Taylor et 
al., 2005, Miller et al., 2008). Macrophage MRC1-mediated entry of HIV-1 results 
in non-productive infection. HIV-1 is processed by the antigen presentation 
pathway, resulting in the presentation of HIV-1 antigens by major 
histocompatibility complex-class II (MHCII) molecules, contributing to host innate 
immune responses (Trujillo et al., 2007, Sukegawa et al., 2018). A recent report 
demonstrates that MRC1 restricts HIV-1 release, and that HIV-1 counteracts this 
antiviral response via transcriptional silencing of MRC1 (Sukegawa et al., 2018). 
As MRC1 is downregulated during ZIKV infection, it may be that ZIKV has adapted 
mechanisms to overcome this innate immune response by reducing MRC1 
expression. Though in this culture system, MRC downregulation is relatively low-
level (Log2FC -1.114), this could be because expression is downregulated 
predominantly in microglia (CNS resident macrophages), which constitute a small 
portion of CNS co-cultures (microglia comprise approximately 7.3% of CNS co-
cultures at DIV31 – Section 4.3.1).  
In summary, this transcriptomic analysis of ZIKV-infected CNS co-cultures at 
early and late timepoints has provided an insight into the global CNS response to 
ZIKV infection. It is apparent from this dataset that ZIKV-infection induces an 
inflammatory response in CNS co-cultures, which is exacerbated over time both 
in the level of upregulation and number of pro-inflammatory molecules. Given 
the complex nature of this mixed-cell culture it is difficult to ascribe any given 
pathological phenotype, such as white matter structure injury, to specific 
molecules or cell-types. However, these analyses have provided a foundation for 
further study of candidate transcripts which may influence ZIKV infection of the 
CNS.  
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6 Concluding Remarks 
The overarching aim of this thesis was to further knowledge surrounding ZIKV 
interactions within the CNS and PNS. Specific objectives included: the 
development/assessment of tools to study ZIKV infection in vitro, the 
identification of ZIKV permissive cell types in the CNS and PNS, and to analyse 
the transcriptome of a biologically relevant cell types infected with ZIKV. 
In Chapter 3, an array of uncharacterised antibodies targeting either ZIKV NS1 or 
E protein were assessed by western blot and immunofluorescence analyses. This 
led to the identification of a highly specific monoclonal antibody which was used 
in downstream investigations (anti-ZIKV E clone 0402166, Aalto Biosciences). 
Using this antibody, it was found that astrocytes, the most prominent cell type 
in the CNS, are permissive to ZIKV infection. In this chapter a method for 
quantifying ZIKV genomic and subgenomic RNA was developed based upon a 
previously described protocol used in DENV research (Bidet et al., 2014); this 
qPCR methodology was subsequently used to determine that subgenomic RNA is 
produced in higher quantities than genomic RNA during ZIKV infection in A549 
cells.  
Mixed cell co-cultures containing the principle cell types of either the CNS or 
PNS were derived from mouse spinal cord or dorsal root ganglion, respectively; 
co-cultures were either WT or KO for the IFN α/β receptor (Ifnar1). In Chapter 4, 
mixed-cell CNS and PNS cultures which contain all the principle cell types of 
their respective nervous system were identified as a biologically relevant, 
complex model to investigate ZIKV infection. It was found that both co-cultures 
are permissive to ZIKV infection, albeit to varying degrees. Furthermore, as 
determined by qPCR and plaque assay, it was found that the species origin of the 
cell line (mammalian vs invertebrate) used to propagate ZIKV affects virus 
replication in Ifnar1 CNS co-cultures. ZIKV PE243 produced in invertebrate cells 
achieved higher titres and increased RNA levels in Ifnar1 CNS co-cultures than its 
mammalian propagated counterpart (Section 3.3.4, Figure 3–13). It was also 
determined that the ZIKV strain MR766 has a significantly increased replicative 
capacity in both Ifnar1 KO/WT CNS and Ifnar1 PNS co-cultures compared with 
ZIKV strain PE243 of either mammalian or invertebrate cell origin (Section 3.3.4, 
Figure 3–13).  
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In Chapter 4, ZIKV infection of CNS and PNS co-culture was explored further. 
Using immunofluorescence techniques, it was found that CNS co-cultures are 
more susceptible to ZIKV infection than PNS co-cultures; PNS co-cultures were 
resistant to ZIKV infection. This indicates that the PNS disorder, Guillain-Barré 
syndrome, is unlikely to be a result of direct infection of cells of the PNS; rather 
ZIKV-associated GBS is likely to be a para- or post-infectious autoimmune 
disorder, as is predominantly the case with other infection related GBS 
aetiologies (Leonhard et al., 2018, Willison et al., 2016). 
 Ifnar1 CNS co-cultures had the highest level of ZIKV infection and were used in 
all downstream investigations. Quantification of cell-type specific infection by 
manual counts of immunofluorescence images identified oligodendrocytes as the 
most vulnerable to infection with ZIKV. Whilst this method proved robust, a 
degree of variation may have been introduced into the experiment owing to 
human error when counting cells from complex images. It would therefore be 
interesting to develop a protocol which would enable the mixed-cell CNS co-
culture to be analysed by cell type using flow cytometry in order to validate our 
cell-type specific quantification of ZIKV infection. This approach was considered 
during experimentation, though numerous factors prevented further exploration. 
The two main factors included 1) once the CNS co-culture is well established i.e. 
DIV28, trypsin does not effectively resuspend cells in this culture to allow it to 
be analysed by this method. 2) technical issues were faced when trying to locate 
a machine that would allow ZIKV-infected cells to be analysed. Another avenue 
that was explored was to develop a pipeline within ImageJ that would identify 
specific cell types, and therefore automate the process of quantifying cells. 
However, to generate and test this model robustly would have taken a 
significant amount of time; given that these data were time-critical upon 
commencement, it was not within the scope of this project. 
Infection of CNS co-cultures at a timepoint reflective of late foetal development 
(approximating to the 3rd trimester, when myelination is starting to take place) 
caused injury to white matter structures leading to a remarkable loss of myelin, 
and axons. Curiously, the loss of axons was not accompanied by either injury to 
neuronal cell bodies, as indicated by healthy neuronal nuclei or marked increase 
in cell death within neuronal cell populations. The mechanism by which this 
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occurs remains to be determined. Given that these studies were performed in 
vitro, it would be prudent to perform the equivalent experiment in vivo. In 
order to make the experiment more authentic to real-life, it would be 
interesting to establish an infection model that uses mosquitoes to transmit ZIKV 
to the mammalian host. However, this would raise significant technical, 
practical and safety concerns and may be difficult to achieve unless in the 
appropriate facility. Instead, a method whereby mosquitoes could be allowed to 
bite the mammal, followed by subsequent injection of virus at the bite site, as 
established in (Pingen et al., 2016) would raise the degree of authenticity 
regarding virus spread and negate the associated biosafety concerns. 
Importantly, in this model the virus would need to be propagated in invertebrate 
cells prior to injection at the bite site, as the virus would need to mimic 
transmission from an invertebrate – as such it would require invertebrate 
glycosylation patterns. Generating a model system which is as close to real life 
as possible is important as it has been demonstrated that different routes of 
injection of virus can lead to altered cellular tropism. This was demonstrated in 
a model of Semliki Forest virus (SFV; an Alphavirus) infection, whereby 
intraperitoneal (IP) and intracranial (IC) injections yielded differing 
neurotropism; IP SFV displayed perivascular localisation in the brain, whereas IC 
SFV had tropism for white matter tracts in the corpus callosum (Fazakerley et 
al., 2006). Interestingly, SFV also infects oligodendrocytes, and has been 
demonstrated to induce a loss of CNS myelin (Mokhtarian et al., 2003, Fragkoudis 
et al., 2009). Using mouse models, adaptive immune responses are involved in 
the loss of myelin induced by SFV infection. This includes cytotoxic T-cell 
responses, B-cell activation, and cross-reactive antibody responses (Mokhtarian 
et al., 2003). The CNS co-culture model of ZIKV infection described in this thesis 
does not contain any lymphocytes, which means that the loss of myelin these 
cultures occurs via different mechanisms to SFV-induced myelin loss.  
In this thesis, experiments demonstrating ZIKV-associated white matter injury 
were performed in CNS co-cultures which are reflective of late foetal/early 
post-natal staging of neurodevelopment. It would be interesting to determine if 
the loss of myelin can occur post-partum. Follow-up studies of human babies 
born to mothers who were ZIKV positive during pregnancy, suggest that the 
likelihood of neurodevelopmental issues decreases with advanced gestation. The 
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continued follow-up of these children will be required to determine if more 
subtle neurodevelopmental issues arise later in life (Nielsen-Saines et al., 2019). 
In chapter 5, the transcriptomes of Ifnar1 CNS co-cultures infected with ZIKV at 
48 h.p.i and 96 h.p.i were analysed. It was found that ZIKV upregulated a 
number of transcripts involved in inflammatory pathways. Notably, ZIKV induced 
the upregulation of nitric oxide synthase (iNOS; produces NO) at 96 h p.i. Nitric 
oxide is the only known substance which is sufficient to cause axonal damage in 
vitro (Smith et al., 2001, Hakim et al., 1996, Kapoor et al., 2003). This may 
contribute in part to ZIKV-induced white matter injury observed in CNS co-
cultures in Chapter4. 
The transcriptomic analysis presented in Chapter 5 highlighted several other 
candidate molecules worthy of further exploration to broaden the molecular 
biology of ZIKV-host interactions. It was found that MRC1, a receptor implicated 
in DENV entry of dermal macrophages and in HIV antiviral responses (Miller et 
al., 2008, Trujillo et al., 2007), was downregulated 96 h after infection with 
ZIKV. It would be interesting to know if MRC1 can act as an entry receptor for 
ZIKV, and if ZIKV actively downregulates MRC1 to evade antiviral defences. 
Another molecule of interest upregulated by ZIKV was Ovol1; at 96 h p.i Ovol1 
was the second most upregulated transcript in CNS co-cultures. As discussed 
previously in Chapter 5 Section 5.4, Ovol1 has roles in regulating stem cell 
differentiation together with KLF4 (Kagawa et al., 2019, Nair et al., 2007). It 
would therefore be interesting to explore the roles of Ovol1 and KLF4 in ZIKV 
infection and its effects on CNS co-culture stem cell populations, via gene 
knockdown or knockout studies.  
Wider concerns for ZIKV research are more clinically oriented. There are still no 
approved vaccines or antivirals against ZIKV. Numerous challenges face the 
successful development and deployment of a ZIKV vaccine. The target recipients 
are ideally pregnant women, which as a cohort are notoriously difficult to test 
medical interventions on given their disposition. Furthermore, socio-economic 
concerns would need to be considered; places were ZIKV are endemic have large 
impoverished regions – ensuring the necessary uptake of vaccines may be also be 
a challenge. Of course, vector control strategies would be favourable in such 
regions as there are also numerous co-circulating arboviruses transmitted by the 
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same mosquito. Again, impoverished regions, for example shanti-towns, are rife 
with mosquito breeding grounds therefore any vector control strategy would 
need to be able to penetrate these areas. Therefore, such outbreaks require 
diverse intervention strategies, which can include the identification of potential 
drug targets. 
As mentioned previously, the follow-up of individuals born during ZIKV outbreaks 
to ZIKV-positive mothers is imperative. This will illuminate the extent of 
neurodevelopmental disorders associated with congenital ZIKV syndrome (CZS) 
and inform clinical practices to treat affected individuals. Continued efforts in 
basic and translational research are also essential in understanding and 
combating CZS. 
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Appendices 
Appendix 1: Differentially expressed genes at 96 h p.i with ZIKV in Ifnar1 CNS co-
cultures, arranged in decreasing Log2FC. 
Gene symbol GeneID Log2FC Q-value 
Ifnb1 ENSMUSG00000048806 10.98223 1.57E-48 
Ovol1 ENSMUSG00000024922 10.00622 2.20E-25 
Heatr9 ENSMUSG00000018925 9.839729 1.57E-27 
Oasl1 ENSMUSG00000041827 8.516512 7.85E-42 
Cxcl11 ENSMUSG00000060183 8.20223 7.24E-34 
Cxcl1 ENSMUSG00000029380 7.659263 6.30E-75 
Ccl5 ENSMUSG00000035042 7.438624 1.58E-41 
Il6 ENSMUSG00000025746 7.348566 2.98E-29 
Gbp5 ENSMUSG00000105504 6.87963 9.54E-42 
Cxcl10 ENSMUSG00000034855 6.747969 3.44E-89 
Cxcl2 ENSMUSG00000058427 6.651629 8.67E-41 
Ccl2 ENSMUSG00000035385 6.209305 1.04E-69 
Ccl7 ENSMUSG00000035373 6.090213 1.13E-28 
Isg15 ENSMUSG00000035692 5.446367 2.11E-27 
Oasl2 ENSMUSG00000029561 5.437856 1.68E-23 
Gbp10 ENSMUSG00000105096 5.246991 1.54E-17 
Ifit1 ENSMUSG00000034459 5.169985 1.86E-73 
UNCHARACTERISED ENSMUSG00000116657 5.044746 2.50E-15 
Rsad2 ENSMUSG00000020641 4.979172 8.02E-32 
Oas1b ENSMUSG00000029605 4.95168 4.25E-36 
Mx1 ENSMUSG00000000386 4.632574 5.74E-15 
Ddx60 ENSMUSG00000037921 4.555893 7.47E-27 
Stx11 ENSMUSG00000039232 4.121373 3.53E-36 
Mir155hg ENSMUSG00000097418 3.882976 4.16E-12 
Steap4 ENSMUSG00000012428 3.796855 1.18E-30 
Mlkl ENSMUSG00000012519 3.713876 6.70E-12 
Lcn2 ENSMUSG00000026822 3.566697 1.12E-21 
Mx2 ENSMUSG00000023341 3.518444 1.04E-26 
Cd40 ENSMUSG00000017652 3.430872 6.09E-12 
Tnfaip2 ENSMUSG00000021281 3.428105 5.12E-28 
Nos2 ENSMUSG00000020826 3.390465 1.14E-08 
Cd69 ENSMUSG00000030156 3.38975 5.46E-10 
H2-K2 ENSMUSG00000067203 3.255757 2.99E-19 
Fosl1 ENSMUSG00000024912 3.229966 1.54E-10 
Acod1 ENSMUSG00000022126 3.122075 2.89E-10 
Gbp3 ENSMUSG00000028268 3.030523 8.33E-29 
Casp4 ENSMUSG00000033538 3.027949 7.49E-18 
Zbp1 ENSMUSG00000027514 3.013457 3.65E-09 
Saa3 ENSMUSG00000040026 2.911601 0.009854 
Ankrd33b ENSMUSG00000022237 2.746735 2.24E-08 
Ptx3 ENSMUSG00000027832 2.71848 3.45E-06 
Lipg ENSMUSG00000053846 2.657271 7.62E-20 
Hes7 ENSMUSG00000023781 2.638918 6.49E-08 
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Gene symbol GeneID Log2FC Q-value 
Gbp2b ENSMUSG00000040264 2.633292 6.91E-26 
Gbp9 ENSMUSG00000029298 2.522424 3.29E-12 
Serpina3h ENSMUSG00000041449 2.515369 2.89E-10 
Tnf ENSMUSG00000024401 2.492198 3.71E-12 
A3galt2 ENSMUSG00000028794 2.486541 8.69E-08 
Isg20 ENSMUSG00000039236 2.475821 2.02E-10 
Maff ENSMUSG00000042622 2.449069 4.68E-11 
Atp4a ENSMUSG00000005553 2.436033 4.61E-09 
Upp1 ENSMUSG00000020407 2.403246 1.31E-06 
Rtp4 ENSMUSG00000033355 2.346549 1.93E-06 
Sphk1 ENSMUSG00000061878 2.33632 3.48E-08 
Tgm1 ENSMUSG00000022218 2.326612 0.001622 
Gbp6 ENSMUSG00000104713 2.320043 9.44E-14 
Serpina3i ENSMUSG00000079014 2.312569 1.12E-08 
Ifi204 ENSMUSG00000073489 2.256098 6.01E-07 
Clec4e ENSMUSG00000030142 2.251443 3.49E-05 
C2cd4b ENSMUSG00000091956 2.234479 0.000107 
Ifi203 ENSMUSG00000039997 2.230407 1.50E-06 
Ppp1r15a ENSMUSG00000040435 2.186211 3.44E-19 
Nfkbie ENSMUSG00000023947 2.185414 1.50E-19 
Icam1 ENSMUSG00000037405 2.164415 7.24E-22 
Irf1 ENSMUSG00000018899 2.143756 1.84E-13 
Chil1 ENSMUSG00000064246 2.113351 6.26E-27 
Tnfsf18 ENSMUSG00000066755 2.09871 9.09E-07 
Irf7 ENSMUSG00000025498 2.077554 0.000541 
Tnip3 ENSMUSG00000044162 2.072711 3.25E-10 
Ier3 ENSMUSG00000003541 2.064412 1.44E-10 
H2-Q5 ENSMUSG00000055413 2.050554 0.000442 
Nfkbia ENSMUSG00000021025 2.030617 1.11E-16 
Vcam1 ENSMUSG00000027962 1.984109 5.69E-26 
Ccrl2 ENSMUSG00000043953 1.975259 5.12E-07 
Relb ENSMUSG00000002983 1.953259 1.03E-21 
Ptgs2 ENSMUSG00000032487 1.930729 0.002346 
Gch1 ENSMUSG00000037580 1.922931 3.40E-09 
Arhgap28 ENSMUSG00000024043 1.912509 2.93E-07 
Gbp7 ENSMUSG00000040253 1.912279 4.41E-14 
Tnfaip3 ENSMUSG00000019850 1.903277 2.41E-25 
Gbp2 ENSMUSG00000028270 1.836212 7.09E-11 
Birc3 ENSMUSG00000032000 1.766359 3.86E-13 
H2-Q6 ENSMUSG00000073409 1.75824 0.041978 
Ifi202b ENSMUSG00000026535 1.720967 3.01E-11 
Hspa1b ENSMUSG00000090877 1.710083 5.89E-08 
Egr1 ENSMUSG00000038418 1.699229 1.10E-17 
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Gene symbol GeneID Log2FC Q-value 
Ifih1 ENSMUSG00000026896 1.670821 2.11E-16 
Gm16465 ENSMUSG00000083994 1.649543 0.001714 
Nfkbiz ENSMUSG00000035356 1.647556 4.04E-18 
Timp1 ENSMUSG00000001131 1.60703 0.00011 
Rnd1 ENSMUSG00000054855 1.581276 2.62E-11 
Tlr2 ENSMUSG00000027995 1.575354 1.11E-30 
Trib3 ENSMUSG00000032715 1.528195 5.74E-05 
Stap2 ENSMUSG00000038781 1.522349 0.000165 
AW112010 ENSMUSG00000075010 1.520008 9.71E-06 
Pmaip1 ENSMUSG00000024521 1.500973 4.95E-08 
Gpr84 ENSMUSG00000063234 1.490917 2.80E-16 
Ccl4 ENSMUSG00000018930 1.487996 0.001099 
Pappa ENSMUSG00000028370 1.483866 0.00071 
Atf3 ENSMUSG00000026628 1.478203 8.52E-06 
Has2 ENSMUSG00000022367 1.47557 1.11E-08 
1810032O08Rik ENSMUSG00000020812 1.471084 1.00E-06 
Epha2 ENSMUSG00000006445 1.46626 0.002563 
Cebpd ENSMUSG00000071637 1.456389 8.32E-07 
Nfkb2 ENSMUSG00000025225 1.430363 1.27E-15 
Ifit3 ENSMUSG00000074896 1.402604 8.16E-07 
Junb ENSMUSG00000052837 1.3934 9.71E-11 
Snhg15 ENSMUSG00000085156 1.383603 1.09E-05 
Bid ENSMUSG00000004446 1.379887 8.55E-08 
Ripk2 ENSMUSG00000041135 1.376231 4.25E-12 
Gadd45b ENSMUSG00000015312 1.374645 3.51E-08 
Cldn23 ENSMUSG00000055976 1.369747 0.030078 
Plekha4 ENSMUSG00000040428 1.36173 7.65E-05 
Il2rg ENSMUSG00000031304 1.353359 8.82E-07 
Serpine1 ENSMUSG00000037411 1.35277 0.015305 
Noct ENSMUSG00000023087 1.349527 8.46E-11 
Gja5 ENSMUSG00000057123 1.343735 0.001763 
Csrnp1 ENSMUSG00000032515 1.339001 7.65E-05 
Ifrd1 ENSMUSG00000001627 1.331742 4.09E-23 
Lif ENSMUSG00000034394 1.315829 0.019062 
Adamts14 ENSMUSG00000059901 1.301778 0.009153 
Ddit3 ENSMUSG00000025408 1.296168 8.29E-09 
Gm20559 ENSMUSG00000106734 1.291044 6.43E-05 
Ripk3 ENSMUSG00000022221 1.283323 0.015958 
Zc3h12a ENSMUSG00000042677 1.280109 1.04E-06 
Ccl12 ENSMUSG00000035352 1.254663 0.020853 
Trim47 ENSMUSG00000020773 1.254361 7.93E-06 
Samd9l ENSMUSG00000047735 1.245596 3.05E-11 
Ptges ENSMUSG00000050737 1.240614 2.58E-06 
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Gene symbol GeneID Log2FC Q-value 
Gm13889 ENSMUSG00000087006 1.236165 7.86E-06 
Hspa1a ENSMUSG00000091971 1.233032 0.000807 
Cd274 ENSMUSG00000016496 1.222071 1.04E-05 
Zmynd15 ENSMUSG00000040829 1.199774 0.006932 
Dusp5 ENSMUSG00000034765 1.193466 0.012799 
Ifit3b ENSMUSG00000062488 1.187206 7.29E-07 
Socs1 ENSMUSG00000038037 1.187069 0.007503 
Oas1c ENSMUSG00000001166 1.182401 0.013967 
Bcl3 ENSMUSG00000053175 1.176314 0.007688 
Grhl1 ENSMUSG00000020656 1.171187 0.002275 
Gm45053 ENSMUSG00000108368 1.158499 0.027982 
Rab20 ENSMUSG00000031504 1.15442 0.000528 
Ocln ENSMUSG00000021638 1.141036 3.39E-05 
Rhbdf2 ENSMUSG00000020806 1.129858 2.17E-06 
Slc43a3 ENSMUSG00000027074 1.117446 5.86E-09 
Pbld2 ENSMUSG00000020072 1.105384 0.035792 
Rrad ENSMUSG00000031880 1.095113 7.65E-05 
Cd74 ENSMUSG00000024610 1.085794 0.013298 
Gm23935 ENSMUSG00000076258 1.082937 0.000334 
Pim1 ENSMUSG00000024014 1.077897 0.025362 
Micall2 ENSMUSG00000036718 1.066716 2.27E-06 
Slc39a4 ENSMUSG00000063354 1.055463 0.015565 
Parp14 ENSMUSG00000034422 1.048938 3.51E-07 
Ier2 ENSMUSG00000053560 1.04863 8.76E-07 
Slamf8 ENSMUSG00000053318 1.039288 0.049214 
Klf4 ENSMUSG00000003032 1.023976 0.004668 
H2-Q4 ENSMUSG00000035929 1.016959 0.017643 
Gem ENSMUSG00000028214 1.014068 0.000224 
Efcab8 ENSMUSG00000044083 1.00994 0.024332 
Cp ENSMUSG00000003617 1.000119 2.02E-06 
Taf4b ENSMUSG00000054321 0.984892 0.000201 
Mir6236 ENSMUSG00000098973 0.980588 0.006554 
Ddx58 ENSMUSG00000040296 0.964819 9.22E-09 
Snhg1 ENSMUSG00000108414 0.964428 2.82E-06 
Plekhf1 ENSMUSG00000074170 0.961454 7.29E-07 
Shisa3 ENSMUSG00000050010 0.955845 0.014802 
Nabp1 ENSMUSG00000026107 0.953856 1.08E-05 
Nupr1 ENSMUSG00000030717 0.950689 0.022489 
A630072M18Rik ENSMUSG00000101013 0.939031 0.001406 
Gm26917 ENSMUSG00000097971 0.938401 8.16E-07 
Pik3r5 ENSMUSG00000020901 0.93835 8.48E-06 
Ddias ENSMUSG00000030641 0.935409 0.016418 
Gtse1 ENSMUSG00000022385 0.934641 0.001336 
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Gene symbol GeneID Log2FC Q-value 
Tnfrsf12a ENSMUSG00000023905 0.93304 0.001914 
Arid5a ENSMUSG00000037447 0.931238 0.001342 
Clec5a ENSMUSG00000029915 0.922174 0.001691 
Eif4ebp1 ENSMUSG00000031490 0.914086 0.005184 
Trim17 ENSMUSG00000036964 0.913327 0.002731 
Helz2 ENSMUSG00000027580 0.902181 7.11E-06 
Ikbke ENSMUSG00000042349 0.897478 8.32E-07 
Pvr ENSMUSG00000040511 0.88012 0.000639 
Bbc3 ENSMUSG00000002083 0.880104 0.003072 
Tnfrsf10b ENSMUSG00000022074 0.876957 0.000664 
Socs2 ENSMUSG00000020027 0.876682 0.009579 
C3 ENSMUSG00000024164 0.872478 0.012903 
2410006H16Rik ENSMUSG00000086841 0.854823 4.79E-05 
Arl5c ENSMUSG00000038352 0.849281 0.026559 
Map3k8 ENSMUSG00000024235 0.84342 0.004593 
Tapbpl ENSMUSG00000038213 0.839065 0.002825 
Cxcl16 ENSMUSG00000018920 0.831651 6.00E-07 
Cebpb ENSMUSG00000056501 0.826168 0.002758 
Neurl3 ENSMUSG00000047180 0.819525 0.032931 
Cd44 ENSMUSG00000005087 0.809505 0.017599 
Ube2l6 ENSMUSG00000027078 0.807948 0.019849 
Phlda1 ENSMUSG00000020205 0.807528 0.000222 
Slc16a10 ENSMUSG00000019838 0.803474 0.004824 
Herc6 ENSMUSG00000029798 0.802781 0.002913 
Rras ENSMUSG00000038387 0.801473 0.00473 
5430416N02Rik ENSMUSG00000097772 0.798025 0.017763 
Arrdc4 ENSMUSG00000042659 0.791839 0.003304 
Ctps ENSMUSG00000028633 0.78739 1.46E-05 
Igsf9 ENSMUSG00000037995 0.777398 0.012592 
Fos ENSMUSG00000021250 0.773808 0.002837 
Snhg12 ENSMUSG00000086290 0.770671 0.016492 
Zc3hav1 ENSMUSG00000029826 0.764452 0.000569 
Tgif1 ENSMUSG00000047407 0.764213 0.000155 
Zfp711 ENSMUSG00000025529 0.761898 0.003507 
Btg2 ENSMUSG00000020423 0.761751 0.000186 
Foxn2 ENSMUSG00000034998 0.761473 4.37E-06 
Cdkn1a ENSMUSG00000023067 0.758626 0.02053 
Slc4a7 ENSMUSG00000021733 0.753568 2.11E-05 
Eda2r ENSMUSG00000034457 0.752044 0.000425 
Dennd3 ENSMUSG00000036661 0.746354 0.010778 
2810474O19Rik ENSMUSG00000032712 0.745389 7.43E-07 
Ets1 ENSMUSG00000032035 0.743016 0.000732 
Chac1 ENSMUSG00000027313 0.719942 0.034353 
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Gene symbol GeneID Log2FC Q-value 
Trp53 ENSMUSG00000059552 0.718825 3.49E-05 
Cd14 ENSMUSG00000051439 0.71719 6.32E-05 
Tiparp ENSMUSG00000034640 0.710561 1.76E-05 
Rnf19b ENSMUSG00000028793 0.710034 1.43E-05 
Jun ENSMUSG00000052684 0.708239 0.021571 
Slc7a1 ENSMUSG00000041313 0.702388 3.40E-05 
Zfp36 ENSMUSG00000044786 0.698112 0.045845 
Hbegf ENSMUSG00000024486 0.694472 0.031739 
Apobr ENSMUSG00000042759 0.693574 0.024366 
Slc25a25 ENSMUSG00000026819 0.692594 7.65E-05 
Gnl3 ENSMUSG00000042354 0.690501 3.96E-05 
Plxnd1 ENSMUSG00000030123 0.687459 0.001631 
Thbs2 ENSMUSG00000023885 0.680782 0.019062 
Itpkc ENSMUSG00000003752 0.680026 0.009257 
Igsf6 ENSMUSG00000035004 0.668832 0.01868 
Rnf213 ENSMUSG00000070327 0.667909 1.13E-05 
Ptpn2 ENSMUSG00000024539 0.666718 0.000224 
Pinx1 ENSMUSG00000021958 0.662955 0.032312 
1110008P14Rik ENSMUSG00000039195 0.662885 0.000572 
Car13 ENSMUSG00000027555 0.660341 0.007683 
Zfp948 ENSMUSG00000067931 0.659014 0.02339 
Dok1 ENSMUSG00000068335 0.655031 0.038499 
Fgf2 ENSMUSG00000037225 0.644459 0.006132 
Ifit2 ENSMUSG00000045932 0.644369 0.00113 
Snhg17 ENSMUSG00000085385 0.641485 0.007567 
Itga5 ENSMUSG00000000555 0.641108 0.004058 
Fam129a ENSMUSG00000026483 0.63822 0.004668 
Mvp ENSMUSG00000030681 0.632117 0.007355 
Zfas1 ENSMUSG00000074578 0.625277 0.005164 
Smad3 ENSMUSG00000032402 0.622829 0.006779 
Zbtb2 ENSMUSG00000075327 0.62254 0.045379 
Mcc ENSMUSG00000071856 0.608918 0.02388 
Ralb ENSMUSG00000004451 0.605752 0.003832 
Aen ENSMUSG00000030609 0.601381 0.006779 
Zbtb10 ENSMUSG00000069114 0.596426 0.005168 
Sirt1 ENSMUSG00000020063 0.594414 0.006454 
Rel ENSMUSG00000020275 0.593104 0.012592 
Plk2 ENSMUSG00000021701 0.583654 0.030078 
Baz1a ENSMUSG00000035021 0.583246 0.016492 
Map3k14 ENSMUSG00000020941 0.581162 0.033662 
Mapkapk3 ENSMUSG00000032577 0.575067 0.046211 
Lacc1 ENSMUSG00000044350 0.574281 0.00406 
Rassf1 ENSMUSG00000010067 0.568801 0.039538 
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Rhbdf1 ENSMUSG00000020282 0.56841 0.023155 
Parp9 ENSMUSG00000022906 0.566044 0.025593 
Rai14 ENSMUSG00000022246 0.561125 0.006313 
Sesn2 ENSMUSG00000028893 0.552715 0.002115 
Atf4 ENSMUSG00000042406 0.550601 0.002382 
Rnd3 ENSMUSG00000017144 0.548773 0.00203 
Fas ENSMUSG00000024778 0.539835 0.010607 
Ermard ENSMUSG00000036552 0.535626 0.031739 
Nop58 ENSMUSG00000026020 0.532125 0.001434 
Stat2 ENSMUSG00000040033 0.527226 0.004381 
Insig1 ENSMUSG00000045294 0.527043 0.000528 
Zfp131 ENSMUSG00000094870 0.519264 0.004932 
Fam46a ENSMUSG00000032265 0.516225 0.037385 
Chl1 ENSMUSG00000030077 0.515374 0.038847 
Tmem39a ENSMUSG00000002845 0.51519 0.027708 
Susd6 ENSMUSG00000021133 0.507249 0.014771 
Klf6 ENSMUSG00000000078 0.503998 0.012944 
Pde4b ENSMUSG00000028525 0.50396 0.021258 
Mthfd2 ENSMUSG00000005667 0.50225 0.041511 
Nfkb1 ENSMUSG00000028163 0.502166 0.001962 
Sap30 ENSMUSG00000031609 0.492761 0.049214 
Traf2 ENSMUSG00000026942 0.491188 0.037139 
Gm8566 ENSMUSG00000047905 0.490643 0.03747 
Cflar ENSMUSG00000026031 0.489013 0.002913 
Vasp ENSMUSG00000030403 0.488591 0.040214 
Slc2a6 ENSMUSG00000036067 0.48606 0.019849 
Bcl10 ENSMUSG00000028191 0.485127 0.020596 
Cebpg ENSMUSG00000056216 0.481012 0.003383 
Nfkbib ENSMUSG00000030595 0.480379 0.031895 
Tgfb1 ENSMUSG00000002603 0.476989 0.027708 
Bach1 ENSMUSG00000025612 0.471628 0.035792 
Pnrc1 ENSMUSG00000040128 0.469079 0.020853 
Brd2 ENSMUSG00000024335 0.466931 0.016492 
Mdm2 ENSMUSG00000020184 0.465562 0.008314 
Trpc1 ENSMUSG00000032839 0.460747 0.045182 
Ptpn12 ENSMUSG00000028771 0.458711 0.013854 
Zc3h7a ENSMUSG00000037965 0.458191 0.022685 
Tnip1 ENSMUSG00000020400 0.443435 0.036386 
Cybb ENSMUSG00000015340 0.441582 0.007688 
Anxa3 ENSMUSG00000029484 0.433356 0.024315 
Slc25a37 ENSMUSG00000034248 0.4199 0.038847 
Arhgef17 ENSMUSG00000032875 0.41939 0.023332 
Ptpn23 ENSMUSG00000036057 0.41599 0.049795 
Ascc3 ENSMUSG00000038774 0.412092 0.040637 
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Crb2 ENSMUSG00000035403 -0.41195 0.040214 
Dhrs3 ENSMUSG00000066026 -0.41956 0.031895 
Psd2 ENSMUSG00000024347 -0.42121 0.049746 
Acot11 ENSMUSG00000034853 -0.42924 0.02636 
Ppp1r1a ENSMUSG00000022490 -0.43669 0.039538 
Spag6 ENSMUSG00000022783 -0.4538 0.027057 
Cfap52 ENSMUSG00000020904 -0.45551 0.016492 
Cfap46 ENSMUSG00000049571 -0.45863 0.049528 
Abhd1 ENSMUSG00000006638 -0.47371 0.033662 
Slc39a12 ENSMUSG00000036949 -0.47989 0.013874 
Ttc21a ENSMUSG00000032514 -0.48127 0.01682 
Cfap65 ENSMUSG00000047021 -0.49049 0.01329 
Drc3 ENSMUSG00000056598 -0.49113 0.017763 
Vsir ENSMUSG00000020101 -0.50713 0.012087 
Ak9 ENSMUSG00000091415 -0.50916 0.013388 
Sema6d ENSMUSG00000027200 -0.51389 0.02139 
Dnah6 ENSMUSG00000052861 -0.51425 0.026219 
Fbln5 ENSMUSG00000021186 -0.52889 0.001582 
Enho ENSMUSG00000028445 -0.53162 0.003507 
Nkain4 ENSMUSG00000027574 -0.5405 0.024315 
Map3k19 ENSMUSG00000051590 -0.54231 0.013967 
Fcgr3 ENSMUSG00000059498 -0.56318 0.026558 
Lcat ENSMUSG00000035237 -0.56365 0.029547 
Vstm4 ENSMUSG00000050666 -0.60156 0.012903 
Bbox1 ENSMUSG00000041660 -0.60195 0.007688 
Id4 ENSMUSG00000021379 -0.62854 0.000604 
Traf1 ENSMUSG00000026875 -0.63995 0.003507 
Ptgs1 ENSMUSG00000047250 -0.66685 0.002376 
Slco2b1 ENSMUSG00000030737 -0.67931 0.014771 
Adamts16 ENSMUSG00000049538 -0.68263 0.033574 
Ppp1r1b ENSMUSG00000061718 -0.72459 0.000103 
Tprkb ENSMUSG00000054226 -0.81679 0.000471 
Trp73 ENSMUSG00000029026 -0.88451 0.02568 
Tlr8 ENSMUSG00000040522 -0.96246 0.011103 
Tmem52 ENSMUSG00000023153 -1.05901 0.029592 
Mrc1 ENSMUSG00000026712 -1.11422 0.003129 
Il11ra2 ENSMUSG00000095456 -7.85813 9.82E-17 
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